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Abstract 
Maternal obesity has been at the forefront of pregnancy-related research in 
recent times. The impact of this chronic health condition has been highlighted in 
reports on maternal mortality (CEMACH, 2007, CEMACH, 2011), where 30% of 
mothers who died from pregnancy related causes were obese (CEMACH, 2011). 
The importance of maternal obesity and how it affects maternal adaptation to 
pregnancy is well documented with obese women exhibiting low grade 
inflammation, greater coagulability and poorer improvement in vascular function 
during pregnancy compared to lean women (Stewart et al., 2007a). These 
findings suggest that obese women display similar characteristics to the non-
pregnant adult metabolic syndrome and these attributes may be important in 
explaining why obese pregnancies have higher rates of obstetric complications 
including gestational diabetes (GDM) and pre-eclampsia (PET). In non-pregnant 
adult obesity it has been found that central or truncal adiposity is associated 
with increased NEFA (non-esterified fatty acids) turnover and ectopic fat 
(especially liver) deposition. It has been suggested that obese pregnant women 
may also preferentially gain fat in central depots and this may be the mechanism 
by which poor vascular improvement and inflammation are initiated. 
The aims of this thesis were to assess subcutaneous fat accumulation and 
distribution throughout pregnancy in both lean and OW/OB women. Furthermore 
this thesis aimed to acquire a better understanding of the impact of anatomical 
fat deposition on metabolic and vascular function during pregnancy. A final aim 
was to assess vascular function and evidence of lipotoxicity during pregnancy 
and test whether the site of fat accumulation and distribution was associated 
with gestational improvement of vascular function.  
 
A longitudinal study was performed and anthropometric data was collected from 
26 lean and 16 OW/OB women at three antenatal time points (15, 25 and 35 
weeks’ gestation) during pregnancy. Direct measurements of energy metabolism 
(basal metabolic rate, substrate utilisation, physical activity and diet) were also 
collected to assess the impact of energy metabolism on fat accumulation and 
distribution. A comprehensive panel of plasma markers of carbohydrate and lipid 
metabolism (fasting glucose, fasting insulin, total cholesterol [TC], total 
triglyceride [TG], high density lipoprotein [HDL] and NEFA) and inflammatory  
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(C-reactive protein [CRP], interleukin-6 [IL6] and tumour necrosis factor alpha 
[TNF]) were quantitated at each study appointment. Endothelial function was 
measured using laser Doppler imaging (LDI). Measurement of plasma and urinary 
biomarkers of endothelial function and lipotoxicity including soluble intracellular 
adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), 
oxidised low density lipoprotein (oxLDL), plasma superoxide and urinary 
isoprostanes were undertaken.  
 
Lean and OW/OB women gained similar amounts of total body weight and fat 
mass during pregnancy. Only in lean women was there an anatomical preference 
for site of fat storage and this was in the upper peripheral subcutaneous depots. 
In healthy OW/OB pregnancy no such anatomical preference of fat deposition 
was found. 
 
The study of energy metabolism found that OW/OB women had higher basal 
metabolic rate and higher fat oxidation than lean women, whilst lean women 
had higher rates of carbohydrate oxidation and physical activity than OW/OB 
women. In the lean and OW/OB groups dietary macronutrient intakes were 
similar. Overall the parameters of energy metabolism were not associated with 
overall fat mass accumulation or distribution.  
 
During pregnancy, OW/OB women were more insulin resistant and pro-
inflammatory (CRP and TNFα) than lean women and lean women had higher 
concentrations of plasma HDL. Interestingly the lean group had higher plasma 
concentrations of IL6 which may be a result of higher rates of vascular 
remodelling and may reflect a physiological rather than pathological process. In 
both lean and OW/OB pregnancies the gestational increase in subcutaneous 
adipose depots was not associated with the gestational changes in markers of 
carbohydrate, lipid or inflammatory profiles.  
 
Both lean and OW/OB women exhibited similar gestational improvement in 
endothelial microvascular function. During pregnancy both groups showed an 
increase in markers of lipotoxicity but levels were not associated with vascular 
function. Changes in anatomical subcutaneous fat distribution were also not 
associated with the changes in vascular function during pregnancy.  
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In conclusion, in pregnancy, only lean women exhibit an anatomical site-specific 
fat accumulation. Although the OW/OB group displayed some aspects of the 
metabolic syndrome in general the OW/OB women studied here adapted to 
pregnancy in a similar way to lean women in terms of vascular function and 
levels of lipotoxicity. However, visceral adiposity was not assessed and OW/OB 
women with larger visceral adipose stores may exhibit a more lipotoxic 
phenotype and more pathological adaptation to pregnancy that may make them 
susceptible to metabolic complications of pregnancy. This study highlights the 
heterogeneity of maternal obesity and suggests that further studies into 
‘metabolically healthy’ and ‘metabolically unhealthy’ lean and OW/OB women is 
warranted.  
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Chapter 1 - Introduction  
 The obesity problem 1.1
In 2008 the World Health Organisation estimated that over 200 million men and 
approximately 300 million women were obese, with the worldwide prevalence of 
obesity having doubled from 1980 to 2008 (WHO, 2013).  
In 2006 the Department of Health predicted that if the trend for the increase in 
obesity was to continue, there would be a further 1 230 573 women of 
reproductive age who were obese by 2010, estimating that in England alone 
there would be approximately six million obese women (Zaninotto et al., 2006). 
In 2009, 23% of all adults in England were obese, and although the trend 
appeared to have slowed, the obesity prevalence was higher than other 
developed counties (DOH, 2010). Recent epidemiological modelling has 
suggested that by 2030 approximately 45% of men and 40% of women may be 
obese (Wang et al., 2011). 
 Body composition in the general adult population and 1.2
metabolic risk 
Human body fat compartments can be pragmatically based on anatomical site 
and can be divided into subcutaneous and visceral compartments. These sites 
can be further demarcated as upper body subcutaneous fat, intra-abdominal and 
visceral fat and lower body subcutaneous fat (Jensen, 2008). Often the term 
‘central obesity’ does not differentiate between visceral and abdominal 
subcutaneous adipose tissue. However, whilst central obesity can be measured 
using waist circumference (Anuradha et al., 2012) visceral obesity relies on 
advanced visualisation techniques such as magnetic resonance imaging (Abate et 
al., 1997). In this thesis, central obesity will refer to both visceral and 
abdominal subcutaneous fat depots. 
In addition, adipose tissue can be classified based on its function. Importantly in 
the context of adult obesity, classification can be based on fat depot sensitivity 
to insulin-induced lipolysis. Central adiposity is recognised as a core feature of 
insulin resistance in obese men (Ross et al., 2002a) and premenopausal women 
(Ross et al., 2002b) and is a stronger predictor of coronary heart disease than 
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BMI (body mass index) alone (Canoy et al., 2007). In the general adult 
population, both central obesity, and more specifically visceral obesity, are 
documented risk factors for the development of both diabetes mellitus and 
coronary heart disease in both men and women (Sattar et al., 2008, Canoy, 
2008).   
Adult central obesity is associated with insulin resistance, high levels of plasma 
triglycerides, low HDL, increased small dense low density lipoprotein (LDL) 
concentration, low grade inflammation and development of a prothrombotic 
environment. This has been collectively termed the metabolic syndrome (Huang, 
2009). 
An excess of upper body subcutaneous (abdominal and truncal) fat is associated 
with an abnormal metabolic and adipokine profile but the relative contributions 
of subcutaneous and visceral fat are unclear. Numerous groups (Hutley and 
Prins, 2005, Despres et al., 2008, Despres and Lemieux, 2006) have discussed the 
role of visceral adipose tissue in the production of inflammatory cytokines such 
as tumour necrosis factor alpha (TNFα) and interleukin 6 (IL6). TNFα is known to 
further stimulate the production of leptin and IL6. In addition, TNFα stimulates 
atherosclerosis formation through the activation of soluble vascular cell adhesion 
molecule 1 (sVCAM-1) and soluble intercellular adhesion molecule 1 (sICAM-1), as 
well as reducing the bioavailability of nitric oxide (NO) for vasodilatation, thus 
further perpetuating endothelial dysfunction (Lau et al., 2005). TNFα is not only 
important in inflammatory and vascular pathways but interferes with insulin-
induced glucose uptake in adipocytes and appears to inhibit phosphorylation of 
the insulin receptor at least in vitro (Hotamisligil et al., 1994).  
IL6 has been proposed to play a role in stimulating the production of acute-
phase inflammatory proteins such as C-reactive protein (CRP) which are found at 
higher levels in obese patients (Fantuzzi, 2005). In vitro studies comparing the 
production of IL6 found that visceral fat produces higher levels of this 
inflammatory cytokine compared with subcutaneous abdominal adipocytes (Fain 
et al., 2004, Fried et al., 1998). However, abdominal subcutaneous adipose 
tissue, along with visceral fat, has been shown to be positively associated with 
biomarkers inflammation and oxidative stress such as CRP, IL6, sICAM-1, and 
TNFα (Pou et al., 2007). Subcutaneous adipose tissue has also been shown to be 
Chapter 1  25 
strongly associated with insulin resistance, even when analysis adjusted for the 
impact of visceral adiposity (Goodpaster et al., 1997). Interestingly, recent data 
has found the positive association between abdominal subcutaneous fat 
thickness and insulin resistance and plasma triglycerides in much younger 
cohorts (ages 6-18 years) (Kelly et al., 2014), as well as abdominal subcutaneous 
fat depots being inversely correlated with HDL cholesterol (Kelly et al., 2014).  
In adult central obesity there are elevated levels of circulating NEFA which 
results in insulin resistance and dysfunction of adipocytes (Frayn, 2000). Both 
upper body subcutaneous and visceral fat is relatively resistant to insulin 
suppression of lipolysis and consequently is estimated to be the source of around 
60% of circulating NEFA (Jensen, 2008). Subcutaneous adipose tissue could be 
considered the main source of circulating NEFA because NEFA from visceral fat is 
transported directly to the liver via the portal circulation (Bevilacqua et al., 
1987). In animal studies, visceral fat adipose tissue is strongly correlated with 
the NEFA concentrations seen in hepatic vein samples (Jensen et al., 2003). 
Therefore, because NEFA from visceral fat drains into the portal circulation 
there is no uptake by peripheral tissues before they reach the liver unlike NEFA 
from subcutaneous fat sources (Jensen et al., 2003). In obese women with a 
propensity for upper body obesity it has been confirmed that in the postprandial 
state, elevated levels of plasma NEFA originated from upper body fat but not 
visceral fat (Guo et al., 1999). Therefore, both visceral and subcutaneous fat 
depots are involved in abnormal lipid, inflammatory profiles and the promotion 
of insulin resistance. 
 
Conversely lower body fat is considered more sensitive to insulin suppression of 
lipolysis, and contributes only 15-20% of circulating NEFA (Jensen, 2008). It has 
been proposed that lower body adipose tissue depots are associated with more 
efficient storage of dietary fat as a result of lower body subcutaneous fat being 
more sensitive to lipoprotein lipase activity in the post prandial state than either 
upper body subcutaneous or visceral adipocytes (McCarty, 2003, Votruba et al., 
2007). There are differences in the storage capacity of lower body fat based on 
gender and BMI. In published literature it has been shown that lean women can 
store fatty acids more efficiently in the lower body fat compartments in the post 
prandial state than either obese women or men of any level of obesity (Santosa 
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et al., 2008). In the general adult population, smaller lower body depots, mainly 
thigh fat, have been highlighted as a risk factor for increased levels of 
triglycerides, lower HDL and hyperglycaemia (Snijder et al., 2005). Further 
studies by the same group have confirmed a reduced risk of carbohydrate and 
lipid dysregulation with greater lower body fat adiposity (Bos et al., 2005, 
Snijder et al., 2004a, Snijder et al., 2004b). Published data has suggested that 
larger hip circumference measurements had an inverse association with 
cardiovascular disease and diabetes which was stronger than the positive 
correlations between these diseases and waist circumference (Lissner et al., 
2001). This proposed preference for lean women to store fat in lower body 
depots could be a reason for their relative protection against metabolic risk and 
endothelial dysfunction compared to men and obese women. 
 
 Metabolic syndrome and the development of 1.3
lipotoxicity  
Central obesity in adults is associated with hypertrophy of adipocytes. This 
hypertrophic obesity results in the reduced uptake and storage of fatty acids 
along with increased lipolysis, inflammatory cell infiltration and adipokine 
secretion (Jensen, 2008). In addition, in adult obesity, there is a reduced 
capacity of the pre-adipocytes population to undergo differentiation to mature 
adipocytes in abdominal subcutaneous adipose tissue (Gustafson et al., 2009). In 
insulin resistant obese adults, there are a disproportionately high number of 
both small preadipocytes and large hypertrophic adipocytes which have a 
reduced capacity to store fatty acids. These two populations of cells which are 
at the extremes of adipocyte size are found to positively correlate with whole 
body insulin resistance (McLaughlin et al., 2007). Thus obesity and insulin 
resistance are associated with defects of adipose tissue function where there is a 
failure to expand the capacity of the tissue to store additional triglyceride via 
developing more normal size adipocytes, in combination with a propensity to 
over fill the adipocytes which are available. 
In the metabolic syndrome, which arises secondary to central obesity, the 
abnormal insulin resistance leads to an increase in plasma NEFA concentrations. 
This excessively high level of NEFA has further detrimental effects on adipocyte 
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function. In the adipocyte, the storage capacity for fatty acids is limited by 
triglyceride synthesising capacity and the ability of the adipocyte to expand as 
discussed above. If excessive fatty acid levels are present this overwhelms the 
triglyceride biosynthesis ability and storage capacity, leading to fatty acid 
accumulation and a reduced cellular homeostatic capacity of both the 
endoplasmic reticulum and mitochondria which will lead to adipocyte 
dysfunction (Garbarino and Sturley, 2009).  
In addition to elevated NEFA having a detrimental effect of adipocyte function 
excessive circulating NEFA have been shown to effect end organ function. In the 
context of lipotoxicity, excessive NEFA accumulates at ectopic or non-adipose 
end organ sites such as skeletal muscle, liver and heart. When excess fatty acids 
from adipose tissue are transported to the liver, the storage and utilisation 
capacity of the hepatocytes is overwhelmed resulting in impaired signalling, 
cellular dysfunction and possible cell death (Trauner et al., 2010). In skeletal 
muscle the initial rise in fatty acid metabolites (palmitoyl carnitine, palmitoyl-
coenzyme (CoA) and oleoyl-CoA) stimulate adenosine triphosphate (ATP) 
synthesis within the mitochondria via fatty acid oxidation. However, eventually 
saturation of the electron transport chain leads to a dose-dependent inhibition 
of ATP synthesis (Abdul-Ghani et al., 2008). Within myocytes, this affects the 
mitochondrial production of ATP, leading to a rise in intramyocellular fatty acid 
CoA and subsequent abnormal glucose oxidation and insulin resistance.  
As is well documented in the literature, liver triglyceride content has been found 
to be elevated in people with type 2 diabetes (Ryysy et al., 2000). Clinical 
experiments have shown that reducing the hepatic triglyceride content in type 2 
diabetic patients using pioglitazone (a thiazolididinedione known to reduce 
hepatic triglyceride levels) for 16 weeks significantly improved fasting and 
postprandial glucose levels (Ravikumar et al., 2008). In addition it has been 
shown in type 2 diabetic patients, adherence to a very low energy dense diet 
(2.5MJ or 600 kcal/day) for eight weeks led to normalisation of pancreatic beta 
cell function, improved hepatic insulin sensitivity and reduced liver and 
pancreatic triacylglycerol stores (Lim et al., 2011, Taylor, 2013). Therefore, 
although the excessive deposition of NEFA in the liver leads to hepatocyte 
dysfunction and insulin resistance, correction of insulin resistance improves fatty 
liver lipid accumulation. This would suggest that both ectopic fat accumulation 
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at the liver as well as insulin resistance perpetuate each other and further 
promote further dysregulation in insulin and triglyceride metabolism (Taylor, 
2008). 
In adult type 2 diabetic populations, elevated gamma-glutamyl transferase 
(GGT) has been linked to ectopic deposition of fat in the liver. It is thought to 
contribute to the development of insulin resistance (Gohel and Chacko, 2013) 
and has been proposed to be a marker of oxidative stress (Lim et al., 2004) and 
atherosclerosis (Bradley et al., 2014). 
 
High plasma triglyceride concentration can lead to formation of small dense LDL, 
a highly atherogenic lipoprotein particle readily susceptible to oxidation forming 
oxidised LDL (oxLDL) because in atherosclerotic plaque formation these low 
density lipoproteins in the intimal layer of blood vessels are a focus for 
oxidation. This process leads to the formation of oxLDL which promotes sterol 
accumulation in macrophages and subsequent foam cell formation but also leads 
to increased expression of sVCAM-1 and macrophage proliferation both of which 
are important in the early inflammatory process seen in the vascular wall 
(Jessup et al., 2004). Pro-inflammatory lipoproteins such as oxLDL have been 
shown to promote endothelial damage through oxidative stress mediated DNA 
damage (Ding et al., 2013). In addition, oxLDL promotes the production of 
reactive oxidative and superoxide species which again are linked to endothelial 
dysfunction and damage. Other in vivo markers such as urinary isoprostanes have 
also been suggested to be markers of vascular damage and oxidative stress 
although there role in clinical disease is still being investigated (Minuz et al., 
2006).  
 
Oxidised metabolites of cholesterol, referred to as oxysterols have been shown 
to have beneficial effects but also to play a role in lipotoxicity (Bjorkhem and 
Diczfalusy, 2002). They can decrease cholesterol biosynthesis via interaction 
with sterol regulatory element binding protein 1c (SREBP-1c) and are also potent 
transactivators of the nuclear receptors liver X α and β (LXRα and β) (Peet et 
al., 1998). LXRα is involved in the regulation of steroid hormone biosynthesis, 
bile acid synthesis, conversion of lanosterol to cholesterol, cellular cholesterol 
efflux and lipid mobilising proteins such as cholesterylester transfer protein 
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(CETP) (Bjorkhem and Diczfalusy, 2002). However, oxysterols can be toxic to 
cells inducing inflammation, oxidative stress and apoptosis (Bjorkhem and 
Diczfalusy, 2002, Brown and Jessup, 2009, van Reyk et al., 2006). Whilst 
oxysterols pay a key role in steroid metabolism through the LXR receptor they 
will also induce expression of inflammatory markers in endothelial cells via LXR-
independent mechanisms (Morello et al., 2009). Therefore they can lead to 
damage of the vascular endothelium via both oxidative and inflammatory means 
(Vejux and Lizard, 2009, Zhou et al., 2000). 
The abnormal oxidation of fatty acids in the liver will also lead to the production 
of reactive oxygen species (ROS), disturbances in cellular membrane fatty acids 
and phospholipid composition, alterations in cholesterol content and ceramide 
signalling (Trauner et al., 2010). Elevated plasma NEFA levels can also induce 
nitroxide radical formation in smooth muscle and endothelial cells, induce 
respiratory burst in white cells and serve as substrates for oxidation themselves 
leading to propagation of lipid peroxides (Trauner et al., 2010). High levels of 
intracellular triglycerides can lead to mitochondrial accumulation of electrons 
within the electron transport chain which when it reacts with oxygen forms 
superoxide radicals. Interestingly, high levels of intracellular triglycerides will 
also directly stimulate the production of reactive oxygen species. Therefore, 
central obesity is linked to oxidative stress as a result of increased production of 
ROS (Pou et al., 2007, Vincent and Taylor, 2005).  
Therefore the excessive plasma levels of NEFA observed in central obesity and 
the subsequent spillover of NEFA into the circulation with the deposition of lipids 
in non-adipose tissue sites can be considered the starting point of lipotoxicity. 
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 Lipotoxicity and endothelial dysfunction 1.4
Sustained elevation of NEFA can lead to a reduction in insulin-mediated 
vasodilation (Jensen, 2008). Pathophysiological levels of fatty acids, such as 
those seen in central obesity, have been shown to directly affect vascular 
reactivity and through impaired activity of the endothelial isoform of nitric oxide 
synthase (eNOS)(Williams et al., 2002). In addition, vascular function can be 
blunted by the activation of nicotinamide adenine dinucleotide (NADPH) oxidase 
leading to the generation of superoxides in the vascular wall and the 
mitochondrial electron transport chain leading to endothelial oxidative stress 
(Williams et al., 2002). 
In human obesity, oxidative stress is thought to lead to endothelial dysfunction 
through mechanisms which promote inflammation and lipid accumulation in the 
vascular wall (Matsuura et al., 2006). Using non-invasive techniques it has been 
shown that endothelial dysfunction is associated with raised plasma triglycerides 
concentrations (Rasmussen et al., 2009a) probably due to the formation of 
oxLDL. OxLDL can induce activation of the pro-inflammatory pro-thrombotic 
plasminogen activator inhibitor 1 (PAI-1) in endothelial cells (Zhao et al., 2009). 
Elevated levels of oxLDL can also lead to endothelial cell dysfunction via NADPH 
oxidase ROS production (Zhao et al., 2009, Silver et al., 2007). Therefore, in the 
context of lipotoxicity, hyperlipidaemia can lead to vascular damage either 
directly or via ROS generation. 
The peroxidation of lipids is associated with oxidative stress and subsequent 
endothelial dysfunction. Lipid peroxidation occurs when free radicals come into 
contact with lipoproteins (Davies and Guo, 2014). These free radicals are 
produced as a results of normal respiration and the resulting effects of both the 
free radical and the lipid peroxides are normally counterbalanced by antioxidant 
defence systems (Little and Gladen, 1999). However when this system is out of 
equilibrium the toxic effect of these lipid peroxides cannot be blunted and 
oxidative stress results. 
It has been suggested that 7β-hydroxycholesterol may be a marker of oxLDL, 
lipid peroxidation and oxidative stress (Bjorkhem and Diczfalusy, 2002, Yoshida 
and Niki, 2006, Iuliano et al., 2003, Vejux and Lizard, 2009). Direct attack on 
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cholesterol by ROS can lead to formation of the relatively stable 7- and 7β -
hydroxyl cholesterol, 7-ketocholesterol and 5,6-epoxycholesterol. Both 7-
ketocholesterol and 7-hydroxycholesterol have been shown to have a toxic effect 
on porcine aortic smooth muscle cells which may contribute to atherosclerosis 
(Hughes et al., 1994). 
 
Plasma oxysterol concentrations have been shown to be raised in metabolic 
syndrome, diabetes and hypercholesterolaemia (Endo et al., 2008). In adolescent 
females plasma oxysterols correlate with BMI, waist circumference and fasting 
plasma insulin and are suggested to be early markers of oxidative stress-
mediated metabolic dysregulation (Alkazemi et al., 2008). High intracellular 
levels of cholesterol can also lead to tissue oxysterol production (e.g. 22(R)-
hydroxycholesterol, 24(S)-hydroxycholesterol, 25-epoxycholesterol) via specific 
enzymes in liver, brain and macrophages and these oxysterols are detectable in 
plasma. Within the diabetic population, 7-ketocholesterol levels were reported 
to be significantly higher, and subjects exhibited increased oxidation potential 
(Murakami et al., 2000). Oxysterols may also interfere with the production of 
long chain polyunsaturated fatty acids (LC-PUFA) which are protective for the 
circulation (Risé et al., 2004).Williams et al explored the impact of adipose 
tissue distribution on endothelial function and found an increased waist-hip ratio 
(as a marker of central obesity), was an independent positive predictor of 
endothelial dysfunction in healthy study participants (Williams et al., 2006). 
These findings together with others described above may suggest that lower 
body fat may be protective against vascular dysfunction (Lissner et al., 2001, Bos 
et al., 2005, Snijder et al., 2004b). 
Therefore, although oxysterols have important physiological roles in steroid 
metabolism, in the context of obesity, oxysterols along with oxLDL and the 
promotion of ROS or superoxides will lead to an increase oxidative stress and 
continued endothelial dysfunction. 
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 Weight gain and body composition in pregnancy 1.5
During pregnancy women will gain weight in response to the increased vascular 
and metabolic demands on the maternal system as well as supporting the 
development and growth of the fetus. The amount of weight a woman gains 
during pregnancy varies greatly. Gestational weight gain (GWG) is markedly 
increased in multiple pregnancies (15-22kg) and adolescents (14.0-18.0kg) 
compared to singleton adult pregnancy (range 10.0-16.7kg) and is inversely 
correlated to prepregnancy BMI (IOM, 2009).  
 
Recent guidelines produced by the Institute of Medicine (IOM) have 
recommended total gestational weight gain based on prepregnancy BMI (IOM, 
2009). The IOM guidelines on gestational weight gain (IOM, 2009) have prompted 
suggested lifestyle interventions to reduce the incidence of adverse pregnancy 
outcome in the obese pregnant population (Nelson et al., 2010). 
Table 1.1: Gestational weight gain recommendations. This table illustrates the published 
recommendations for gestational weight gain by the Institute of Medicine, 2009 
BMI group Total gestational weight gain 
recommendations (kg) 
<18.5kg/m2 12.5-18.0 
18.5-24.9kg/m2 11.5-16.0 
25.0-29.9kg/m2 7.0-11.5 
>30kg/m2 <5-9 
 
Current research suggest that the impact of excessive GWG is variable 
(Rasmussen et al., 2009b). Some authors suggests that the evidence linking 
excessive GWG (defined as being above the IOM GWG recommendations) to 
gestational diabetes and antenatal hypertensive disorders at best ‘weak’ due to 
methodological variations. However, women who gain excessive weight in 
pregnancy have an increased likelihood to retain this weight in the postpartum. 
For these women the retention of this weight is significant as they then enter 
their next pregnancy with a higher BMI leading to an increased  risk of 
hypertensive disorders, gestational diabetes, caesarean section, stillbirth and 
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macrosomia (Villamor and Cnattingius, 2006). Published data has suggested that 
in an obese obstetric population a gestational weight gain of less than 7kg 
reduced the risk of pre-eclampsia, caesarean section and large for gestational 
age birth weights but a higher risk of small for gestational age infants (Kiel et 
al., 2007). A more recent study also found the increased risk of small for 
gestational age birth weight in obese women who gained less than 5kg during 
pregnancy and urges caution in recommending very low gestational weight gains 
in the obese and overweight population (Catalano et al., 2014). 
 
Previous studies have shown that in healthy pregnancy there is a mean total 
gestational weight gain of 10.4+0.53kg, with 6.08kg gained between 12 to 26 
weeks (Pipe et al., 1979). Total maternal fat mass increased rapidly in the first 
trimester and peaked at 28 weeks before falling slightly towards the end of 
pregnancy (Pipe et al., 1979). Interestingly the increase seen in the visceral fat 
compartment was concentrated in the third trimester when assessed 
longitudinally during pregnancy using ultrasonography (Kinoshita and Itoh, 2006). 
Assessment of the subcutaneous fat compartment has suggested that, consistent 
with the increase in total body weight, the main increase in this fat depot was 
seen between 10-30 weeks’ gestation (Taggart et al., 1967). 
There is evidence that during pregnancy obese women have similar or smaller 
increases in total weight, fat mass, % fat and total body fat compared to lean 
women (Catalano et al., 1998, Catalano et al., 1999, Ehrenberg et al., 2003, 
Soltani and Fraser, 2000). Anthropometric studies of skinfold thickness have 
shown that obese women put on more fat in the upper body subcutaneous 
compartment (suprailiac and subscapular skinfold), and that lean women put on 
more fat in the lower body compartment (mid-thigh skinfold) (Taggart et al., 
1967, Soltani and Fraser, 2000). What is not known is the precise anatomical 
distribution of gestational fat accumulation and how this may be linked to 
metabolic risk.  
In late pregnancy and the postpartum period, peripheral fat stores in the thighs 
and triceps are utilized to a greater extent (Sidebottom et al., 2001). In women 
who chose to breastfeed there was greater mobilisation of fat from the thighs 
compared to those who did not (Kramer et al., 1993).  In addition, for the 
women who did breastfeed, there was a reduction in waist hip ratio (WHR). This 
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was not found in women who did not breastfeed suggesting that breastfeeding 
improves utilisation of peripheral adipose tissue in the postpartum period 
(Kramer et al., 1993).  
 The impact of energy metabolism during pregnancy 1.6
There are important confounding variables which may play a role in fat 
accumulation and distribution. Basal metabolic rate as well as diet and exercise 
are important factors in fat accumulation in the general population. It would be 
anticipated that these aspects of energy metabolism would be important in body 
fat accumulation and distribution during pregnancy.  
For a well-nourished woman the energy costs of pregnancy can be considered as 
comprising of three components. First there is the energy cost of accumulating 
new tissue in the conceptus (including the fetus, placenta, amniotic fluid and 
the expansion of blood volume) approximated at 20 megajoules (MJ). Secondly, 
the energy required to deposit fat in mother and fetus (150 MJ), and finally the 
energy spent on maintaining this new tissue (150 MJ) (Prentice and Goldberg, 
2000). In order to support the energy cost of these three components, the 
maternal basal metabolic rate (BMR) must increase during pregnancy (Forsum 
and Lof, 2007). The timing of the reported increase in BMR varies, some authors 
suggest that this is concentrated in the third trimester – presumably as an 
anticipation to labour and breastfeeding (Lof et al., 2005). Other authors have 
found that the BMR increases throughout gestation (Butte et al., 2004), and that 
women with higher BMI have higher BMR. Further published data supports the 
theory that during pregnancy obese women show a significantly greater rise in 
their basal metabolic rate than non-obese women (Bronstein et al., 1996). This 
would seem logical as in the general adult population an increased BMI is 
associated with a rise in BMR. 
Previous assessment of maternal diet in pregnancy in humans has concentrated 
on the general obstetric population (Rogers and Emmett, 1998), the effect of 
social deprivation (Mouratidou et al., 2006) and maternal diet in the developing 
world (Cheng et al., 2009). These data, which largely predate the obesity 
epidemic, have been extremely informative in the context of healthy eating, but 
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little comparison of patterns of dietary intake in lean and obese pregnant 
populations has been performed.  
In the context of obese pregnancy, certain aspects of maternal diet are 
problematic, such as folic acid intake, iron status and essential fatty acid 
profile. Obese women are more at risk of having a pregnancy affected by neural 
tube defects, and high dose folic acid (5mg daily) has been shown to significantly 
reduce this risk (Super et al., 1991) and is now recommended (Fitzsimons and 
Modder, 2010). In the non-pregnant, obese women are more folate-deficient 
than leaner women (Laraia et al., 2007). Antenatal anaemia has been shown to 
be extremely common in a British teenage obstetric population and 29.2% of 
these women were overweight or obese (Baker et al., 2009). Fatty acids, 
especially LC-PUFA, are essential for the cell membrane synthesis and play 
important key roles in neural development and maturation in the offspring (Uauy 
et al., 2000). The fetus is dependent on maternal circulatory delivery of LC-
PUFA and the placenta expresses a number of fatty acid specific binding proteins 
which facilitate transport into the fetal system (Haggarty, 2002). In non-obese 
pregnancies complicated by pre-eclampsia and intrauterine growth restriction, 
maternal erythrocyte measurements of LC-PUFA (specifically n-6 and n-3) were 
over 50% lower than compared to healthy controls (Mackay et al., 2012). 
Recent guidance on the management of obese pregnancies (Fitzsimons and 
Modder, 2010), highlighted the need for advising women about the importance 
of a healthy diet during pregnancy. The only specific nutritional guidance for 
obese woman regarded increased supplementation of folic acid and vitamin D 
(5mg and 10ug daily respectively), and did not discuss other aspects including fat 
and complex carbohydrate consumption. 
British nutritional guidance (Vulliemoz et al., 2010) discusses dietary reference 
values (DRV) for energy intake and some micronutrients for pregnant women. 
Interestingly, the recommended increase in energy intake is only required in the 
third trimester 8117kilojoules [kJ] (1940 kilocalories [kcal]) to 8954kJ (2140 
kcal, which translates to an increase of 837kJ (200kcal) (DOH, 1991). There is no 
distinction for maternal age in the UK recommendations. Recommendations from 
Australian sources (nhmrc.gov.au, 2006) suggest that although there is no 
additional energy intake requirement in the first trimester, energy intake should 
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increase by 1400kJ (335 kcal) in the second trimester, and 1900kJ (454kcal) in 
the third trimester. Australian recommendations for energy requirements are 
calculated on predicted basal metabolic rate (BMR) multiplied by physical 
activity level (PAL) and are also related to body mass index (BMI) of the 
individual. Thus energy requirement in pregnancy would be 8100kJ, 9500kJ and 
10000kJ, and 7900kJ, 9300kJ and 9800kJ respectively for a 19-30 year old and a 
31-50 year old expectant mother across gestation.  
UK recommendations for daily protein intake suggest an increase from 45g/day 
to 51g/day. There are no specific values for the daily intake of carbohydrate and 
total fat and it is recommended that the proportion of energy derived from 
carbohydrate sources remains at 50% and from fat at 35%.  
The Food and Nutritional Board of the Institute of Medicine, published a series of 
guidance reports on DRV for nutrients in North America and Canada across all 
ages including pregnancy and lactation (IOM, 2002). During pregnancy, there 
should be an increase in daily protein (46g to 71g) and carbohydrate (130g to 
175g). Fat intake was not determined, on the basis that all individuals should try 
to keep their dietary intake of cholesterol, trans fatty acids and saturated fats 
to a minimum.  
Another aspect of energy metabolism which can have an impact on gestational 
weight gain and adipose tissue accumulation is physical activity during 
pregnancy. Guidance on physical activity during pregnancy encourages exercise 
on most days but not at maximum aerobic capacity (RCOG, 2006). Currently 
there is substantial interest in the benefits of exercise maintenance and 
commencement in pregnancy. Not only is aerobic exercise recommended but 
resistance training has been found to be safe and beneficial for pregnant women 
(White et al., 2013). Maintaining exercise programmes and even starting a new 
regimen during pregnancy has been suggested to decrease depression, anxiety 
and fatigue (Gaston and Prapavessis, 2013). In terms of physical health, authors 
have suggested that regular exercise in the second trimester of pregnancy may 
attenuate GDM-related complications such as fetal macrosomia and the need for 
caesarean section (Barakat et al., 2013). Investigation in mouse models has also 
suggested that exercise prevents placental vascular endothelial growth factor 
(VEGF) gene expression which may have an impact on angiogenesis and pre-
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eclampsia risk (Joles and Poston, 2010). The available data which focus on the 
impact of exercise and diet in obese pregnancy are limited (Gardner et al., 
2011). Interventional studies are ongoing (Poston et al., 2013) suggesting a 
change in dietary (lower glycaemic index and dietary saturated fat), rather than 
exercise alone may have beneficial effects. For obese women it has been 
suggested that there are many barriers (available time, concerns regarding fetal 
health) to taking part in an exercise programme. Obese women who were more 
likely to partake in exercise were psychologically more positive about the impact 
of exercise on their health and had better family and health professional support 
(Sui and Dodd, 2013). Novel factors which appear to improve involvement in 
exercise in maternal obesity such as dog walking activities have been suggested 
(Westgarth et al., 2012). 
As highlighted above, obese women have similar or smaller increases in 
percentage fat and total body fat mass than lean women (Kinoshita and Itoh, 
2006, Ehrenberg et al., 2003, Catalano et al., 1999, Soltani and Fraser, 2000, 
Okereke et al., 2004). It is not clear whether minimum gestational weight gain 
or perhaps loss of weight during pregnancy will necessarily improve metabolic 
profile and downstream consequences for obese women. In addition, healthy 
pregnant women store fat earlier in pregnancy despite little change in energy 
intake (O'Sullivan, 2009). Thus the location and timing of fat accumulation in 
pregnancy, its association with energy intake and expenditure and its impact of 
obesity and the subsequent metabolic syndrome of pregnancy has not been 
explored. 
Based on the above evidence diet, exercise and metabolic rate are significant 
confounding variables on total weight  and fat gain during pregnancy and may 
work with the above interventions or against them within the obese population. 
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 Changes in lipid and carbohydrate metabolism during 1.7
healthy pregnancy 
During pregnancy a multitude of complex alterations in lipid, carbohydrate and 
inflammatory metabolism take place in order to establish a healthy maternal 
adaptation to pregnancy. Early pregnancy is characterised by an anabolic state 
and late pregnancy by a more catabolic profile to optimise energy utilisation by 
the fetus for growth and development. As mentioned above, maternal fat mass 
increases significantly in the earlier stages of pregnancy when the fetal energy 
demands are less. This increase in maternal fat mass may be brought about 
partially by behavioural changes, including changes in activity and diet, but also 
as a result of a shift towards lipogenesis promoting the storage of adipose tissue. 
Plasma triglycerides increase gradually leading to a two- to three-fold increase 
in plasma concentration which peaks at term before falling to pre-pregnancy 
levels at six weeks post partum (Salameh and Mastrogiannis, 1994). Total 
cholesterol levels, including very low density lipoprotein (VLDL), LDL and HDL 
are increased by 50-60% by term and all lipoprotein particles have increased 
their cholesterol content by term (Salameh and Mastrogiannis, 1994).  In 
addition, in early pregnancy insulin sensitivity remains normal or slightly 
improved (Catalano et al., 1991). Together, along with the effects of oestrogen, 
progesterone and cortisol, adipose tissue accumulation is favoured (Huda et al., 
2009).  
 
Healthy pregnancy shows a progressive increase in insulin secretion with a 
decrease in insulin sensitivity which is approximately half of that of non-
pregnant women (Huda et al., 2009). A modest rise in fasting glucose levels is 
seen in line with the above adaptations but in healthy pregnancy this does not 
cross the threshold of GDM. Interestingly central obesity in early pregnancy has 
been shown to be linked to glucose intolerance in late gestation (Martin et al., 
2009). 
 
In late pregnancy, when fetal growth demands are at their maximum, the 
metabolic environment favours lipolysis and an insulin resistant profile that 
allows the mother to utilise fat as an energy source for labour and lactation and 
so the fetus can preferentially utilise circulating glucose for growth. In rat 
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models, there is an increase in mRNA expression hormone-sensitive lipase and a 
reduction in expression of lipoprotein lipase which promotes the rise in free 
fatty acids and glycerol seen in pregnancy (Martin-Hidalgo et al., 1994).  
 
 Vascular adaptation in healthy pregnancy 1.8
The maternal cardiovascular system undergoes many changes from early in 
pregnancy in order to meet to oxygen demands of both fetus and mother.  
By eight weeks’ gestation, cardiac output has increased by 20% and will increase 
by a further twenty percent by the third trimester. The change in cardiac output 
is facilitated by an increase in stroke volume but also by an increase in basal 
heart rate (Nelson-Piercy, 2006). However the primary vascular adaptation seen 
in pregnancy is peripheral vasodilatation. 
 
Longitudinal assessment of healthy pregnancies have shown a fall in blood 
pressure during the second trimester before a rise in the third trimester to pre-
pregnancy levels (Grindheim et al., 2012). The peripheral vasodilation which 
leads to the fall in blood pressure is mediated predominantly by endothelium- 
dependent factors which are upregulated by oestradiol and prostaglandins 
(Nelson-Piercy, 2006).  
 
Because endothelial dysfunction in the context of cardiovascular disease is 
systemic, assessing the peripheral circulation can be used as a surrogate marker 
for cardiovascular disease (Anderson et al., 1995). Peripheral microvascular 
function can be assessed by non-invasive or invasive techniques (Kasprzak et al., 
2006). Flow mediated dilation (FMD) by brachial artery ultrasonography and 
peripheral arterial tonometry (PAT) have been used to assess peripheral macro- 
and microvascular function respectively. Although these techniques have been 
found to correlate significantly with each other, FMD was found to be more 
reproducible (Onkelinx et al., 2012). Within pregnancy however, FMD did not 
reflect the vasodilatation seen as gestation progressed (Miyague et al., 2013). 
Peripheral arterial tonometry has also been shown to be less reliable in 
pregnancy as women were more vasodilated and therefore the change in the 
diameter of peripheral vessels during reactive hyperaemia was not observed 
(Carty et al., 2012). Other groups have focused on the use of laser doppler 
imaging (LDI) for microvascular assessment function in pregnancy. This 
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technique has been shown to be reproducible and reliable (Jadhav et al., 2007, 
Ramsay et al., 2002b, Ramsay et al., 2002a) This approach uses a vasodilator 
agent which is delivered transdermally by iontophoresis and the hyperaemia is 
then captured as an image by the laser. Published data have shown that in the 
third trimester obese women have a poorer response to acetylcholine (ACH) 
iontophoresis than lean women, indicating poorer endothelial dependent 
vasodilatation (Ramsay et al., 2002a). Further studies by the same group 
assessed microvascular function throughout gestation and found that although 
both lean and obese women exhibited improvement in endothelial microvascular 
function, obese women started pregnancy with pre-existing endothelial 
dysfunction and did not show as much improvement across gestation as lean 
women (Stewart et al., 2007a).  
 
It is well documented that during pregnancy there is a significant improvement 
in endothelium dependent vascular function (Ramsay et al., 2002a, Stewart et 
al., 2007a, Dørup et al., 1999). In healthy pregnancy, the improvement in 
endothelial function is thought to be related in part to increased nitric oxide 
activity which contributes to the fall in peripheral resistance in the systemic 
vascular system (Anumba et al., 1999). In healthy premenopausal women 
oestrogen has a protective role on vascular health (Barrett-Connor, 2013). It has 
been reported that in human endothelial cells the G protein-coupled estrogen 
receptor (GPER) is found in intact intracellular membranes and enhances eNOS 
activation and NO formation which may provide a pathway for oestrogen 
mediated vascular protection (Meyer et al., 2014). In addition, oestrogen has 
been shown to attenuate the effects of vascular injury by inhibiting the 
expression of TNFα and the cascade of inflammation via the  NFκB signalling 
pathway (Xing et al., 2009). In pregnancy plasma oestrogen concentration rises 
(Branch, 1992) and therefore the above mechanism may also promote an 
improvement in vascular function.  
 
In adult populations vascular remodelling and improvement has been stimulated 
by shear stress at the level of the blood vessel (Rodríguez and González, 2014), 
and it has been suggested that this pathway can be promoted through regular 
exercise (Kim et al., 2014). In vitro studies have compared subcutaneous 
arteries from pregnant and non-pregnant women subjected to shear stress 
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indicated that in pregnancy there is greater relaxation of these vessels (Cockell 
and Poston, 1997), which is suggested as an important mechanism for the fall in 
peripheral resistance during pregnancy.   
 
Valdes et al comprehensively described the additional factors which are thought 
to play a part in the improvement in pregnancy related endothelial function, 
such as prostacyclin, kallikren, angiotensin and VEGF which appear to inhibit 
vasoconstriction pathways (Valdes et al., 2009).  
 
 Clinical impact of maternal obesity 1.9
The increase in maternal obesity is now well established in the pregnant 
population and obstetric practice, with an estimated one in five pregnant 
women being obese in the UK (Heslehurst et al., 2010). Epidemiological data 
from Scotland has indicated that the incidence of maternal obesity in the 
obstetric population has doubled, rising from 10% to 19% over a ten year period 
(Kanagalingam et al., 2005).  Similar trends have been seen in American 
populations with a rise of almost 70% in the rate of maternal obesity from 1993 
to 2003 (Kim et al., 2007). The impact of maternal obesity on maternal mortality 
rates was highlighted in 2007, when it was estimated that 15% of women who 
died from causes directly related to pregnancy were obese (CEMACH, 2007). 
More recent reports indicate that 30% of mothers who died from pregnancy 
related causes were obese (CEMACH, 2011). Despite the fact that maternal 
mortality remains very low in the UK, this is a startling figure to see in black and 
white. 
The increased rate of maternal obesity has had ramifications for all aspects of 
female reproduction, with maternal adiposity being strongly associated with an 
increase of essentially all maternal and fetal complications (table 1.2). 
Observational studies have demonstrated that obesity in pregnancy increases the 
risk of antenatal complications such as GDM, pregnancy induced hypertension 
and PET (Gate and Ramsay, 2007). Furthermore, data examining the impact of 
obesity in women under the age of 19 showed a stepwise increase in the risk of 
pre-eclampsia and gestational diabetes (Sukalich et al., 2006) with increasing 
BMI. It is a concern that such a young population, with a long reproductive 
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potential, are exhibiting such serious obstetric complications at this age. In 
addition, an increase in BMI between pregnancies has been highlighted as a risk 
factor for PET, gestational hypertension, GDM, caesarean section and large for 
gestational age birth weight in a subsequent pregnancy (Villamor and 
Cnattingius, 2006).  
The risk of other pregnancy-related complications such as venous 
thromboembolism, caesarean section, postpartum haemorrhage, surgical wound 
infection, post-operative endometritis and prolonger hospital stay are all 
increased in maternal obesity (Jarvie and Ramsay, 2010).  For the fetus, there 
are increased risks of fetal anomalies, birth trauma, neonatal tachypnoea and 
admission to the neonatal high dependency units (Gate and Ramsay, 2007, Jarvie 
and Ramsay, 2010).  
Consequently the increased risk of maternal and neonatal complications 
secondary to maternal obesity results in a significant rise in socioeconomic costs 
(Chu et al., 2008).  
Table 1.2 - Potential effects of maternal obesity. The table below is adapted from Jarvie E & 
Ramsay J, Obstetric management of obesity on pregnancy Semin Fetal Neonatal Med.(2010) and 
illustrates the impact of maternal obesity at all stages of a woman’s reproductive life. 
  Medical Complications  Technical 
Complications 
Pre-pregnancy   Menstrual disorders   
 Infertility   
Early-pregnancy   Miscarriage  Difficult Ultrasound 
Examination 
 Fetal Anomalies   
Antenatal  Pregnancy induced 
Hypertension 
 Auscultation of the 
fetal heart 
 PET   
 GDM   
 Venous Thromboembolic 
Disease 
  
Intrapartum  Increased induction of 
labour 
 Operative issues 
surgical access 
restrictions, increased 
time of surgery and 
increased blood loss 
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 Caesarean Section 
(elective & emergency) 
 Anaesthetic issues – 
difficulties siting 
regional anaesthesia, 
increased failed 
intubation risk 
Intrapartum fetal 
monitoring  
Postpartum  Haemorrhage   
 Infection   
 Venous Thromboembolic 
Disease 
  
Fetal  Macrosomia  Birth injury 
 Fetal Distress   
 Perinatal 
Morbidity/Mortality 
Reduced breast feeding 
rate 
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 Obesity and the metabolic syndrome of 1.10
pregnancy 
Maternal obesity is linked to increased perinatal complications and there is a 
body of literature as mentioned which suggests that obese women gain weight in 
central body compartments. This suggests that obese women are at risk of 
developing the metabolic syndrome as pregnancy progresses. As metabolic 
syndrome increases the risk of cardiovascular disease and diabetes in the general 
adult population due to dysregulated fatty acid metabolism and lipotoxicity, 
then in pregnancy, lipotoxicity potentially may be a factor in the development 
of hypertensive disorders and GDM. 
Cross sectional studies have indicated that in the third trimester of obese 
pregnancies there is exaggerated hypertriglyceridaemia associated with an 
abnormal lipid profile (high VLDL, low HDL concentration), hyperinsulinaemia 
and increased inflammation (Ramsay et al., 2002a). From early pregnancy, it has 
been observed that obese mothers are less insulin sensitive than overweight and 
normal weight mothers (Catalano et al., 1999, Catalano and Ehrenberg, 2006). 
Further studies have confirmed that, in early pregnancy, obese women had 
higher triglycerides, increased insulin resistance and higher markers of 
inflammation compared to lean women (Stewart et al., 2007a). In addition 
gestational CRP levels in pregnancy were significantly correlated to pre-
pregnancy BMI (Retnakaran et al., 2003). High levels of inflammatory markers, 
such as CRP, correlate with impaired endothelial function which may partly 
explain the altered vascular function seen in obese pregnancy (Retnakaran et 
al., 2003). It is unclear whether this is established before pregnancy, with obese 
women entering pregnancy with a more pro-inflammatory and insulin resistance 
profile or if there is an exaggerated adaptive response early in gestation. 
The abnormal lipid profile in obese pregnancy also includes higher plasma levels 
of LDL (Ramsay et al., 2002a) particularly of smaller size (Meyer et al., 2013). In 
addition, the ease at which LDL is oxidised has been shown to directly correlate 
with maternal BMI (Sánchez-Vera et al., 2007) this  may be related to an 
increased proportional of readily oxidisable small, dense LDL. Interestingly in 
obese women with GDM the relationship between LDL oxidisability and BMI was 
strengthened indicating the high risk nature of GDM and also suggesting that 
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obesity lowers the threshold of the lipotoxic effect of LDL (Sánchez-Vera et al., 
2007). When metabolic risk factors (such as insulin resistance, low HDL and 
raised triglycerides) were measured in early pregnancy, they were found to 
correlate more strongly with visceral fat thickness than BMI (Bartha et al., 2007) 
suggesting that body fat distribution in pregnancy plays a key role in the 
production of lipotoxic biomarkers. 
 
Figure 1.1 Maternal metabolic syndrome. Schematic representation of the effect that maternal 
obesity has on metabolic and inflammatory pathways which may explain the increased risk of 
hypertensive disorders observed in obese pregnancies 
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 Oxidative stress in pregnancy 1.11
Oxidative stress has been linked to microvascular damage. A number of 
molecules have been suggested as markers of oxidative stress (Matsuura et al., 
2006) such as ROS and lipid peroxides. It has been proposed that in maternal 
obesity the poorer endothelial improvement is related to a pathway of increased 
plasma lipids with the promotion of oxidative stress (Vincent and Taylor, 2005). 
Endothelial dysfunction can be measured by the physiological and ex vivo 
methods suggested above but also by looking at in vivo biomarkers of endothelial 
activation such as sVCAM-1 and sICAM-1 which have been found to be elevated in 
pre-eclamptic pregnancies (Farzadnia et al., 2013), where endothelial damage is 
a hallmark of the disease. 
 
The impact of pregnancy on the levels of lipid peroxides has been reviewed 
previously (Little and Gladen, 1999) and the data are rather equivocal. When 
compared to non-pregnant controls, lipid peroxides in the first trimester were 
sometimes higher and sometimes lower in the pregnant group. By the second 
trimester there was an observed increase of 10-50%, and in the third trimester 
these levels sometimes fell. When compared with healthy pregnancies, all 
diabetic women (including type 1, type 2 and GDM) had higher levels of lipid 
peroxides, which may be related to the increased risk of vascular complications 
in pregnancy associated with diabetes (Toescu et al., 2004). Lipid peroxidation 
products have been noted to be markers of oxidative stress (Niki, 2008). In 
circumstances where there are elevated fatty acids and triglyceride 
concentrations – as in obese pregnancy – lipid peroxidation may be enhanced 
leading to increased oxidative stress and subsequent endothelial damage. High 
lipid peroxide levels were particularly apparent in pregnant women with type 2 
diabetes– a population characterised by a predisposition to central obesity 
(Toescu et al., 2004).  
The LDL-III subfraction of cholesterol is a readily oxidised form (Griffin, 1999), 
which can be a potential source of lipotoxic oxysterols for both the fetus and the 
mother although data is limited. In maternal obesity, approximately a third of 
women had at least 50% of LDL in the smallest fraction LDL-III, indicative of an 
atherogenic phenotype, compared to lean women who had no LDL in the LDL-III 
fraction (Meyer et al., 2013). It is possible that in the context of maternal 
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obesity, this lipoprotein is an important factor in the development of 
lipotoxicity. 
The literature on oxysterols during pregnancy is limited. Gestational increases in 
(7-ketocholesterol, 7 alpha and 7 alpha-hydroxycholesterol and the total sum of 
5 alpha, 6 alpha and 5 beta, 6 beta-epoxycholesterols) have been reported in 
healthy pregnancy, most notably in the second and third trimester, and 
oxysterol levels are higher in pregnancies in women with type 1 diabetes 
(Bodzek et al., 2002). In non-pregnant type 2 diabetics, high plasma oxysterol 
levels are particularly observed when plasma LDL levels are above 3.62mmol/L 
(Endo et al., 2008), and LDL concentrations frequently exceed this level in 
overweight and obese women in late gestation (Stewart et al., 2007a, Ramsay et 
al., 2002a).  
Oxysterols can bind and activate both the LXRα and LXRβ receptors which are 
important regulators of lipid and cholesterol metabolism (Jakobsson et al., 
2012). Furthermore (Peet et al., 1998) oxLDL can inhibit trophoblastic invasion 
via interaction with LXRβ receptors expressed by human placenta. Oxysterol 
activation of the LXRβ receptor could contribute to the observed increase in 
placental complications such as intrauterine growth restriction (IUGR) and PET in 
obese pregnancy (Pavan et al., 2004).  
 
In summary, there are significant data which suggest that the biomarkers of 
lipotoxicity may be linked to endothelial dysfunction in the mother and 
placenta. Interestingly, little research has looked at the gestational changes in 
these markers of lipotoxicity and their impact on microvascular function in 
pregnancy. In addition, what is not explored in the current literature is whether 
differences between lean and obese women can be explained by either the 
presence of central adiposity at the beginning of pregnancy or the accretion of 
adipose tissue in the central distribution during gestation.  
 
  
Chapter 1  48 
 Consequences of lipotoxicity in pregnancy 1.12
Obese women enter pregnancy with poorer overall vascular function compared 
to lean women (Stewart et al., 2007a). In addition, during pregnancy although 
both lean and obese women showed an improvement in vascular function, the 
endothelium- dependent microvasculature improvement was blunted in obese 
pregnancies (Stewart et al., 2007a). A high risk group for early onset coronary 
artery disease is women with familial hypercholesterolaemia, an autosomal 
dominant condition characterised by elevated LDL, tendon xanthomas and 
premature death (Austin et al., 2004). Women with familial 
hypercholesterolaemia exhibit increased lipid levels, pro-coagulant activity and 
enhanced endothelial activation during pregnancy (Amundsen et al., 2007). This 
high-risk group also exhibits a reduction in uterine blood flow during pregnancy 
which indicates increased uteroplacental vascular resistance with subsequent 
risk of PET and IUGR (Khoury et al., 2009). As well as an intrinsic elevated 
cholesterol concentration, in a mouse model of PET it has been shown that a 
high fat diet can lead to higher levels of fat infiltration in the maternal liver 
(Sun et al., 2012). However, early onset pre-eclampsia tends to have a more 
severe clinical impact and thus these findings may not be applicable to other 
gestational hypertensive disorders. However, these findings do support 
dysfunctional lipid metabolism consistent with the development of lipotoxicity in 
early onset PET.  
In pregnancies which are complicated by GDM, women are insulin resistant and 
hyperlipidaemic (Catalano et al., 1999). This group show evidence of increased 
oxidative stress where the degree of hyperglycaemia correlates with lipid 
peroxide concentrations (Chen and Scholl, 2005). Pregnancies affected by GDM 
are also found to have poorer endothelial function than control women (Paradisi 
et al., 2002).  
 
Although these are two examples of extreme metabolic conditions (GDM and 
familial hypercholesterolaemia), in conjunction with the data in the non-
pregnant population relating high lipid levels to oxidative stress and endothelial 
dysfunction, the evidence suggests that lipid abnormalities arising from NEFA 
excess could contribute to the observed endothelial dysfunction of obese 
pregnancy.  
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 The potential impact of lipotoxicity on offspring 1.13
health 
Babies born to overweight and obese mothers have been noted to have 
significantly more total fat mass than babies born to mothers of normal weight 
(Hull et al., 2008). In addition to having more body fat, babies of obese mothers 
have been shown to have significantly higher levels of insulin resistance 
(expressed as HOMA) and inflammation (IL6 levels) in umbilical cord blood 
samples obtained at delivery compared to the offspring of lean women (Catalano 
et al., 2009). If these babies are already born with a degree of insulin resistance 
and chronic inflammation there may to a propensity to childhood obesity and the 
development of vascular dysfunction in later life (Freeman, 2010). In terms of 
fetal complications, excessive GWG was strongly correlated with the incidence 
of babies born small or large for gestational age and the risk of an unplanned 
caesarean section. Interestingly, excessive GWG-associated risk of excessive 
fetal growth and large for gestational age babies was linear even within cohorts 
of women who were of a normal weight (Dietz et al., 2009).  
 
It is now recognised that the intrauterine environment has the potential to 
impact on early fetal growth and development and subsequent adult ill-health, 
including potential programming of future obesity (Freeman, 2010, Catalano, 
2003). Placentae from obese pregnancies have shown accumulation of 
macrophages and increased expression of the inflammatory cytokines IL6, TNF-α, 
IL1 and increased infiltration of CD14+ cells (Challier et al., 2008). In addition, 
maternal plasma levels of CRP have been shown to be positively associated with 
the presence of atherosclerosis in childhood aortic samples (Liguori et al., 2008).  
It is not only within the maternal and fetal circulation that lipotoxicity may 
exert an effect. The LXR receptors have been proposed to be important in 
placental cholesterol transport from the mother to the fetus (Plosch et al., 
2007). The LXRα and LXRβ receptors have been detected in early gestation 
placental tissue (Marceau et al., 2005) and could act as a binding site for 
oxysterols within the placenta. Oxysterols have shown a high affinity to the LXRα 
receptor and through this mechanism may prevent the esterification of 
cholesterol, leading to a further build up of oxysterols (Bjorkhem and Diczfalusy, 
2002). Oxidised LDL contains a high proportion of oxysterols, and these have an 
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affinity to the LXRβ receptors. Through activation of these receptors, oxysterols 
and this oxidised LDL have been shown to inhibit trophoblastic cell invasion in 
human in vitro models (Pavan et al., 2004). Inhibition of trophoblast cell 
invasion would have serious consequences not only for successful early 
embryonic development but for maintenance of a healthy pregnancy across 
gestation. However, oxysterols are involved in important pathways such as sonic 
hedgehog signalling proteins, and deficiencies with in these pathways can lead 
to fetal structural anomalies such as Smith–Lemli–Opitz syndrome (Javitt, 2007).  
In women with type 1 diabetes, a hyperlipidaemic group with a significant 
increased risk for fetal anomalies, there were 49 alterations in gene expression 
at important stages of placental energy metabolism. (Radaelli et al., 2009). Two 
thirds of these alterations took place within lipid pathways and 9% in regulatory 
glucose pathways. In addition, this data also studied placentae from women with 
GDM which suggested that the genes responsible for fetoplacental lipid 
metabolism were also unregulated when compared to non-diabetic pregnancies. 
In term primary trophoblast cells, raised insulin and NEFA levels enhance the 
formation of fatty acid droplets within the placentae (Elchalal et al., 2005). In 
the fetuses of non-diabetic women with established hypercholesterolemia there 
were significantly more aortic atherosclerotic plaques associated with oxidised 
LDL in monocytes (Napoli et al., 1997). The presence of LDL in the intima of 
these aortic samples suggests that risk of cardiovascular disease is established in 
utero.  
In both human and animal models, the placentae could be a site of fatty acid 
accumulation. In an early onset pre-eclamptic mice models, placental histology 
has shown an increased in lipid deposition when the dams were exposed to a 
high fat diet (Sun et al., 2012). In human studies, placentae from obese women 
have shown a greater accumulation of lipid in placental macrophages in an 
analogous way to adipose tissue (Challier et al., 2008). Thus the placenta may 
act as a site for ectopic fat accumulation in obese pregnancy similar to skeletal 
muscle, liver and brain seen in adult obesity.  In non-human animal models a 
diet which is high in cholesterol can lead to lipotoxicity of the fetal liver 
(McCurdy et al., 2009). Interestingly, changing the maternal diet to a low fat 
version improved fetal triglyceride levels, indicating how vulnerable fetal end 
organs are to lipotoxicity.  
Chapter 1  51 
 The utility of maternal BMI as an indicator of 1.14
high risk pregnancy 
One in five women of reproductive age is obese, and obstetric clinics often have 
an antenatal obstetric population where over 20% of patients are obese 
(Heslehurst et al., 2010) with significant socioeconomic costs directly 
attributable to the increased risk of maternal and neonatal complications. The 
current lack of understanding as to how, where and when mothers put fat on 
during pregnancy makes it difficult to advise obese mothers how to manage their 
weight during pregnancy. However, not all obese women are at risk of 
developing antenatal and fetal complications linked to their obesity (Jarvie and 
Ramsay, 2010) (table 1.2), and in addition, a smaller but still significant number 
of lean women may develop metabolic complications of pregnancy. Direct 
evidence for lipotoxicity, which may only occur in a proportion of obese 
pregnancies, which may link maternal obesity and placentally-related adverse 
pregnancy outcome, is lacking. The placenta may transmit metabolic 
abnormalities resulting from lipotoxicity to the offspring via in utero 
programming and hence there could be far-reaching consequences for offspring 
health. 
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Figure 1.2 Summary of the potential obstetric complications associated with maternal 
obesity. The diagram illustrates the increased incidence of metabolic obstetric complications which 
are more common in obese pregnancy, but still occur in a lean obstetric population. These 
complications include both maternal and fetal conditions which are explained in the figure key for 
reference. 
 
Identification of women who are at risk of lipotoxicity-mediated pregnancy 
complications is required in order to ensure that additional antenatal 
surveillance is focused on the group of women who are at increased risk of these 
obstetric complications. Research in the field of cardiovascular and diabetic 
medicine suggests ways of manipulating lipid metabolism using both lifestyle and 
pharmacological interventions that may have potential utility in obese 
pregnancy. Because of the potential for harm to both mother and baby, a study 
of the degree, causes and impact of lipotoxicity in obese pregnancy is warranted  
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 Hypothesis 1.15
The 70-100% increase in maternal obesity over the last decade has had 
ramifications for all aspects of female reproduction, with maternal adiposity 
strongly associated with an increased risk of maternal and fetal complications. 
Our hypothesis is that in lean pregnant women, fatty acids required for fetal 
growth are efficiently stored and mobilised from lower body fat depots. In obese 
pregnant women, lower body fat depots are replete and/or there is a preference 
to store fat centrally with the potential of fatty acid spillover and lipotoxicity. 
Lipotoxicity can be defined as the vascular, metabolic and ultimately clinical 
manifestation of excessive plasma fatty acids and ectopic fat deposition. In this 
thesis we suggest that it is lipotoxicity which leads to maternal endothelial 
dysfunction, decreases trophoblast invasion and influences placental metabolism 
and function (figure 1.3) 
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This is the pathological link between maternal obesity and adverse “metabolic” 
pregnancy outcomes such as pregnancy-induced hypertension and PET and may 
have consequences for the programming of obesity in the offspring. 
 
 
Figure 1.3 Fatty acid metabolism in pregnancy. The figure above is adapted from Jarvie E et al 
‘Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and obesity in 
the offspring’, Clin Sci (Lond). 2010. Central fat accumulation during pregnancy leads to fatty acid 
overspill from adipose depots and lipotoxicity. Lipotoxic effects include maternal endothelial 
dysfunction, decreased trophoblast invasion and altered placental metabolism. These may result in 
adverse pregnancy outcome (such as pre-eclampsia or miscarriage) and programming of obesity in 
the offspring. A lower-body fat accumulation allows ‘safe’ storage of fatty acids and a normal 
metabolic and physiological adaptation to pregnancy with appropriate nutrient transfer to the 
offspring. 
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 Study aims and objectives 1.16
The aim of the study reported in this thesis was to assess the impact of 
anatomical fat distribution and accumulation throughout pregnancy in both lean 
and obese women and examine its importance on metabolic and vascular 
function. Biomarkers of lipotoxicity and vascular function will be considered the 
consequence of this process. 
 
Objective 1 (Chapter 3) 
To carry out detailed anthropometric assessment of lean and obese women 
during pregnancy in order to test the hypothesis that the anatomical variation in 
accumulation of subcutaneous adipose tissue in lean and obese women is 
different and that this has an impact on the metabolic response seen in 
pregnancy.  
 
Objective 2 (Chapter 4) 
To assess different aspects of energy metabolism in lean and obese women 
throughout pregnancy to assess whether differences exist between lean and 
obese pregnancies and if this relates to adipose tissue accretion and distribution 
during gestation. To record measurements of BMR, substrate utilisation, physical 
activity and diet throughout pregnancy.  
 
Objective 3 (Chapter 5) 
To assess whether gestational changes in markers of lipid and carbohydrate 
metabolism and inflammatory status are related to site of body fat accumulation 
in pregnancy. Plasma concentrations of biomarkers of carbohydrate (fasting 
glucose, fasting insulin), lipid (total cholesterol, total triglyceride, HDL and 
NEFA) metabolism and inflammatory profiles (CRP, IL6, TNF) will be 
quantitated. 
 
Objective 4 (Chapter 6) 
To examine the impact of anatomical fat accumulation during pregnancy on the 
gestational improvement of vascular function and markers of lipotoxicity. To 
explore whether a difference in body fat distribution between lean and obese 
women in combination with lipotoxicity may be a mechanism for any differences 
in vascular function between these groups.  
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Chapter 2 - General Methods 
2.1 Introduction 
This chapter discusses the inclusion and exclusion criteria, the formulation of 
the patient information leaflets and the recruitment process itself. The next 
section in this chapter describes each of the investigation techniques employed 
and the protocols which were used in the study. This study was reviewed and 
approved by the West of Scotland Research Ethics Committee 3 (REC reference 
09/S0701/105), and Greater Glasgow & Clyde NHS Research and Development 
(R&D reference GN09KH553).There were no competing interests. 
 
2.1.1 Inclusion & exclusion criteria 
Healthy Caucasian women between the ages of 16-40 years with no significant 
past medical history were invited to participate in this study. The cohort 
recruited was further selected based on BMI – either less than 25kg/m2 or greater 
or equal to 27kg/m2. The BMI groups were widened (initially <25kg/m2 and > 30 
kg/m2) after the rate of recruitment to the obese group remained poor despite 
adequate study publicity and additional assistance with recruitment. 
 
Parous women with previous healthy pregnancies with no obstetric or fetal 
complications were not excluded from participation. This was decided after 
discussion with senior Obstetricians, as it was felt that a previous healthy 
pregnancy would not have an impact on the index pregnancy. However, any 
women was excluded if they had suffered a previous fetal loss beyond 12 weeks’ 
gestation or a miscarriage of any gestation secondary to fetal anomaly (e.g. 
Edward’s syndrome) or complex maternal condition (e.g. confirmed 
thrombophilia).  
 
Women with known metabolic disease such as diabetes mellitus, thyroid disease 
or polycystic ovarian syndrome (PCOS) and cardiovascular disease were excluded 
from recruitment as these women are known to have higher risks of metabolic 
disease in pregnancy.  
Pregnancies achieved through assisted conception, including ovulation induction 
were excluded because of the potential link with anovulatory infertility and 
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PCOS. Women with multiple pregnancies were also excluded from the study as 
these pregnancies are generally more high risk for PET (Duckitt and Harrington, 
2005) and gestational diabetes (Santolaya and Faro, 2012).  
 
Any women who developed an obstetric antenatal complication in the current 
study were excluded from analysis retrospectively.   
Table 2.1 study inclusion criteria and rationale  
Criteria Rationale 
 
Parous or primigravid women 
 
 
 
maternal age 
 
 
Two groups BMI<25 and BMI>27 
 
 
 
 
 
Caucasian 
 
 
uncomplicated previous obstetric 
history or primiparity will have no 
effect on index pregnancy 
 
poorer outcomes out with 16-40 years 
of age 
 
Established poorer outcome and 
greater obstetric risk in overweight 
obese pregnant population  
(CEMACH, 2007)  
WHO criteria for obesity(WHO, 2004) 
 
Predominant ethnic group in Glasgow 
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2.1.2 Recruitment 
Women who booked their pregnancies at either the Princess Royal Infirmary or 
the Southern General Hospital in Glasgow were recruited at their first antenatal 
appointments (12-14 weeks’ gestation).  
 
Suitable women were identified at the initial antenatal appointment by either 
the midwifery team or the researcher (Eleanor Jarvie). Following the 
confirmation of a continuing intrauterine pregnancy and gestational age by 
ultrasound the potential participants had their BMI calculated (routine clinical 
practice). If this was within the criteria for the study, the participants had a 
short consultation with the researcher regarding the study and were issued with 
an information sheet (Appendix I). A contact number was taken for the potential 
subject to allow them time to read the sheet and decide whether they wished to 
participate. Each potential study participant was contacted by the researcher 
and a date for the first study visit was arranged. This was followed up with a 
letter and a phone call prior to the visit 1 date to confirm the appointment. 
Figure 2.1 illustrates the recruitment and retention of participants to the study. 
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Figure 2.1 Flow diagram of recruitment to study. Figure illustrates the number of participants 
recruited to the study and the number of participants who attended each of the gestational and 
postnatal appointments. For each gestational time point the participants excluded or those lost to 
follow up are included. The abbreviation,.’DNA’ refers to ‘did not attend’.  These women arranged a 
first visit but did not take part in the study. Indicated in the diagram is also the delivery data and 
delivery specimens which were obtained. 
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2.1.3 Study Design 
All women underwent the same study appointment protocol throughout the 
study (figure 2.2, appendix II). Each study participant attended the Metabolic 
Suite (West Medical Building, University of Glasgow) at 0800 after an overnight 
fast (participants were advised not to eat after 22:30 the previous night and to 
only drink water) to undergo assessment. Each participant was asked to attend 
three antenatal appointments at approximately 15, 25 and 35 weeks’ gestation 
and one postnatal visit at approximately 12 weeks postpartum.  
 
At the initial appointment a consent form (appendix II) was completed, the 
participant retained a copy and one was kept by the researcher separately from 
all other visit documentation. At the start of each study appointment the 
participants’ general medical, obstetric, family, social and medication histories 
were taken (See appendix II for visit documentation). At visits 2, 3 and 4 
documentation was updated on any medical or pregnancy-related health 
problems which had occurred since the last appointment to ensure that the 
subject was still suitable to be in the study 
.  
Figure 2.2 Study appointment protocol. Detailed above is the protocol time line for study 
participants, including assessments performed at each visit and tissue samples to be obtained 
at delivery 
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2.2 Anthropometric Measurements 
2.2.1 Maternal height 
Maternal height was measured by the research nurse or the researcher using a 
stadiometer (Invicta Plastics Ltd, Leicester, UK). The same stadiometer was used 
for each study participant. The participant was measured without shoes standing 
with their back and head touching the vertical board and ensuring that the legs, 
back and head were straight and the feet were flat. The measurements were 
recorded with participant positioned and relaxed and a moveable horizontal 
headboard was lowered onto the head with light pressure maintaining the head 
in the neutral position. The measurements were recorded to the nearest 0.01 
metre. 
 
2.2.2 Maternal body mass 
Maternal body mass was measured using a calibrated integral system which was 
part of the BODPOD chamber (COSMED USA Inc, Concord, USA) (see 2.2.5 for 
details). The same scale was used for each study visit and was periodically 
calibrated using a 20kg weight as per the manufacturer’s guidelines. Study 
participants were asked to change into shorts and a vest top or similar minimal 
clothing and were supplied with a swimming cap. Additional clothing and 
jewellery was removed prior to measurement recording. Their weight was then 
measured with them standing on the scales for 20 seconds prior to entering the 
BODPOD chamber. Measurements were recorded to the 0.01kg. 
 
2.2.3 Maternal circumference measurements 
All maternal circumference measurements were performed by the researcher in 
a private setting with the research nurse present documenting the 
measurements. Measurements were recorded to the nearest 0.1cm using a 
plastic tape measure. Circumference measurements were taken with the stub of 
the tape controlled in the left hand using the cross-hand technique and with the 
right hand stabilising the tape at the correct anatomical point for measurement. 
All circumference measurements were performed with the subject standing. The 
two waist measurements were taken at the end of expiration with the abdominal 
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muscles relaxed. Waist and hip circumferences were measured with the 
participant’s feet together and gluteal and midthigh circumference 
measurements were measured with the study participant’s feet shoulder width 
apart and weight evenly distributed across both feet. 
 
Minimum waist circumference was measured at the narrowest point of the 
abdomen between the lower costal edge and the anterior superior iliac spine. 
Umbilical waist circumference was measured the level of the umbilicus. Hip 
circumference was measured as the circumference of the buttocks at the level 
of their greatest protuberance. Two thigh measurements were performed; 
gluteal thigh circumference was measured 1cm inferior to the gluteal fold and 
midthigh circumference was measured at the midpoint between the inguinal 
crease and the proximal edge of the patella (the same point as the midthigh 
skinfold). 
 
Each circumference was recorded twice and the mean was calculated to be used 
for analysis. If a difference of >0.5cm was found a third measurement was 
performed and the mean of the two closest measurements was used for analysis.  
 
The researcher underwent anthropometric training with a Level 3 ISAK 
(International Society for the Advancement of Kinanthropometry 
www.isakonline.com) Instructor. Prior to commencement of the study the 
researcher performed a validation series on healthy volunteers to assess 
technique. To achieve basic competency (ISAK level 1) required a technical error 
of the mean (TEM) of circumference measurements to be less than 1.5%. TEM 
variations for each circumference were waist umbilicus 0.7%, hips 0.5%, gluteal 
thigh 0.3% and midthigh 0.4%. 
 
2.2.4 Maternal skinfold thickness measurements 
All measurements of skinfold thickness were performed by the researcher in a 
private setting with the research nurse present documenting the measurements.  
Measurements were recorded to the 0.2mm using Holtain skinfold callipers 
(Holtain Ltd, Crymych UK) or Harpenden skinfold callipers (Cranlea & Company, 
Birmingham, UK) when the skinfold was greater than 40mm.  
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Seven skinfold thickness sites were measured during this study. These sites were 
based on published work validating the use of skinfold measurement in 
calculating subcutaneous adipose tissue and total fat in pregnancy (Presley et 
al., 2000). The skinfold was held between the thumb and the index finger of the 
left hand and the callipers applied with the right hand. The callipers were held 
in place for 20 seconds at every measurement throughout the study. The 
rationale for this technique was to minimise the impact of interstitial oedema 
observed in late gestation. This phenomenon occurs to a different extent in most 
women so for consistency this technique was applied to all measurements 
performed.  
 
All skinfolds were measured on the left hand side of the body. The study 
participant was standing for the assessment of triceps, biceps, subscapular, 
costal and suprailiac skinfolds and was sitting with the left leg horizontal and 
supported at the knee and ankle for midthigh and suprapatellar recordings. The 
triceps skinfold was measured at the midpoint between the acromion process of 
the shoulder and the olecranon of the elbow in the longitudinal plane. The 
biceps skinfold was measured at the midpoint between the acromion process and 
the antecubital fossa in the longitudinal plane. The subscapular skinfold was 
measured medial to distal border of the scapular at 45° to the vertical plane. 
The costal skinfold was measured at the inferior border of the costal margin in 
the midaxillary line in the horizontal plane. The suprailiac skinfold was 
measured at the midpoint between the anterior superior iliac spine and the 
lower edge of the costal margin in the vertical plane. The midthigh skinfold was 
measured on the front of the thigh at the midpoint between the inguinal crease 
and the proximal edge of the patella in the vertical plane. The suprapatellar 
skinfold was measured at the proximal border of the patella in the vertical 
plane. The researcher stood behind the participant for the triceps and 
subscapular measurements, on the left hand side of the study participant for the 
costal, midthigh and suprapatellar measurements and in front of the study 
participant for the biceps and suprailiac measurements. 
 
Each skinfold measurement was recorded twice and the mean measurement used 
for analysis. If a difference of 0.8mm or above existed between the recordings 
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then a third measurement was performed and the mean of the two closest 
measurements recorded used for analysis.  
 
A similar validation set based on ISAK level 1 competencies was performed for 
skinfold measurements and the TEM was required to be <7.5% for each skinfold. 
TEM variations for each of the skinfolds were triceps 1.8%, biceps 3.8% 
subscapular 2.4%, costal 3.5%, suprailiac 4.8%, midthigh 2.2% and suprapatellar 
2.5%. 
 
2.2.5 Air Displacement Plethysmography 
Each subject underwent ADP, using the commercially available BODPOD system 
(COSMED USA Inc, Concord, USA), which calculates fat mass, fat free-mass and 
percentage body fat. The detailed principles of ADP have been reported by 
Dempster and Aitkens (Dempster and Aitkens, 1995). ADP works on the principle 
of Boyle’s law, stating that within a fixed volume a change of mass will cause a 
change of pressure within that fixed volume. This allows for measurement of 
body volume which is corrected for predicted lung volume based on age and 
height. From this measurement body density (DB) is calculated and fat mass and 
fat-free mass (two compartment model) can be derived using Siri’s equation: 
 
  
 WFM (kg) = WB/100 x (495/DB – 450)   (equation 2.1)  
 
Where WFM is fat mass in kilograms, WB is body weight in kilograms and DB is body 
density in kg/m3. 
 
Subjects were measured in the fasting state wearing either a bathing suit or 
tight fitting shorts and vest top and an acrylic bathing cap. The subjects’ body 
mass was measured first using the integrated scales to the nearest 0.01kg for 20 
seconds. The BODPOD is calibrated with the chamber empty (baseline) and then 
with a 50 litre aluminium calibration cylinder present in the chamber. Each 
subject then sat in the chamber with the door closed for two measurements 
each lasting 45 seconds. These volume measurements were averaged, but if they 
were not within the reproducibility criteria (150ml or 0.2%), a third 
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measurement was taken and the three measurements were averaged. If the 
variation persisted then the system was recalibrated and the measurements 
repeated. The corrected body volume was calculated using an assumed 
predicted lung volume and surface area artefact. 
 
The principle of ADP works on the basis that the body can be split into two 
compartments: fat-free (muscle, bone and water) and fat mass and that the 
density of these two compartments remain constant. In pregnancy however, the 
density of each of these compartments changes over the course of gestation as a 
result of accumulation of interstitial fluid and oedema. Raaij et al (van Raaij et 
al., 1988) formulated a series of equations to account for this change in body 
density and therefore data from this cohort was first corrected using these 
equations prior to analysis. 
 
10 week gestation equation 
 WFM (kg) = WB/100 x (496.4/DB – 451.6)   (equation 2.2) 
20 week gestation equation 
 WFM (kg) = WB/100 x (502.2/DB – 458.0)   (equation 2.3) 
30 week gestation equation 
 WFM (kg) = WB/100 x (510.8/DB – 467.5)   (equation 2.4) 
 
The above equations were applied to the raw data which was collected from the 
BODPOD at each antenatal appointment. During the postnatal appointment (visit 
4) uncorrected data was used as participants were no longer pregnant and had 
no observed oedema. Reproducibility of the ADP data has previously show that 
the typical error is 0.48kg, 0.43kg and 0.56% for fat free mass, fat mass and 
percentage body fat respectively. 
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2.3 Energy balance and substrate metabolism in 
pregnancy 
2.3.1 Indirect Calorimetry 
Study participants had their BMR and substrate utilisation measured at each 
study appointment (4 visits). All measurements were performed in the morning 
following a 10 hour fast using the Oxycon ventilated hood system (Jaegar Oxycon 
Pro, Hoechberg, Germany). The Oxycon ventilated hood system required to be 
switched on and calibrated 45 minutes prior to measurement. The equipment 
was calibrated for ambient atmospheric pressure using a traditional barometer. 
To ensure that the fraction of expired O2 (FEO2) and CO2 (FECO2) was accurate 
the gas analyser of the Oxycon was calibrated against a standard gas, and the 
turbine was manually calibrated for volume. The examination room was kept at 
a temperature of 23.9+/- 0.8 C with the researcher and the research nurse 
present. 
 
Study participants lay in a semi-supine position on an examination couch with 
adequate support of the lower back. The ventilation hood was placed over their 
head and shoulders with the plastic skirt covering upper torso and tucked under 
the pillows (see figure 2.3). The participants in this study did not lie in a supine 
position due to the potential of the gravid uterus to cause inferior vena cava 
compression and hypotension. The ventilation hood has two apertures; a cranial 
aperture which draws air into the hood and a caudal aperture which is attached 
to the Oxycon ventilated hood system via plastic tubing.  
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Figure 2.3 Oxycon ventilated hood system. Resting metabolic rate and substrate utilisation 
being recorded by indirect calorimetry with a volunteer subject. 
 
At each study visit the participants were under the hood for 25 minutes. During 
the first ten minutes no readings were recorded to allow the participant time to 
acclimatise to the hood and the environment.  
 
The indirect calorimetry system draws air through the hood and then measures 
FEO2 and FECO2. Using these parameters the rate of consumption of oxygen (VO2, 
ml/min) and the rate of carbon dioxide production (VCO2, ml/min) can then be 
calculated. These parameters were recorded every sixty seconds. Using these 
values respiratory exchange ratio (RER), substrate utilisation and basal 
metabolic rate (BMR) are derived from Frayn’s (Frayn, 1983) equations for 
indirect calorimetry.  
 
In order to extrapolate substrate utilisation and basal metabolic rate one must 
first account for protein metabolism. One method of calculating this is to 
measure urinary nitrogen, but this was not measured in this study as 24 hour 
urine collection was impractical. For healthy adults a constant rate of nitrogen 
excretion may be assumed. Investigation of protein balance and nitrogen 
metabolism in pregnancy shows that nitrogen excretion changes with gestation 
and thus a constant cannot be applied to this cohort. Gestational age-specific 
nitrogen excretion has been described (Mojtahedi et al., 2002). Using these 
calculated values nitrogen excretion is 0.00014g/kg/min at 12 weeks’ gestation, 
0.00012g/kg/min at 23 weeks’ and 0.00011g/kg/min at 34 weeks’. When 
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nitrogen excretion (N) is considered a constant at each gestation, then it can be 
subtracted from Frayn’s equations in order to calculate non-protein oxygen 
consumption (NPVO2) and non-protein carbon dioxide production (NPVCO2), and 
non-protein respiratory exchange ratio (NPRER), as shown in the following 
equations: 
 
 NPVO2 (ml/min) = VO2 – 6.04N    (equation 2.5) 
 
 NPVCO2 (ml/min) = VCO2 – 4.89N    (equation 2.6) 
 
 NPRER = NPVO2/NPVCO2    (equation 2.7) 
 
 
Using the corrected values for NPVO2 and NPVCO2, the individual’s substrate 
utilisation and subsequently basal metabolic rate (expressed as energy 
expenditure (EE, kilojoules kJ) can be obtained: 
  
Fat oxidation (fat ox) (g/min) = (NVO2 – NPVCO2)/0.6 (equation 2.8) 
 
Carbohydrate oxidation (CHO ox) (g/min) = (NPVO2 – 2.03 x fat ox)/0.746  
        (equation 2.9) 
 
Estimated protein oxidation (prot ox) (g/min) = N x 6.25   
(equation 2.10) 
 
EE (kJ) = (fat x 39.0) + (carbohydrate x 15.5) + (protein x 17.0) 
        (equation 2.11) 
 
Validation assessment of the Oxycon Pro ventilated hood system was performed 
by comparing values for VO2 and VCO2 obtained using the Oxycon Pro ventilated 
hood system against values obtained using Douglas bag expired air collections in 
11 volunteers in the fasted state (unpublished data).  The Pearson correlation 
coefficients between measurement techniques were 0.964 (p < 0.0005) for VO2 
and 0.972 (p < 0.0005) for VCO2. 
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The reliability of the Oxycon Pro ventilation hood system was determined by 
comparing resting VO2 and VCO2 measurements made in the fasted state in 10 
volunteers made on two occasions with an interval of 1-2 weeks (these were 
different volunteers from those used to determine the system’s validity).  The 
Pearson correlation coefficients between measurements were 0.913 (p < 0.0005) 
for VO2 and 0.943 (p < 0.0005) for VCO2. 
 
2.3.2 Physical Activity 
To objectively access physical activity the participants were asked to wear a 
physical activity monitor during waking hours for seven days following each visit. 
The monitors used were the Actigraph GT3X or the Actitrainer accelerometer 
(ActiGraph Pensacola, FL, USA) which were worn on a waist belt or clipped to 
the waistband. The participants were given a simple diary sheet to indicate 
when the monitor was worn, and advised to remove it when sleeping, showering 
or swimming. Once the week of data had been collected the device was sent 
back in a stamped addressed envelope. 
 
The accelerometer is a small device which detects vertical accelerations at 
specified time points (referred to as epochs). For this study each ‘epoch’ is 
defined as sixty seconds. Each device was initiated using Actilife software 
Version 5.3.0 (ActiGraph Pensacola, FL, USA) prior to the study visit to record 
activity every sixty seconds over the course of the seven days. When the data 
from each device was downloaded this created a CVS Microsoft file which 
displays a number (displayed in counts/min) for each epoch. Each count/min 
refers to an intensity level which is defined by the Freedson cut points (Freedson 
et al., 1998). Therefore sedentary activity <100 counts/min, light activity is 100-
1951 counts/min, moderate activity 1952-5724 counts/min and vigorous activity 
is >5724 counts/min. For the purposes of the current analysis three activity 
intensities were used; sedentary, light and moderate & vigorous physical activity 
(MVPA), because as a pregnancy progressed the amount of time spent in vigorous 
activity alone was expected to be very small and therefore not useful for 
comparison. Each CVS file was then saved as an excel spreadsheet file.  
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In order to analyse the data, the seven days of information was first split into 
each calendar day. Sleep time was removed, guided by the diaries. In addition, 
if more than one hour of ‘0’ counts (i.e. more that sixty consecutive ‘0’ 
counts/min) were recorded this was considered non-wear time and was removed 
from the excel spreadsheet. The Freedson cut points were then applied to the 
remaining data and the time spent in each of the intensity levels was calculated 
in minutes as well as an average wear time in minutes for the day. Using each 
calendar day data an average was calculated for each visit. Previous studies in 
adults have determined what is considered to be a valid wear time and have 
suggested that three to five days (Trost et al., 2005) of accelerometer data will 
provide a valid estimation of physical activity. Other published data on activity 
levels in pregnancy using accelerometers have suggested using four days for valid 
activity assessment (Kinnunen et al., 2011).  A valid calendar day was considered 
for the purposes of this study to have 9 hours of wear time data and it was 
required that at least four days of data were collected. Across gestation and 
between the two groups there was no difference in valid wear time (appendix 
III) 
 
2.3.3 Dietary Assessment 
At each study visit, participants completed a multiple pass 24 hour dietary recall 
questionnaire (Conway et al., 2004). The questionnaire (appendix II) recorded 
everything that the participant had had to eat and drink in the twenty four hours 
preceding the study visit. The questionnaire was filled out by either the 
researcher or the research nurse and was administered according to protocols 
used for the Food Standard Authority’s Low Income Diet and Nutrition Survey 
(Bush, 2008). The multiple pass method is not time consuming (approximately 
15-20 minutes to complete) and has been widely implemented in different 
demographic study groups. 
 
Participants also completed a food frequency intake questionnaire, which has 
been validated in a Scottish population (Lean et al., 2003). The analysis of the 
food patterns estimates food intake in relation to national dietary targets of 
fish, fruit and vegetables, breakfast cereals and intake of fat and sugary foods 
(appendix II). 
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Data from the questionnaires was then entered into the Dietplan 6 analysis 
package (Forestfield Software Ltd, West Sussex, UK). Total energy, 
macronutrient and micronutrient intake were then exported from this database 
into Microsoft excel spreadsheets for analysis. 
2.4 Peripheral vascular function assessment 
Laser Doppler Imaging (LDI) is a non-invasive method for assessing peripheral 
vascular function.  This technique has been used in pregnancy to highlight the 
differences in vascular function between obese and lean women (Ramsay et al., 
2002a, Stewart et al., 2007a).  
 
Before the examination all women were acclimatised in a temperature- 
controlled room (23.9+/- 0.8 C) for a ten minute period. Women were asked to 
recline in a semi-recumbent position with the volar aspect of the forearm 
exposed resting on an armrest.  All participants were fasted. 
 
 
Figure 2.4 Laser Doppler imaging assessment. Volunteer positioned for LDI assessment. 
 
 
 
  
Laser unit 
Computer with scans 
being displayed 
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In order to assess peripheral vascular reactivity, iontophoresis of vasoactive 
solutions was used. Vasodilatation is considered the expression of vascular 
reactivity, and this response can be considered either endothelium-dependent 
(mediated through direct stimulation of the endothelial cells) or endothelium-
independent (mediated through the effect of NO on vascular smooth muscle 
cells). Iontophoresis is based on the principle that a charged molecule migrates 
across the skin under the influence of an applied electrical field. In order to 
measure endothelium-dependent vasodilatation, acetylcholine (ACH) was used to 
stimulate the endothelial cells through its binding to muscarinic receptors and 
the subsequent generation of NO. To assess endothelium-independent 
vasodilatation, Sodium Nitroprusside (SNP) which acts as a NO donor to vascular 
smooth muscle cell was used.  
 
Drug delivery was achieved using a battery-powered constant current 
iontophoresis MIC-1e controller (Moors Instruments Ltd, Axminster, UK). The 
chambers used for iontophoresis were ION-6 Perspex chambers (Moor 
Instruments Ltd, Axminster, UK) which had an internal diameter of 22mm and 
area of 3.8cm2 and an internal platinum wire electrode. These chambers were 
attached using double-sided adhesive disks to the volar aspect of the forearm 
avoiding any broken skin, hair and superficial veins. These chambers were 
connected to the iontophoresis controller. In addition, a digital multimeter was 
connected in parallel to record the voltage across the chambers. This is 
important as skin resistance has an effect on the delivery of the iontophoresis 
drugs. As the constant current source is being used, skin resistance can be 
calculated using Ohm’s law where resistance is equal to voltage divided by 
current. A 2.5ml dose of 1% ACH which is a positively charged ion (Sigma, Poole, 
UK) was introduced into the anode chamber while a 2.5ml 1% dose of SNP 
(Sigma, Poole, UK) which is a negatively charged ion was introduced into the 
cathode chamber. Drug delivery was delivered simultaneously during 
administration of the current. The vehicle for these drugs was 0.5% sodium 
chloride (NaCl) in deionised water. Cover slips were placed over each chamber 
to minimise loss of fluids during the procedure (figure 2.5). 
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Figure 2.5 LDI laser scanning over the area of interest. The two chambers are attached to the 
volar aspect of the arm. Each chamber is attached to the iontophoresis unit. The chamber with the 
white dot indicates the chamber with the SNP solution in it and the other chamber contains the 
ACH solution. A temperature probe is taped adjacent to the chambers to record skin temperature 
throughout the experiment. 
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Measurement of the perfusion of the skin and thus the vasodilatation of the 
peripheral vascular bed was performed using a laser Doppler imager (Moor 
Instruments Ltd, Axminster, UK) equipped with a red laser (wavelength, 633 nm; 
power, 1mW; beam diameter, 1 mm) which was scanned over both chambers 
through the coverslips. The technique is based on the Doppler shift effect 
imparted by the moving blood cells in the underlying skin to the backscattered 
light collected by the photodetectors on the laser unit. The backscattered light 
is converted into an arbitrary perfusion (or flux) unit (PU) that is displayed as a 
colour coded image on the computer monitor (figure 2.6). Twenty scans are 
performed with an incremental iontophoresis current protocol with the first scan 
indicating baseline perfusion (pre-current administration) followed by an 
incremental current protocol; four scans at 5 microamps (5 A), four at 10A, 
four at 15A, two at 20A and four recovery scans. The total current delivered 
was 8 milliCoulombs (8 mC).  
  
 
Figure 2.6 LDI scans indicating both endothelium-dependent (ACH left chamber) and -
independent (SNP right chamber) vasodilatation. The laser beam and subsequent back 
scattered light is distorted by the increase in movement of red blood cells through the peripheral 
circulation, this is then interpreted by the computer software and produces a series of scan images.  
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perfusion 
unit 
Perfusion measurements were performed using the image manufacturer’s image 
analysis software of outlining the region of interest (ROI) around the internal 
circumference of the chamber. A median value for each scan flux value was 
calculated across approximately 700 measurement points. The median value was 
first corrected for skin resistance as described above. The sum of the corrected 
median values from each scan is referred to as the total perfusion.time area 
under the curve (AUC). The incremental perfusion.time area under the curve is 
considered the total perfusion.time curve minus the baseline scan (pre-current 
administration), illustrated in Figure 2.7. 
 
 
 
Figure 2.7 Illustration of perfusion.time curve. The above figure relates to the scan displayed in 
figure 2.6. Total perfusion.time curve is area under the blue line. The incremental perfusion.time 
curve is the perfusion observed above the baseline only.  
 
  
Incremental 
perfusion time 
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Image number/ time  
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In order to calculate the value for the total perfusion.time curves, the sum of 
these values is multiplied by 5/6 as current delivery for each scan was 50 
seconds which can be expressed as 50/60 or 5/6: 
 
Total perfusion.time curve = sum of median values x 5/6 (equation 2.12) 
 
In order to calculate the value of the incremental perfusion.time curve, first the 
baseline median value is subtracted from each of the twenty scans and then 
multiplied by 5/6: 
 
Incremental perfusion.time curve  
    = median scan1 – baseline etc for scans 1-20 
    = sum incremental scan values x5/6    (equation 2.13) 
  
Responses were observed with the vehicle alone as a control experiment. The 
within-day, between site coefficient of variation (CV), measured on the same 
morning in four subjects, was 2.6 ± 1.3% for ACH and 1.3 + 1.1% for SNP. 
Previous studies have shown that the mean (± SD) between-day CV for the ACH 
response, measured in four subjects on 2 separate days, was 6.4 ± 3.3%. The 
within-day, between-site CV, measured in both forearms on the same morning in 
four subjects, was 8.9 ± 5.3% (Ramsay et al., 2002a).  
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2.5 Biological sample analysis 
At each study visit blood samples were collected for glucose, insulin, lipid (total 
cholesterol, total triglycerides, NEFA and HDL cholesterol, oxLDL), CRP, IL6 and 
TNF, GGT, sICAM-1, and sVCAM-1 assays. Urine samples were obtained for 
isoprostanes assessment. Superoxide levels were detected in whole blood 
samples.  
 
2.5.1 Plasma preparation and storage 
Fasting venous blood was collected from each study participant at each visit as 
follows; 1 x 9 millilitre (ml) lithium heparin tubes, 1 X 5ml serum tubes, 2x9ml 
EDTA tubes and 1 x 4ml EDTA tube. The lithium heparin and EDTA samples were 
separated into plasma by centrifugation (1800g) and divided into aliquots. A 
950ul lithium heparin sample was removed and transported on ice to complete 
the superoxide assessment.  A proportion of the aliquots were stored under 
antioxidant conditions (0.01% BHT and the tube filled with nitrogen gas).  
Buffy coat samples were collected from a proportion of the standard EDTA 
aliquots. Serum samples were left to stand for 30 minutes before centrifugation 
and then dispensed into aliquots. All of the above samples were stored in a -80C 
freezer within the department until analysis. 
 
2.5.2 Urine sample collection & storage 
At each study visit, the participant was requested to provide a sample of urine. 
Urine aliquots were stored under standard and antioxidant conditions at -80C. 
2.5.3 Routine biochemical assays 
Routine assays were carried out on an autoanalyser (ILAB 600 Chemistry 
Analyser). Total cholesterol, HDL cholesterol, and triglycerides were measured 
by enzymatic colorimetric methods using commercially available kits (Roche 
Diagnostics GmbH, Mannheim, Germany). Non-esterified fatty acids (NEFA) 
concentrations were analysed by enzymatic colorimetric methods using a 
commercially available kit (Wako Chemicals GmbH, Neuss, Germany). Fasting 
glucose was measured with the hexokinase/glucose-6-phosphate dehydrogenase 
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enzymatic method using a commercially available kit (Randox Laboratories Ltd, 
Co Antrium, UK). Gamma glutamyl transferase (GGT) was assayed by rate 
reaction absorptive techniques using a commercially available kit 
(Instrumentation Laboratory, USA). Highly sensitive CRP was analysed by an 
immunoturbidimetric technique using a commercially available kit (Randox 
Laboratories, Laboratories Ltd, Co Antrium, UK). 
 
Accuracy and precision of the assays were monitored by internal quality control 
(Roche Diagnostics GmbH, Mannheim, Germany. Wako Chemicals GmbH, Neuss, 
Germany. Randox Laboratories Ltd, Co Antrium, UK. Instrumentation Laboratory, 
USA). Coefficients of the variation were 2.9% for cholesterol, 2.8% for HDL, 3.8% 
for triglycerides, 5.2% for NEFA, 2.0% for glucose and 2.7% for CRP. 
 
2.5.4 Enzyme linked immunoassays 
All kits employed the quantitative sandwich enzyme immunoassay technique.  
Assays were performed using commercially available kits: insulin by 
ultrasensitive kit (Mercodia, Uppsala, Sweden), haemoglobin (Universal 
Biologicals, UK), oxidised LDL (OxLDL), urinary isoprostanes (Oxford Biomedical 
Research, Oxford, UK) and sICAM-1, sVCAM-1, IL6 and TNF (R&D Systems, 
Oxford, UK). With regards to data on urinary isoprostanes, due to the change in 
glomerular filtration rate during pregnancy these data were corrected for 
creatinine concentration prior to analysis. 
 
The precision of the kits were monitored by internal quality control (Mercodia, 
Uppsala, Sweden and R&D Systems, Oxford, UK). Coefficients of the variation for 
intra-assay were 4.9% for insulin, 4.6% for sICAM-1, 3.1% for sVCAM-1, 7.4% for 
IL6 and 5.3% for TNF. Coefficients of the variation for inter-assay were 2.8% for 
insulin, OxLDL 8%, 5.5% for sICAM, 7.0% for sVCAM, 7.6% for IL6 and 8.4% for 
TNF. No coefficients of the variation were quoted in the manufacturer’s 
guidance for haemoglobin or urinary isoprostanes. 
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2.5.5  Superoxide analysis 
Electron paramagnetic resonance (EPR) is a spectroscopic technique which 
detects species of unpaired electrons, such as those produced by reactive 
oxygen species (ROS). The method detects the transition of unpaired electrons in 
an applied magnetic field. Unpaired electrons have a spin which gives them a 
magnetic property known as a magnetic moment, making the electron behave 
like a small magnet. When an external magnetic field is applied, the 
paramagnetic electrons will orientate in either direction parallel or antiparallel 
to the direction of the magnetic field. This creates two distinct unpaired 
electron energy levels and the unpaired electrons in the superoxides can then be 
measured as they are driven between these two levels by the magnetic field. 
Superoxide levels were detected in whole blood samples using an electron 
paramagnetic resonance e-scan R Biospin analyser (Bruker GmBH, Osterreich, 
Austria) with a CPH (1-hyroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine) 500 µM 
spin probe (Noxygen, Elzach, Germany). Superoxides are measured in whole 
blood. Throughout pregnancy total blood volume changes. Before analysis was 
performed on this data, a haematocrit and haemoglobin (Quantichrom, BioAssay 
Systems, Universal Biologicals Ltd Cambridge, UK) were measured for each 
sample and the blood volume was corrected as per the method used by Dill and 
Costill (Dill and Costill, 1974). 
 
2.5.6 Homeostatic Model Assessment 
Homeostatic model assessment was performed as a measure of insulin resistance 
on all plasma samples. The method employed in this thesis was HOMA-1 which 
has been shown to correlate with the euglycaemic clamp data. Methodology 
employed in this data analysis was as per Matthew et al (Matthews et al., 1985) 
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2.6 Statistical Analysis 
The numbers recruited were based on power calculations for differences in the 
anthropometric measures ((Soltani and Fraser, 2000), energy expenditure 
(Catalano et al., 1998)), endothelial function (Stewart et al., 2007a) and 
lipotoxic measures (Stewart, 2007)) but not for biological assays. 
 
The number of participants required was worked out was based on the mean 
obese measurement of the descried parameter minus the mean lean 
measurement divided by the mean lean. This is described at the standardised 
delta. The second calculation required for the power was the sigma of the lean 
group divided by the mean lean. These results were then exported to Minitab 
vs16 where numbers needed to recruit were based on a 2 sample t power 
calculation, described in table 2.2. As the largest number needed to recruit was 
based on endothelial function (n=24), it was decided to aim to recruit 30 women 
to each BMI group in order to detect a difference and cover any study drop outs. 
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Table 2.2 Power Calulations 
Parameter Delta (obese 
minus lean)/ 
mean lean 
[standardise
d] 
Sigma of 
lean group/ 
mean lean 
[standardise
d] 
Power 
80% 
(n) 
Power 
90% 
(n) 
Source 
Fat distribution 
Ratio change in 
central  vs lower 
body skinfold 
 
 
+2.31 /2.16 
[1.07] 
 
18.61/30.26 
[0.62] 
Used total 
skinfold SD 
 
7 
 
9 
Soltani 
2000 
Lower body fat  
Skinfold change 
(mm) 
 
 
-4/6 
[0.67] 
 
2/6 
[0.33] 
 
5 
 
7 
Soltani 
2000 
Energy 
expenditure 
Total (kcal/day) 
CHO 
(mg/min) 
Fat 
(mg/min) 
 
76/373  
[0.20] 
43.7/56.4 
[0.77] 
12.8/6.3 
[2.03] 
 
372/7886 
[0.20] 
59.4/164.1 
[0.36] 
29.2/49.6 
[0.59] 
 
17 
 
5 
 
3 
 
23 
 
6 
 
4 
Catalano 
1998, 
Okereke 
2004 
 
Endothelial 
Function 
Microvascular 
function – LDI 
[PUMΏmin] 
 
 
Trimester 1 
5930/15112 
[0.39] 
 
 
Trimester 1 
5982/15112 
[0.40] 
 
 
 
18 
 
 
 
24 
Stewart 
2007 
Lipotoxic 
mediators 
LDLIII mass (mg/dL) 
 
Trimester 3 
25.7/37.7 
[0.68] 
 
Trimester 3 
18.32/37.73 
[0.49] 
 
 
10 
 
 
12 
Frances 
Stewart 
MD Thesis 
2007 
 
In order to normalise data for analysis, raw values were log or square root 
transformed when necessary. Statistical analysis was performed using a linear 
mixed model in IBM SPSS Statistics version 19. The statistical model assessed the 
effect of gestation (quoted as ‘p time’), the effect of the group (quoted as ‘p 
type’) and their interaction (pattern of change; quoted as ‘p time x type’) of 
each variable. For the mixed model effect of time and type were considered 
significant with a p<0.01, and the interaction model was considered significant 
with a p<0.05.  
 
Post hoc analysis was performed if a statistically significant difference was found 
for the interaction. Post hoc analysis assessed the change in each variable in 
early (V1-V2), late (V2-V3) and total (V1-V3) gestation using 2 sample t-tests 
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(Minitab vs16). This analysis was performed in Minitab vs16 and p<0.05 was 
considered significant.  
 
Univariate analysis was performed to assess the impact of anatomical fat depots 
on the total fat mass gained during pregnancy. If significant relationships were 
found using Pearson’s correlations then general linear modelling was performed 
to assess each sites contribution to the fat mass gained. This analysis was 
performed in Minitab vs16 and p<0.01 was considered significant.  
Any statistical analysis which was specific to a subset of data has been described 
in the relevant methods section in each results chapter. 
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Chapter 3 - Relationship between mass and pattern 
of subcutaneous adipose tissue accumulation in 
healthy lean and OW/OB pregnancies 
3.1 Introduction 
The amount of gestational weight which women gain during pregnancy varies 
greatly. Guidance from the IOM in 2009, recommends that underweight 
(BMI<18.5kg/m2) women aim for a total GWG of 12.5-18.0kg, normal weight 
(BMI18.5-24.9kg/m2), aim for 11.5-16.0kg, overweight (BMI 25.0-29.9kg/m2) to 
aim for 7.0-11.5kg and obese (BMI>30.0 kg/m2) women aim to gain no more than 
5-9kg. Excessive gestational weight gain has been extensively researched and 
the impact of GWG on maternal obstetric complications is variable. What is 
known conclusively is that pre-pregnancy obesity is a recognised risk factor for a 
range of congenital, antenatal, intrapartum and postnatal complications (Jarvie 
and Ramsay, 2010).  
 
It has been observed that subcutaneous fat stores in the mother increase 
markedly from 10-30 weeks’ gestation and thereafter remain fairly constant 
until parturition (Taggart et al., 1967). Further examination of the anatomical 
variation in subcutaneous adiposity has suggested that obese women 
preferentially store fat in the subcutaneous central compartments when 
compared to their lean counterparts (Soltani and Fraser, 2000). As highlighted, 
upper body centrally located fat is associated with an abnormal metabolic 
profile; although the contribution of the subcutaneous and visceral compartment 
is unclear. If obese women do store fat preferentially in central compartments 
then this may be a contributory factor to any abnormal inflammatory and 
vascular response exhibited (Ramsay et al., 2002a). It has been suggested that, 
in the non-pregnant population increased thigh circumference may provide 
protection against cardiovascular disease independent of abdominal and general 
obesity (Heitmann and Frederiksen, 2009). Furthermore, it has been noted that 
lower body fat is more sensitive to insulin suppression of lipolysis thus inhibiting 
the release of NEFA and consequent production of lipotoxic products such as ROS 
and oxysterols as well as ectopic fat deposition. 
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There are now established data on the differences seen in gestational weight 
and fat gain in lean and obese pregnancies. A detailed observation of the impact 
of maternal booking obesity on the distribution of this gestationally-accumulated 
fat is now required. Centrally accumulated fat could potentially explain the link 
between maternal obesity, lipotoxicity and adverse pregnancy outcome. 
 
Within the context of this longitudinal study detailed anthropometric assessment 
of lean and OW/OB women during pregnancy was performed in order to test the 
hypothesis that the anatomical variation in accumulation of subcutaneous 
adipose tissue in lean and OW/OB women was different and that this had an 
impact on the metabolic response seen in pregnancy. The visceral fat 
compartment was not measured in this study. Ultrasound assessment was not 
available and there were ethical consideration in using other imaging modalities 
in pregnancy – such as the theoretical risk of deafness in the fetus if using 
magnetic resonance imaging.  
 
3.2 Research Questions 
1. Do lean and OW/OB women gain weight and fat mass during 
pregnancy, and is there a difference in the amount they gain? 
2. Does this gain in weight and fat mass happen throughout pregnancy or 
is it concentrated at a particular gestational time period and is there 
any difference in pattern between the BMI groups? 
3. What is the anatomical pattern of subcutaneous fat accumulation 
during pregnancy and is it different between lean and OW/OB 
pregnancies? 
4. What contribution does each of the subcutaneous fat depots (upper 
body peripheral, abdominal and lower body) have to the total 
gestational fat mass?  
 
3.3 Methods 
Anthropometric methodology has been detailed in section 2.2 of the General 
Methods Chapter. All measurements were performed by the researcher. 
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3.4 Baseline Demographics 
Study participants were recruited as described in section 2.1.2. As described in 
Chapter 2, recruitment to the obese group was more challenging than 
anticipated, and the BMI group was extended to include recruitment of 
primigravid and parous women with a BMI of greater than 27 kg/m2. The mean 
BMI of the obese group was 31.5kg/m2, and the range was 27.1-37.4kg/m2. For 
the purposes of this thesis the BMI groups have been referred to as ‘lean’ and 
‘overweight/obese’ (OW/OB). 
For analysis of data, the total number of lean participants was 26 and the 
OW/OB cohort was 16 unless otherwise stated.  
 
There were no smokers in either of the groups. The baseline demographics of 
the groups are illustrated in table 3.1. The OW/OB group had a higher baseline 
systolic and diastolic blood pressure than the lean women. In addition, the 
OW/OB group had a greater baseline weight, umbilical waist circumference, hip 
circumference, WHR, fat and fat free mass compared to the lean group. 
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Table 3.1 Baseline anthropometric characteristics for the lean and OW/OB groups. Statistical 
analysis was performed for each demographic variable listed below. Analysis was performed using 
the 2 sample t-test, for parity the assessment used *fishers exact test. 
Variable lean n=26 
mean(SD) 
[range] 
 
OW/OB n=16 
mean(SD) 
[range] 
p value 
 
age (years) 
 
30.1 (2.9) 
[22.0-36.0] 
 
30.8 (4.7) 
[21.0-37.0] 
 
0.61 
parity n prim(%) 26 (100) 14 (88) 0.17* 
gestation at  
visit 1 (weeks) 
15.7 (1.1) 
[14.0-19.0] 
16.0 (1.4) 
[14.0-19.0] 
0.42 
booking BMI 
(kg/m2) 
22.0 (1.7) 
[18.0-24.9] 
31.5 (2.7) 
[27.1-37.4] 
<0.0001 
booking systolic 
BP (mmHg) 
110 (10) 
[90-125] 
119 (10) 
[103. -140] 
0.011 
booking diastolic 
BP (mmHg) 
68 (6) 
[60-78] 
74 (8) 
[64-89] 
0.008 
height (m) 1.66 (0.07) 
[1.56-1.81] 
1.67 (0.06) 
[1.58-1.78] 
0.56 
weight (kg) 60.7 (7.2) 
[48.5-75.7] 
87.0 (10.2) 
[72.0-103.3] 
<0.0001 
umbilical waist 
circumference 
(cm) 
83.3 (5.6) 
[75.4-96.0] 
103.5 (6.6) 
[91.7-115.1] 
<0.0001 
hip circumference 
(cm) 
98.2 (5.3) 
[89.7-111.6] 
113.8 (5.4) 
[107.0—122.0] 
<0.0001 
WHR 0.85 (0.04) 
[0.77-0.91] 
0.91 (0.05) 
[0.83-1.03] 
<0.0001 
fat mass (kg) 16.4 (4.4) 
[11.1-26.3] 
35.9 (7.3) 
[25.3-49.1] 
<0.0001 
% fat mass of total 
weight (%) 
 
26.9 (5.4) 
[17.9-37.4] 
41.0 (5.0) 
[34.5-50.5] 
<0.0001 
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3.5 Gestational changes in lean and OW/OB 
anthropometry 
3.5.1 Longitudinal changes in total body weight 
In lean and OW/OB pregnancy there was a linear relationship between 
gestational age and total body weight. Both groups showed a significant increase 
in total body weight during pregnancy; average visit 1 total body weight 70.7kg 
(standard deviation [SD] 15.4) versus average visit 3 total weight 80.8kg 
(SD15.5), p time<0.0001. The OW/OB group was significantly heavier throughout 
gestation; lean average total body weight 65.8kg (SD8.2) versus OW/OB average 
total body weight 91.7kg (SD10.9), p type<0.0001. Total gestational weight gain 
was 10.4kg (SD 2.4) in lean pregnancy and 9.4kg in OW/OB pregnancy; this was 
not significantly different.  
 
The pattern of increase in total body weight between the two groups was similar 
(p time x type=0.26).  
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Figure 3.1 Total body weight at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean total body weight (raw data) and standard deviations at each gestational 
time point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’.  
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3.5.2 Longitudinal changes in total fat mass  
Both groups showed a significant increase in fat mass during pregnancy; average 
visit 1 fat mass 23.9kg (SD 11.0) versus average visit 3 27.9kg (SD 11.3), p 
time<0.0001. The OW/OB group had significantly more body fat throughout 
gestation; lean average total fat mass 18.8kg (SD 5.2) versus OW/OB average 
total fat mass 37.9kg (SD 7.4) p type<0.0001. Total gestational fat mass gain was 
4.3kg (SD 3.6) in lean pregnancy and 4.0kg (SD 4.0) in OW/OB pregnancy and this 
was not significantly different between the groups.  
 
As with total body mass, there was a linear relationship between both lean and 
OW/OB fat mass and gestational age, and the pattern of change was similar        
(p time x type=0.80).  
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Figure 3.2 Fat mass at each gestational time point in lean and OW/OB pregnancy. Illustrated 
is the mean fat mass (raw data) and standard deviations at each gestational time point in lean and 
OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between the lean and 
OW/OB groups as ‘p type’ and pattern of change in the variable between the groups as ‘p time x 
type’.  
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3.5.3 Longitudinal changes in circumference measurements 
Circumference measurements were taken for minimum waist, umbilical waist, 
hip, upper thigh and midthigh. Methodology of the circumference measurements 
are detailed in section 2.2.3. During pregnancy lean and OW/OB women had a 
significant increase in all circumference measurements (data not shown). On 
reflection, the increases in circumference would not only have represented an 
increase in the subcutaneous adipose tissue component but also the increase in 
muscle mass, which has been demonstrated by other authors (Butte et al., 
2003). The abdominal measurements would have represented not only maternal 
circumference increase but growth of the uterus and fetus. For this reason it 
was decided not to use the circumference measurements in the comparison of 
the lean and OW/OB cohort. 
 
3.5.4 Longitudinal changes in individual skinfold measurements 
Measurements were taken for biceps, triceps, subscapular, costal, suprailiac, 
midthigh and suprapatella skinfolds. All seven skinfolds measurements were 
taken at each study appointment. The methodology of the skinfolds assessment 
is detailed in section 2.2.4. Each individual skinfold measurement increased 
across pregnancy but there was no difference in the pattern of change observed 
between the groups (data not shown). The OW/OB groups had significantly larger 
individual skinfold measurements than lean women.  
 
To assess changes in anatomical distribution of subcutaneous fat during 
pregnancy, skinfolds were assessed in anatomical groups. The skinfold 
measurements were assessed in three different ways: total skinfold represented 
the sum of all skinfolds (biceps, triceps, subscapular, costal, suprailiac, midthigh 
and suprapatella); upper body peripheral skinfold was the sum of biceps and 
triceps; upper body truncal skinfold comprised subscapular, costal and suprailiac 
skinfolds, abdominal skinfold included costal and suprailiac skinfolds; and lower 
body skinfold comprised midthigh and suprapatella skinfolds.  
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3.5.5 Longitudinal changes in total skinfold measurements 
When total skinfold measurements were assessed there was a significant 
increase across gestation; mean visit 1 total skinfold measurement 137.6mm (SD 
45.3), versus visit 3 mean value 163.3mm (SD 51.2), p time<0.0001. The OW/OB 
group had thicker total skinfolds than the lean group; total body skinfold 
119.3mm (SD 22.8) versus OW/OB 202.9mm (SD 33.5), p type<0.0001.  
 
The interaction model indicated that there was a difference in the pattern of 
increase in total skinfold measurements between the two groups (p time x 
type=0.013). In lean pregnancy total skinfold thickness was 107.7mm (SD 21.1), 
121.0mm (SD 19.6) and 129.0mm (SD 23.0) at visit 1, 2 and 3 respectively. In 
OW/OB pregnancy total skinfolds were 186.1mm (SD 28.7), 203.6mm (SD 34.0) 
and 218.9mm (SD 31.0) at each gestational time point. 
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Figure 3.3 Total skinfold measurements at each gestational time point in lean and OW/OB 
pregnancy. Illustrated are the mean total skinfold measurements (raw data) and standard 
deviations at each gestational time point in lean and OW/OB pregnancy. Differences across 
gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern 
of change in the variable between the groups as ‘p time x type’.  
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3.5.6 Longitudinal changes in grouped skinfold measurements 
3.5.6.1 Upper body peripheral skinfold measurements 
In both groups there was a significant increase in the upper body peripheral 
skinfold measurements across gestation; average visit 1 upper body peripheral 
skinfold 37.4mm (SD11.1) versus visit 3 41.0mm (SD 13.2) p time<0.0001. The 
OW/OB group had significantly thicker upper body peripheral skinfolds 
throughout pregnancy; lean average 32.1mm (SD 6.4) versus OW/OB 50.9mm (SD 
9.1), p type<0.0001.  
The interaction model suggested that there was a difference in the pattern of 
the increase upper body peripheral skinfold thickness (p time x type=0.047). In 
lean pregnancy, upper body peripheral skinfolds were 30.6mm (SD 6.3), 32.8mm 
(SD 6.1) and 33.0mm (SD 6.8) at each gestational time point. In OW/OB 
pregnancy the upper body peripheral skinfolds were 48.4mm (SD 7.8), 50.5mm 
(SD 8.6) and 54.0mm (SD 10.3) respectively.  
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Figure 3.4 Upper body peripheral skinfold measurements at each gestational time point in 
lean and OW/OB pregnancy. Illustrated are the mean upper body peripheral skinfold 
measurements (raw data) and standard deviations at each gestational time point in lean and 
OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between the lean and 
OW/OB groups as ‘p type’ and pattern of change in the variable between the groups as ‘p time x 
type’.  
  
p time<0.0001 
p type<0.0001 
p time x type=0.047 
OW/OB 
lean 
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3.5.6.2 Upper body truncal skinfold measurements 
Both groups showed a significant increase in the thickness of upper body truncal 
skinfold during pregnancy; average visit 1 upper body skinfold 54.9mm (SD 20.5) 
versus average visit 3 upper body skinfold thickness 66.2mm (SD 22.3), p 
time<0.0001. The OW/OB group had significantly thicker upper body truncal 
skinfolds throughout gestation; lean average upper body truncal skinfolds 
47.5mm (SD 11.8) versus OW/OB average upper body truncal skinfold 83.0mm 
(SD 15.2), p type<0.0001.  
The pattern of the increase in these skinfolds were similar in both groups, p time 
x type=0.27.  
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Figure 3.5 Upper body truncal skinfold measurements at each gestational time point in lean 
and OW/OB pregnancy. Illustrated are the mean upper body truncal skinfold measurements (raw 
data) and standard deviations at each gestational time point in lean and OW/OB pregnancy. 
Differences across gestation were expressed as ‘p time’, between the lean and OW/OB groups as 
‘p type’ and pattern of change in the variable between the groups as ‘p time x type’.  
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3.5.6.3 Abdominal skinfold measurements 
Both groups showed a significant increase in the thickness of abdominal skinfold 
fat during pregnancy; average visit 1 abdominal skinfold 37.5mm (SD 14.1) 
versus average visit 3 abdominal skinfold thickness 43.6mm (SD 14.5),                    
p time<0.0001. The OW/OB group had significantly thicker abdominal skinfolds 
throughout gestation; lean average abdominal skinfolds 31.5mm (SD 7.6) versus 
OW/OB average abdominal skinfold 54.0 (SD 9.6), p type<0.0001.  
The pattern of increase in abdominal skinfolds were similar in both groups, p 
time x type=0.62. 
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Figure 3.6 Abdominal skinfold measurements at each gestational time point in lean and 
OW/OB pregnancy. Illustrated are the mean abdominal skinfold measurements (raw data) and 
standard deviations at each gestational time point in lean and OW/OB pregnancy. Differences 
across gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and 
pattern of change in the variable between the groups as ‘p time x type’.  
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3.5.6.4 Lower body skinfold measurements 
In both groups there was a significant increase in the lower body skinfold 
measurements across gestation; mean visit 1 lower body skinfold 45.3mm (SD 
16.3) versus visit 3 mean value 56.1mm (SD 18.7), p<0.0001. OW/OB women had 
significantly thicker lower body skinfold than lean women; lean average lower 
skinfold measurement 36.9mm (SD 8.5) versus OW/OB 69.0mm (SD 14.4), p 
type<0.0001.  
The pattern of increase in lower body skinfolds was different between the two 
groups (p time x type=0.005). At each gestational time point, in lean pregnancy 
lower body skinfolds were 35.3mm (SD 7.4), 39.7mm (SD 6.8) and 43.9mm (SD 
9.2). In OW/OB pregnancy this was 61.5mm (SD 13.4), 69.6mm (SD 13.9) and 
75.8mm (SD 12.8) respectively.    
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Figure 3.7 Lower body skinfold measurements at each gestational time point in lean and 
OW/OB pregnancy. Illustrated are the mean lower body skinfold measurements (raw data) and 
standard deviations at each gestational time point in lean and OW/OB pregnancy. Differences 
across gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and 
pattern of change in the variable between the groups as ‘p time x type’.  
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3.5.7 Summary of gestational anthropometry in lean and OW/OB 
pregnancy 
 
Figure 3.8 Summary of gestational anthropometry in lean and OW/OB pregnancy. This figure 
summarises the gestational differences (previously expressed as ‘p time’), the differences between 
the groups (‘p type’) and the differences in the pattern of change (‘p time x type’) seen in lean and 
OW/OB pregnancy. 
 
During pregnancy total body weight and fat mass increased. Each of the 
measured subcutaneous fat depots increases during pregnancy. OW/OB and lean 
women gain similar amounts of total body weight and fat mass during pregnancy. 
OW/OB women have thicker subcutaneous fat depots compared to lean women. 
From the above analysis there appears to be a difference in the pattern of fat 
accumulation in the total skinfolds, upper body peripheral and lower body 
skinfolds in lean and OW/OB women. 
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3.6 Gestational pattern of change in subcutaneous fat 
accumulation in lean and OW/OB pregnancies 
From the above analysis, it would appear that there are difference in the 
pattern of change seen in total body skinfolds, upper body peripheral skinfolds 
and lower body skinfolds between the lean and OW/OB groups. Further analysis 
was performed to assess the pattern of change in early (V1-V2), late (V2-V3) and 
total gestation (V1-V3) for these grouped skinfolds between lean and OW/OB 
women. 
 
3.6.1 Total body skinfolds 
When total body skinfolds were assessed, as Figure 3.3 suggested, it was the 
OW/OB women gain more fat in total body skinfolds during pregnancy than lean 
women (p=0.046).OW/OB. 
Table 3.2 Changes in total body skinfold measurements in lean and OW/OB pregnancy 
during different gestational time periods. Illustrated are the mean measurements (raw data) and 
standard deviations for the changes seen in total skinfolds during each gestational period. 
Statistical analysis performed using 2 sample t-test assessing each gestational time period: early 
(V1-V2), late (V2-V3) and total gestation (V1-V3), where V1=visit 1, V2=visit 2 and V3=visit 3. 
anthropometric 
parameter 
 
visit  
(gestation 
wk) 
lean  
mean (SD)  
(n=26) 
OW/OB  
mean (SD) 
(n=16) 
lean versus 
OW/OB 
2 sample t-
test p value 
 
change in total 
body skinfold 
(millimetres)  
 
V1-V2 
 
V2-V3 
 
V1-V3 
 
13.2 (12.5) 
 
8.1 (12.0) 
 
21.3 (15.2) 
 
17.5 (17.8) 
 
15.3 (11.8) 
 
32.8 (18.5) 
 
0.41 
 
0.065 
 
0.046 
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3.6.2 Upper body peripheral skinfolds 
When upper body peripheral skinfolds were assessed, results indicated that 
OW/OB women gained more fat in upper body peripheral skinfolds in late 
pregnancy compared to the lean group but this was of borderline significance 
(p=0.053). 
Table 3.3 Changes in upper body peripheral skinfold measurements in lean and OW/OB 
pregnancy during different gestational time periods. Illustrated are the mean measurements 
(raw data) and standard deviations for the changes seen in upper body peripheral skinfolds during 
each gestational period. Statistical analysis performed using 2 sample t-test assessing each 
gestational time period: early (V1-V2), late (V2-V3) and total gestation (V1-V3), where V1=visit 1, 
V2=visit 2 and V3=visit 3. 
anthropometric 
parameter 
 
visit  
(gestation 
wk) 
lean  
mean (SD)  
(n=26) 
OW/OB  
mean (SD) 
(n=16) 
lean versus 
OW/OB 
2 sample t-
test p value 
 
change in upper 
body peripheral 
skinfold 
(millimetres)  
 
V1-V2 
 
V2-V3 
 
V1-V3 
 
2.2 (4.3) 
 
0.1 (4.9) 
 
2.4 (5.2) 
 
2.2 (4.6) 
 
3.5 (5.4) 
 
5.6 (6.9) 
 
0.96 
 
0.053 
 
0.12 
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3.6.3 Lower body skinfolds 
When lower body skinfolds were assessed as suggested in Figure 3.5, the OW/OB 
women gain more fat in the lower body compartments during pregnancy than 
lean women but this is not specific to any gestational time period, (p=0.034).  
Table 3.4 Changes in lower body skinfold measurements in lean and OW/OB pregnancy 
during different gestational time periods. Illustrated are the mean measurements (raw data) and 
standard deviations for the changes seen in lower body skinfolds during each gestational period. 
Statistical analysis performed using 2 sample t-test assessing each gestational time period: early 
(V1-V2), late (V2-V3) and total gestation (V1-V3), where V1=visit 1, V2=visit 2 and V3=visit 3. 
anthropometric 
parameter 
 
visit  
(gestation 
wk) 
lean  
mean (SD)  
(n=26) 
OW/OB  
mean (SD) 
(n=16) 
lean versus 
OW/OB 
2 sample t-
test p value 
 
change in lower 
body skinfold 
(millimetres)  
 
V1-V2 
 
V2-V3 
 
V1-V3 
 
4.4 ((4.4) 
 
4.3 (4.9) 
 
8.6 (5.2) 
 
8.1 (8.1) 
 
6.2 (7.1) 
 
14.3 (9.2) 
 
0.10 
 
0.36 
 
0.034 
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3.7 Gestational pattern of subcutaneous adipose tissue 
accumulation in lean and OW/OB women  
From the previous analysis, there was some evidence that lean and OW/OB 
women gained subcutaneous fat in different patterns during pregnancy. We 
wanted to further explore this further and assess the gestational timing of 
subcutaneous fat accumulation separately within the groups. In order to achieve 
this we performed repeated measures ANOVA with Tukey post hoc analysis.  
3.7.1 Lean pregnancy  
3.7.1.1 Total skinfolds 
In lean pregnancy, repeated measures ANOVA and post hoc analysis indicated 
that there was a significant increase in total body skinfolds in early and late 
pregnancy and across total gestation (p<0.0001). This would suggest that lean 
women gain fat in the measured subcutaneous fat depots across gestation, but 
that there is no specific gestational time period when this gain is concentrated. 
This suggests that the trend observed in section 3.6.1 is not a true trend. 
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Figure 3.9 Temporal accumulation of adipose tissue in the total skinfolds in lean pregnancy. 
Gestational time points are illustrated on the x axis and logged values are quotes on the y axis. 
Analysis performed on logged values following Ryan-Joiner normality testing. Analysis performed 
using repeated measures ANOVA, significant result if p<0.01. Data with different superscript levels 
a,b,c
 are significantly different from each other. There was a significant increase in total skinfolds 
measurements between 15 weeks and 25 weeks, and between 25 weeks and 35 weeks, and 
between 15 weeks and 35 weeks gestation in lean pregnancy.   
 
  a              b              c            p<0.0001 
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3.7.1.2 Upper body peripheral skinfolds 
In lean pregnancy, repeated measures ANOVA and post hoc analysis showed that 
lean women do gain fat in the upper body peripheral skinfolds during pregnancy. 
Post hoc analysis indicated that this increase was significant in early pregnancy 
but not late pregnancy. This suggests that lean women gain fat in this depot in 
early pregnancy but not late pregnancy, confirming the trend seen in section 
3.6.2.  
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Figure 3.10 Temporal accumulation of adipose tissue in the upper body peripheral skinfolds 
in lean pregnancy. Gestational time points are illustrated on the x axis and logged values are 
quotes on the y axis. Analysis performed on logged values following Ryan-Joiner normality testing. 
Analysis performed using repeated measures ANOVA, significant result if p<0.01. Data with 
different superscript levels 
a,b
 are significantly different from each other. There was a significant 
increase in upper body peripheral skinfolds measurements between 15 weeks and 25 weeks and 
between 15 weeks and 35 weeks gestation, but not between 25 weeks and 35 weeks in lean 
pregnancy. 
 
 
 
  
  a              b             b            p=0.002 
Chapter 3  102 
3.7.1.3 Lower body skinfolds 
In lean pregnancy, repeated measured ANOVA and post hoc analysis indicated 
that there was a significant increase in lower body skinfolds in early and late 
pregnancy and across total gestation (p<0.0001). This would indicate that lean 
women accumulate a significant amount of adipose tissue in the lower body 
compartment across gestation rather than at a specific gestational time point, 
confirming findings in section 3.6.3. 
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Figure 3.11 Temporal accumulation of adipose tissue in the lower body skinfolds in lean 
pregnancy. Gestational time points are illustrated on the x axis and logged values are quotes on 
the y axis. Analysis performed on logged values following Ryan-Joiner normality testing. Analysis 
performed using repeated measures ANOVA, significant result if p<0.01. Data with different 
superscript levels 
a,b,c
 are significantly different from each other. There was a significant increase in 
lower body skinfolds measurements between 15 weeks and 25 weeks, and between 25 weeks and 
35 weeks, and between 15 weeks and 35 weeks gestation in lean pregnancy.   
. 
 
 
 
 
 
  
  a              b              c            p<0.0001 
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3.7.2 OW/OB pregnancy 
3.7.2.1 Total skinfolds 
In OW/OB pregnancy, repeated measures ANOVA and post hoc analysis indicated 
that there was a significant increase in total body skinfolds in early and late 
pregnancy and across total gestation (p<0.0001). This would suggest that OW/OB 
women gain fat in the measured subcutaneous fat depots across gestation, but 
that there is no specific gestational time period when this gain is concentrated, 
confirming findings in section 3.6.1. 
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Figure 3.12 Temporal accumulation of adipose tissue in the total skinfolds in OW/OB 
pregnancy. Gestational time points are illustrated on the x axis and logged values are quotes on 
the y axis. Analysis performed on logged values following Ryan-Joiner normality testing. Analysis 
performed using repeated measures ANOVA, significant result if p<0.01. Data with different 
superscript levels 
a,b,c
 are significantly different from each other. There was a significant increase in 
total skinfolds measurements between 15 weeks and 25 weeks, and between 25 weeks and 35 
weeks, and between 15 weeks and 35 weeks gestation in OW/OB pregnancy.   
 
 
 
 
  
  a              b              c            p<0.0001 
Chapter 3  104 
3.7.2.2 Upper body peripheral skinfolds 
In OW/OB pregnancy, repeated measures ANOVA and post hoc analysis indicated 
that there was no significant increase in upper body peripheral skinfold thickness 
during early or late gestation but that the total gestational increase in this fat 
depot was significant (p=0.002). Therefore, OW/OB women do gain fat in the 
depot but it is continuous across pregnancy not concentrated in early or late 
pregnancy, which confirms findings in section 3.6.2. 
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Figure 3.13 Temporal accumulation of adipose tissue in the upper body peripheral skinfolds 
in OW/OB pregnancy. Gestational time points are illustrated on the x axis and logged values are 
quotes on the y axis. Analysis performed on logged values following Ryan-Joiner normality testing. 
Analysis performed using repeated measures ANOVA, significant result if p<0.01. Data with 
different superscript levels 
a,b,
 are significantly different from each other. There was a significant 
increase in upper body peripheral skinfolds measurements between 15 weeks and 35 weeks, but 
not between 15 weeks and 25 weeks, and between 25 weeks and 35 weeks gestation in OW/OB 
pregnancy.   
 
 
 
 
 
  
    a             ab             b            p=0.002 
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3.7.2.3 Lower body skinfolds 
In OW/OB pregnancy, repeated measures ANOVA and post hoc analysis indicated 
that there was a significant increase in lower body skinfolds in early and late 
pregnancy and across total gestation (p<0.0001). This would indicate that 
OW/OB women accumulate a significant amount of adipose tissue in the lower 
body compartment across gestation rather than at a specific gestational time 
point, which confirms findings in section 3.6.3. 
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Figure 3.14 Temporal accumulation of adipose tissue in the lower body skinfolds in OW/OB 
pregnancy. Gestational time points are illustrated on the x axis and logged values are quotes on 
the y axis. Analysis performed on logged values following Ryan-Joiner normality testing. Analysis 
performed using repeated measures ANOVA, significant result if p<0.01. Data with different 
superscript levels 
a,b,c
 are significantly different from each other. There was a significant increase in 
lower body skinfolds measurements between 15 weeks and 25 weeks, and between 25 weeks and 
35 weeks, and between 15 weeks and 35 weeks gestation in OW/OB pregnancy.   
 
 
 
 
 
 
  
  a              b              c            p<0.0001 
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3.8 The contribution of subcutaneous fat depots to fat 
mass in pregnancy in lean and OW/OB women  
Having assessed the different patterns of fat accumulation between groups, 
further analysis was performed to assess what contribution all anatomical sites 
subcutaneous adipose tissue (upper body peripheral, abdominal and lower body) 
had on the total gestational fat mass gain. This was performed using the 
Pearson’s correlation for univariate associations and General Linear Model for 
multivariate analysis. 
 
3.8.1 Lean pregnancy  
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in grouped skinfolds, total skinfolds 
and fat mass. The change in upper body peripheral and abdominal but not lower 
body skinfold thickness significantly correlated with the change seen in fat mass 
(table 3.5).  
Table 3.5 Univariate analysis of the association between gestational change in 
anthropometric fat depots and the gestational change seen in fat mass in lean pregnancy. 
Analysis was performed using Pearson’s correlation, significant result if p<0.01. Total body 
skinfolds shown as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as 
LBS.  
 TBS 
(mm) 
UPBS 
(mm) 
ABS 
(mm) 
LBS 
(mm) 
V1-V3 fat mass (kg) 
Pearson correlation 
P value 
 
0.725 
<0.0001 
 
0.508 
0.009 
 
0.581 
0.002 
 
0.437 
0.029 
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Multivariate analysis using the General Linear Model is illustrated in Table 3.6. 
This indicated that there was no anatomical fat depot which was independently 
associated with the gain seen in fat mass during gestation in lean pregnancy.  
Table 3.6 Multivariate analysis of the contribution of gestational change in anthropometric 
fat depots to the gestational change seen in fat mass in lean pregnancy. Assessment 
performed using the General Linear Model, significant result if p<0.01. Upper body peripheral 
skinfolds as UPBS, abdominal skinfolds as ABS and lower body skinfolds as LBS. The contribution 
of each component expressed as a percentage (%).  
 anthropometric 
parameter 
 
p value % contribution 
 
V1-V3 fat mass  
 
UBPS 
 
 
ABS 
 
LBS 
 
0.45 
 
 
0.11 
 
0.13 
 
0.02% 
 
 
7.6% 
 
6.6% 
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3.8.2 OW/OB pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in grouped skinfolds, total skinfolds 
and fat mass (table 3.7). The changes in the grouped anatomical skinfolds did 
not correlate with the changes seen in fat mass in OW/OB pregnancy. The 
change in total skinfolds and the change seen in fat mass were of borderline 
significance.  
Table 3.7 Univariate analysis of the association between gestational change in 
anthropometric fat depots and the gestational change seen in fat mass in OW/OB 
pregnancy. Analysis was performed using Pearson’s correlation, significant result if p<0.01. Total 
body skinfolds shown as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds 
as LBS. 
 TBS 
(mm) 
UPBS 
(mm) 
ABS 
(mm) 
LBS 
(mm) 
V1-V3 fat mass (kg) 
Pearson correlation 
P value 
 
0.585 
0.017 
 
0.444 
0.085 
 
0.310 
0.24 
 
0.441 
0.088 
 
 
Multivariate analysis using the General Linear Model is illustrated in Table 3.8. 
This indicated that in OW/OB pregnancy the changes in grouped subcutaneous 
fat depots contributed little to the overall change seen in fat mass. This may 
indicate that subcutaneous fat is not the main site of fat accumulation during 
OW/OB pregnancy.  
Table 3.8 Multivariate analysis of the contribution of gestational change in anthropometric 
fat depots to the gestational change seen in fat mass in OW/OB pregnancy. Assessment 
performed using the General Linear Model, significant result if p<0.01 Upper body peripheral 
skinfolds as UPBS, abdominal skinfolds as ABS and lower body skinfolds as LBS. The contribution 
of each component expressed as a percentage (%).  
 anthropometric 
parameter 
 
p value % contribution 
 
V1-V3 fat mass  
 
UBPS 
 
 
ABS 
 
LBS 
 
0.17 
 
 
0.55 
 
0.47 
 
12.2% 
 
 
2.1% 
 
3.2% 
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3.9 Discussion 
Gestation is associated with a significant increase in total body weight and fat 
mass in both lean and OW/OB pregnancies. Our results (average increase in total 
body weight 10.1kg (SD 3.5) and fat mass 4.2kg (3.7) for entire cohort) were 
consistent with published data. Soltani (Soltani and Fraser, 2000) demonstrated 
significant increases in total body weight and fat mass accumulation from 13-36 
weeks gestation of 10.9kg [SD 4.7]kg (p<0.001) and 4.6 [SD 3.3]kg (p<0.001) 
respectively. The OW/OB group remained significantly heavier in terms of both 
total body weight and fat mass throughout pregnancy. Ehrenberg et al 
(Ehrenberg et al., 2003) showed that lean and OW/OB women gained similar 
amounts in total body weight (lean 12.3kg versus OW/OB 13kg, p=0.61) and fat 
mass (lean 4.7kg versus 4.2kg (p=0.58) respectively. When compared, our 
findings showed that lean and OW/OB women also gained similar amounts of 
total body weight (lean gain 9.5 [4.8]kg versus OW/OB gain 10.4 SD [2.4]kg 
p=0.48) and fat mass during pregnancy (lean gain 4.3 [3.6]kg versus OW/OB gain 
4.0 [4.0]kg, p=0.80). Thus the data shown here are consistent with the 
literature.    
 
Compared to the IOM guidelines for GWG, on average the lean group gained less 
(10.4kg [SD 2.4]) than the minimum recommended GWG of 11.5kg (BMI 18.5-
24.9kg/m2 total recommended GWG 11.5-16kg). When examined further, 19 lean 
women gained less than the minimum recommended 11.5kg and only 7 lean 
women gained between the recommended GWG (11.5-16kg). No lean woman 
gained more than the maximum recommended 16kg. On average the OW/OB 
group gained more (9.5kg [4.8]) than the maximum of 9kg (BMI>30kg/m2 total 
recommended GWG 5-9kg). Further analysis indicated that 50% of the OW/OB 
group (n=8) gained more than the maximum 9kg recommended (this included 
three women with overweight booking BMI of less than 30kg/m2), 6 women 
gained between the recommended 5-9kg and 2 women (both booking 
BMI>35kg/m2) gained less than the minimum recommended GWG of 5kg. This 
may illustrate that in a healthy lean Scottish cohort the IOM GWG 
recommendations are too high and not reflective of this population’s behaviour 
and lifestyle. In the OW/OB population this finding may reflect that the public 
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health message regarding excessive gestational weight gain is not being 
acknowledged or in fact being disseminated to this pregnant population. 
All measured skinfolds increased significantly during gestation indicating that 
both lean and OW/OB women gain subcutaneous fat in the measured depots 
during pregnancy. OW/OB women had significantly larger subcutaneous fat 
depots at all measured gestational time points. Therefore it is likely OW/OB 
women enter pregnancy with larger subcutaneous fat depots than lean women.  
The increase in all depots during pregnancy suggests that the measured 
subcutaneous fat depots were important sites of fat accumulation during 
pregnancy for both lean and OW/OB women.  In lean women, a smaller increase 
in subcutaneous fat skinfold reflects a larger proportional increase in fat mass 
compared to the OW/OB counterparts. Taggart found that obese women had 
smaller relative gains in total skinfolds than lean women during pregnancy 
(Taggart et al., 1967). Our data does not suggest that OW/OB women gain less in 
the subcutaneous depot, and post hoc analysis of the grouped skinfolds suggests 
they gain more subcutaneous fat in the lower depots compared to the lean 
women (14.3 [SD 9.2]mm versus 8.6 [SD5.2]mm respectively (p=0.034). 
 
The contribution of the subcutaneous fat depots to gestational fat mass gained 
was assessed. In univariate analysis, lean pregnancy fat mass was significantly 
associated with upper body peripheral skinfolds, abdominal skinfolds and total 
body skinfolds. However, in multivariate analysis, each anatomical fat depot 
group did not explain the variation seen in the change in gestational fat seen in 
lean pregnancy. This may reflect that in lean women subcutaneous fat in general 
is an important site of fat storage in pregnancy. In OW/OB pregnancy, no 
specific subcutaneous skinfolds depots or the total skinfolds contributed 
significantly to gestational fat mass.  This finding may suggest that OW/OB 
women are gaining fat preferentially in other depots such as visceral 
compartments during pregnancy. 
 
However, as the measured skinfolds are increasing during pregnancy then they 
must contribute to the increase seen in gestational fat mass to a greater or 
lesser extent. Therefore this raised the question as it how accurately the 
methods employed were in measuring fat mass in this study. In terms of skinfold 
thickness, this seven point method was validated against underwater weighing 
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by Presley et al (Presley et al., 2000). Total body weight and fat mass was 
measured by air displacement plethysmography which, because it is a two 
compartment method, cannot account for the changes in either visceral and 
subcutaneous depot sites nor the changes which are occurring in the fetal 
compartment. In addition, assessing the changes in fat accumulation at three 
gestational points may not be adequate enough, for instance measurements 
prepregnancy and before 12 weeks of pregnancy may be valuable. This may be a 
reason why not significant associations were reported in this analysis.  
 
The current analysis, indicated that although the timing of the accumulation of 
total fat was similar there was a difference between lean and OW/OB women in 
the anatomical location of fat at different gestations indicated by significant 
interaction terms in the mixed model.  
 
The pattern of change in the accumulation of fat in the upper body peripheral 
depots was different between lean and OW/OB women (p=0.047). Post hoc 
analysis suggested that OW/OB women continued to gain fat in this depot in late 
pregnancy but the lean did not. This finding was supported by the repeated 
measures ANOVA analysis which indicated that lean women gained adipose tissue 
in this depot in early pregnancy but not in late pregnancy. Interestingly, the 
finding in the lean group of no increase in the upper body peripheral skinfold 
thickness during late pregnancy, is supportive of one of the outcomes of 
Taggart’s early work which showed no increase in the triceps skinfold in late 
pregnancy.  
 
For the lower body depots the pattern of accumulation of adipose tissue was the 
same in the lean and OW/OB groups as both groups continued to accumulate fat 
in this depot throughout gestation. Therefore, this finding does not support our 
hypothesis that lean women gain fat preferentially in lower body fat stores. 
 
The lack of correlations between accumulated fat mass and the change in total 
skinfold in OW/OB women suggests that OW/OB women may accumulate fat in 
other anatomical sites. In lean women, although there was a correlation 
between abdominal depots, upper body peripheral depots and fat mass, neither 
variable explained the increase in gestational fat mass in multivariate analysis. 
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Therefore the significant correlation could be the result of colinearity between 
the depots.  One subcutaneous fat depot which was not measured directly was 
the buttock. An indirect assessment of this depot, the hip and upper thigh 
circumference, was performed. This indicated that there were gestational 
increases in these depots, but that these were not significantly different from 
lean women.  
 
Another variable which has not been accounted for in this cohort is the impact 
of visceral fat accumulation on total body weight and fat mass during pregnancy. 
Visceral fat is comprised of a variety of potentially functional different depots 
including omental fat, prepertitoneal fat and adipose tissue attached directly to 
the organs. Kinoshita (Kinoshita and Itoh, 2006) performed ultrasonographic 
assessment of preperitoneal fat and showed that there was an increase in this 
fat depot during pregnancy suggesting that a proportion of the gestational fat 
mass is gained in the intra-abdominal compartment. Sohlstrom and Forsum 
(Sohlstrom and Forsum, 1995) used MRI to assess fat accumulation and 
distribution in a non-obese cohort (prepregnancy BMI 23.3 (SD 3.2) range 17.3-
29.1, n=25). They showed that the majority of adipose tissue was accrued in the 
subcutaneous compartment, and that 68% of this was in the trunk. We did not 
directly measure lower back adipose tissue skinfolds and thus our assessment of 
truncal adiposity may be incomplete. Our lack of ultrasound or MRI assessment 
of visceral fat highlights the difficulty in performing a full anthropometric 
assessment and suggests that further investigation needs to involve assessment 
of the visceral fat compartment in a manner which is acceptable to participants 
and researchers alike. 
 
Another explanation for the lack of association between fat mass and 
subcutaneous fat depots in the OW/OB group is that during pregnancy although 
OW/OB women may gain fat in both subcutaneous and visceral sites they store 
proportionately more fat in the visceral depots as their subcutaneous sites are 
already replete. If we assume no colinearity then in lean pregnancy, women are 
able to keep accumulating fat in the subcutaneous depots throughout pregnancy 
therefore less accretion is seen in the visceral compartment.  
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The differences in the pattern of subcutaneous fat accumulation seen in the 
groups may reflect the higher rates of insulin resistance seen in OW/OB 
pregnancy compared to lean pregnancy in the later stages of pregnancy.  
 
The observation that lean women stop accumulating fat in the upper body 
peripheral skinfolds between 25 and 35 weeks, whereas OW/OB women do not 
may suggest that lean women are able to switch easily from a lipogenic to a 
lipolytic profile in later gestation whereas the OW/OB women remain lipogenic 
as well as lipolytic i.e. have higher NEFA turnover. If this is the case then this 
may indicate a lack of metabolic flexibility within the adipose tissue in OW/OB 
pregnancy, increased NEFA flux and consequently an increase in metabolic risk 
factors such as hyperinsulinaemia, hypertriglyerideamia and diastolic blood 
pressure (Bartha et al., 2007).  
 
The strength of the present study was the systematic methodology of the 
anthropometric measurements. All were performed by the same researcher who 
was trained in ISAK anthropometric techniques and recorded by the assisting 
research nurse in order to reduce bias. All study appointments were performed 
at the same time of day and all study participants attended following an 
overnight fast. The limitations of this analysis is that we did not measure the 
visceral compartment and therefore cannot confirm our above discussion points 
regarding the ratio of visceral to subcutaneous storage of adipose tissue in lean 
and OW/OB pregnancies. As discussed above, three anatomical groups were used 
for subcutaneous fat accumulation (upper body peripheral, abdominal and lower 
body). These groups did not include direct buttock measurements and therefore 
we may not have collected a data set which is truly representative of the 
changes in subcutaneous fat accumulation during pregnancy. In addition, due to 
difficulties recruiting women with very high BMI’s our OW/OB group included 
overweight women as well which will not represent the fat accumulation and 
distribution of very obese women. Such results may differ from our observations. 
 
In conclusion, as illustrated in figure 3.15, there are certain similarities in 
anthropometric gestational changes seen in lean and OW/OB pregnancies. Both 
gain total body weight and fat mass during pregnancy. Lean and OW/OB women 
gain similar amounts of both total body weight and fat mass during pregnancy. 
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However, lean women appear to accumulate fat in upper body peripheral 
storage sites in early pregnancy whereas OW/OB women gain fat globally 
throughout gestation. Therefore there is a difference in the lipolytic activity of 
this depot which may relate to metabolic flexibility in pregnancy. There was no 
significant contribution of the increase in the measured subcutaneous depots to 
the variation seen in gestational increase in fat mass in either lean or OW/OB 
pregnancies. This suggests that in both lean and OW/OB pregnancy other sites of 
fat storage which were not measured were important. Further analysis involving 
measurement of the visceral compartment would be helpful to explore the 
importance of this depot in gestational changes in body fat in lean and OW/OB 
pregnancies. 
 
Figure 3.15 Summary of anthropometric changes seen in healthy lean and OW/OB 
pregnancy. Summary of the similarities and differences seen in the anthropometric variables 
measured in healthy lean and OW/OB pregnancies and the impact of these findings on fat mass. 
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Chapter 4 - Energy metabolism during pregnancy 
and its relationship with mass and distribution of 
subcutaneous adipose tissue in lean and OW/OB 
pregnancy    
4.1 Introduction  
The energy demands on the mother during pregnancy can be categorised into 
three components. These are the conceptus (including the fetus, placenta, 
amniotic fluid and the expansion of blood volume) fat deposition in the mother 
and finally the energy spent on maintaining this new tissue (Prentice and 
Goldberg, 2000). It has been recognised that during pregnancy the basal 
metabolic rate increases and it has been observed to be higher in obese women 
compared to non-obese controls (Bronstein et al., 1996).  
In the past, nutrition and diet in pregnancy were often overlooked as it was 
assumed that the expectant mother would optimise her health and wellbeing for 
the good of her unborn child. In the context of the increasing rates of maternal 
obesity, women are entering pregnancy less healthy and more at risk from a 
range of serious maternal and fetal complications. Dietary intake during 
pregnancy should aim to provide enough energy, macro and micronutrients for 
both the metabolic needs of the mother and fetus without excessive maternal 
weight gain or fetal growth.  
General dietary advice, in the “ready steady baby!” publication (NHS, 2012b), is 
provided during the course of antenatal care but this does not specifically 
address the obese population. Recent guidance on the management of obese 
pregnancies (RCOG, 2010) highlighted the need for advising women about the 
importance of a healthy diet and exercise during pregnancy in order to avoid 
excessive weight gain and gestational diabetes. However, this recommendation 
was within the context of general dietary advice. The only specific nutritional 
guidance for obese woman was increased supplementation of folic acid and 
vitamin D (5mg and 10ug daily respectively), and the guidance did not discuss 
other aspects including fat and complex carbohydrate consumption. 
General levels of physical activity among adults have declined dramatically as a 
result of changes in work practices and technological advances. Previous 
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recommendations for physical activity during pregnancy were not based on 
scientific evidence but more on cultural and traditional norms. Current 
recommendations from the Royal College of Obstetricians & Gynaecologists 
suggest that exercise activities must balance the benefits and risks to both the 
mother and fetus (RCOG, 2006). Guidance for exercise intensity suggests a 
maximum heart rate of 60-70% for women who were sedentary prior to 
pregnancy. Recommendations from the American College of Obstetricians & 
Gynecologists suggests that pregnant women may safely engage in > 30 minutes 
of moderate physical activity on most, if not all days of the week (Artal and 
O'Toole, 2003). 
 
In the current literature, little is known about the impact of diet and exercise on 
gestational weight gain and their relationship with fat mass and distribution of 
adipose tissue during pregnancy. Given the current obesity epidemic seen in the 
obstetric population it is now even more important that these relationships are 
explored in order to optimise the management of obese pregnancies.  
 
This chapter examines the relationships between energy metabolism 
components, adiposity and fat distribution during pregnancy. 
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4.2 Research Questions  
1. Do measures of energy metabolism (basal metabolic rate, substrate 
utilisation and non-protein respiratory exchange ratio) change during 
pregnancy and do they differ between lean and OW/OB pregnancy?   
2. Do physical activity levels change during pregnancy and do they differ 
between lean and OW/OB women? 
3. Does dietary intake change during pregnancy and do they differ between 
lean and OW/OB pregnancy? 
4. If there are significant differences in the above aspects of energy 
metabolism between lean and OW/OB pregnancy, are these factors 
related to gestational fat mass accumulation and/or anatomical fat 
deposition during pregnancy? 
 
4.3 Methods 
Basal metabolic rate and substrate utilisation, physical activity and dietary 
intake assessment methodologies have been detailed in section 2.3 of the 
General Methods Chapter. All measurements were recorded by the researcher. 
Data for macronutrient intake is quoted in kilojoules per day, which is the same 
unit used for basal metabolic rate and substrate utilisation. The conversion 
factor for kilojoules to kilocalories is 1kilojoule=0.24 kilocalories. (www.unit-
conversion.info). 
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4.4 Gestational changes in basal metabolic rate and 
substrate utilisation  
4.4.1 Basal metabolic rate 
Basal metabolic rate (BMR) was assessed across time and between groups (figure 
4.1). Both groups show a significant increase in BMR during pregnancy (p 
time<0.0001); V1 average 5530 kJ/day (standard error of the mean [SEM] 142) 
versus V3 average 6080 (SEM 154) kJ/day.  The OW/OB group had a significantly 
higher BMR at all gestational time points (p type<0.0001); the mean lean BMR 
was 5341 kJ/day (SEM 85) versus OW/OB 6492kJ/day (SEM 127) across gestation.   
 
The pattern of increase in BMR between the two groups was similar (p time x 
type=0.15).  
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Figure 4.1 Basal metabolic rate at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean basal metabolic rate (BMR) (raw data) and the standard error of 
the mean at each gestational time point in lean and OW/OB pregnancy. Differences across 
gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern 
of change in the variable between the groups as ‘p time x type’.  
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4.4.2 Basal metabolic rate per kilogram body weight (BMR/kg) 
In order to ascertain whether the higher BMR observed in the OW/OB group was 
reflective of a true difference between the groups or whether this was simply a 
result of differences in maternal body mass, the BMR/kg body weight was 
compared between the groups using the linear mixed model. 
Across gestation there was no significant change in BMR/kg, p time=0.12. Lean 
women had a significantly higher BMR per kilogram of weight than OW/OB 
women; average lean 81.7kJ/Day/kg (SEM 1.3) versus OW/OB 70.9kJ/day/kg 
(SEM 0.8). 
The pattern of change in the BMR per kilogram was not significantly different 
between the lean and OW/OB pregnancies. 
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Figure 4.2 Basal metabolic per kilogram at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean basal metabolic rate per kilogram (BMR/kg)) (raw data) and the 
standard error of the mean at each gestational time point in lean and OW/OB pregnancy. 
Differences across gestation were expressed as ‘p time’, between the lean and OW/OB groups as 
‘p type’ and pattern of change in the variable between the groups as ‘p time x type’. 
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4.4.3  Non-protein respiratory exchange ratio  
Non-protein respiratory energy ratio (NPRER) expresses the ratio of carbohydrate 
oxidation to fat oxidation by calculating the rate of VO2 consumption to CO2 
production (see Chapter 2, section 2.3.1). The greater the ratio (i.e. the closer 
to 1.00 the value is), the higher the proportion of carbohydrates as opposed to 
fats being utilised as any energy source. 
 
NPRER was assessed across time and between groups (figure 4.3). There was no 
effect of gestation on NPRER (p time=0.72), There was a significant difference 
between the two groups (p type<0.0001); average lean NPRER 0.87 (SEM 0.02) 
versus OW/OB average NPRER 0.81 (SEM 0.08). The pattern of change in NPRER 
was not significantly different between the groups (p time x type=0.36). 
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Figure 4.3 NPRER at each gestational time point in lean and OW/OB pregnancy. Illustrated is 
the mean NPRER (raw data) and the standard error of the mean at each gestational time point in 
lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between the 
lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the groups as ‘p 
time x type’. 
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4.4.4 Fat oxidation 
Using the linear mixed model, fat oxidation was assessed across time and 
between groups (figure 4.4). There was no effect of gestation on fat oxidation (p 
time=0.59). Fat oxidation was different between the groups (‘p type’). OW/OB 
women utilised fat as an energy source to a greater extent than lean women; 
average lean fat oxidation 1947kJ/day (SEM 199) versus OW/OB average fat 
oxidation 2997 kJ/day (SEM 200).   
 
There was no difference in the fat oxidation across gestation (‘p time’) or 
pattern of change (‘p time x group’).  
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Figure 4.4 Rate of fat oxidation at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean rate of fat oxidation (raw data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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4.4.5 Carbohydrate oxidation 
The change in carbohydrate (CHO) oxidation was assessed across time and 
between the groups (figure 4.5). There was a trend for an increase in CHO 
utilisation during pregnancy (p time=0.039). There was a significant difference 
between the groups (‘p type’ <0.0001); average lean CHO oxidation 2319 kJ/day 
(SEM 192) versus OW/OB 1864 kJ/day (SEM 211).   
 
The interaction term (‘p time x group’) was not significant indicating that the 
lean and OW/OB have similar changes in CHO oxidation during pregnancy.  
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Figure 4.5 Rate of CHO oxidation at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean rate of CHO oxidation (raw data) and the standard error of the 
mean at each gestational time point in lean and OW/OB pregnancy. Differences across gestation 
were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change 
in the variable between the groups as ‘p time x type’. 
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4.5 Longitudinal changes in physical activity  
4.5.1 Sedentary activity time 
Sedentary activity time was assessed across time and between groups (figure 
4.6). There was no effect of gestation on sedentary activity time (p time=0.23).  
There was no difference in sedentary activity between the groups  
(p type=0.068).  
 
There was no difference in the pattern of change in sedentary activity time 
between the two groups, shown as the interaction term (‘p time x group’).  
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Figure 4.6 Daily sedentary activity time at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean daily sedentary activity time (raw data) and the standard error 
of the mean at each gestational time point in lean and OW/OB pregnancy. Differences across 
gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern 
of change in the variable between the groups as ‘p time x type’. 
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4.5.2 Light activity time 
There was no difference in daily light activity time across gestation and between 
the groups as shown in figure 4.7. There was no difference in the pattern of 
change in sedentary activity time between the two groups, show as the 
interaction term (‘p time x group’).  
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Figure 4.7 Daily light activity time at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean daily light activity time (raw data) and the standard error of the 
mean at each gestational time point in lean and OW/OB pregnancy. Differences across gestation 
were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change 
in the variable between the groups as ‘p time x type’. 
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4.5.3 Moderate & vigorous activity time 
Moderate and vigorous physical activity (MVPA) time was assessed across time 
and between the groups (figure 4.8). Across gestation, there was a significant 
fall in MVPA, p time=0.008; average visit 1 MVPA 29.4mins/day (SEM 3.0) versus 
visit 3 average MVPA 18.2mins/day (SEM 2.7). During pregnancy, lean women 
spent significantly more time in MVPA than OW/OB women; average lean 28.3 
mins/day (SEM 2.6) versus 18.6mins/day (SEM 1.8) respectively.  
 
There was no difference in the pattern of change in MVPA between the two 
groups, show as the interaction term (‘p time x group’).  
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Figure 4.8 Daily MVPA time at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean daily MVPA time (raw data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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4.6 Gestational changes in macronutrient dietary intake  
4.6.1 Daily energy intake 
Daily energy intake was assessed across time and between groups (figure 4.9). 
There was no impact of gestation or group on daily energy intake as shown in the 
figure below.  
 
The pattern of change in daily energy intake seen between the groups was also 
not significantly different. 
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Figure 4.9 Daily energy intake at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean daily energy intake (raw data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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4.6.2 Daily total fat intake 
The change in daily fat intake was assessed across gestation and between the 
groups (figure 4.10). There was no difference across gestation or between the 
groups in terms of daily fat intake.  
 
The pattern of change in daily fat intake between the two groups, (‘p time x 
group’) was similar.  
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Figure 4.10 Daily fat intake at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean daily fat intake (raw data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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4.6.3 Total carbohydrate intake 
The change in daily carbohydrate intake was assessed across gestation and 
between the groups (figure 4.11). There was no impact of gestation or group on 
daily carbohydrate intake.  
 
There was no difference across gestation in the pattern of change in daily 
carbohydrate intake seen between the groups. 
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Figure 4.11 Daily carbohydrate intake at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean daily carbohydrate intake (raw data) and the standard error of 
the mean at each gestational time point in lean and OW/OB pregnancy. Differences across 
gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern 
of change in the variable between the groups as ‘p time x type’. 
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4.6.4 Total protein intake 
The change in daily protein intake was assessed across gestation and between 
the groups (figure 4.12). There was no impact of gestation or group on daily 
protein intake.  
 
When the statistical model was applied to the data there was no difference in 
the pattern of change in daily protein intake seen between the groups as shown 
in figure 4.11.  
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Figure 4.12 Daily protein intake at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean daily protein intake (raw data) and the standard error of the 
mean at each gestational time point in lean and OW/OB pregnancy. Differences across gestation 
were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change 
in the variable between the groups as ‘p time x type’. 
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4.7 Summary of gestational changes seen in energy 
metabolism 
 
Figure 4.13 Summary of energy metabolism changes seen in healthy lean and OW/OB 
pregnancy. This figure summarises the gestational differences (previously expressed as ‘p time’), 
the differences between the groups (‘p type’) and the differences in the pattern of change (‘p time x 
type’) seen in lean and OW/OB pregnancy. 
 
Figure 4.13 summarises the analysis of the components of energy metabolism 
assessed in lean and OW/OB pregnancy. Across gestation BMR rose and MVPA 
time fell. Lean women had higher BMR/kg, NPRER, and carbohydrate oxidation 
and lower BMR and fat oxidation compared to OW/OB women. The higher BMR in 
OW/OB women is due to their greater body mass. After correction for body 
mass, it was seen that BMR/kg was in fact significantly higher in lean women. In 
addition lean women were more active than OW/OB women during pregnancy. 
There were no differences in the pattern of change in the above components of 
energy metabolism between lean and OW/OB women.  
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4.8 The contribution of energy metabolism to gestational 
fat mass and anatomical fat distribution  
Further analysis was performed on the components of energy metabolism which 
changed over gestation or differed between lean and OW/OB mothers and their 
relationship with observed changes in fat mass and specific subcutaneous fat 
depots. This analysis was performed using the entire cohort as the lack of 
interactions for any of the measurements of energy metabolism indicated that 
lean and OW/OB women responded to pregnancy in the same way. Using the 
entire cohort increased the sample size and added more power to the analysis. 
BMI was included in the analysis where appropriate as a covariate.   
 
Univariate analysis was performed using Pearson’s correlation to assess the 
relationships between absolute change in the anthropometric variables and 
BMR/kg, NPRER, and MVPA. A significant result was taken as p<0.01, but trends 
(p<0.05) were also explored further in multivariate analysis. These variables 
were chosen as NPRER incorporates both carbohydrate and fat oxidation. BMR/kg 
was included as this corrected for the increase in BMR associated with increased 
body mass in the OW/OB group.  
 
If a significant univariate correlation was found, multivariate analysis was 
performed. This was performed using the General Linear Model (significance 
level p<0.05) including the above variables and covariates. BMR and BMR/kg are 
related to therefore they were not analysed in the same model. BMI as a 
confounding variable was added to a further multivariate analysis when 
appropriate (i.e. when it was not represented elsewhere in the model).  
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4.8.1 Gestational changes in energy metabolism and total fat 
mass 
Univariate correlation analysis (table 4.1) was performed to assess the 
relationship between the absolute change in fat mass and absolute change in 
components of energy metabolism. 
Table 4.1 Univariate analysis of the association between gestational change in fat mass and 
the gestational change in energy metabolism in the entire cohort. Analysis performed using 
Pearson’s correlation, significant result if p<0.01. The basal metabolic rate/kilogram is shown as 
BMR/kg, non-protein respiratory exchange ratio as NPRER and moderate & vigorous activity as 
MVPA.  
 BMR/kg 
V1-V3 
NPRER 
V1-V3 
MVPA 
V1-V3 
V1-V3 fat mass  
Pearson correlation 
P value 
 
0.111 
0.50 
 
-0.023 
0.89 
 
0.186 
0.33 
 
There were no significant associations between the increase in fat mass during 
pregnancy and the change in BMR/kg, NPRER or MVPA.  
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The relationship between BMR/kg and MVPA was explored. The absolute values 
for BMR/kg and MVPA at each time point during gestation were plotted (figure 
4.14). Analysis of the data for all time points showed that BMR/kg was 
significantly correlated to MVPA. Thus women with a higher BMR/kg are more 
active. This may explain why the BMR/kg is higher in lean women. 
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Figure 4.14 Relationship between basal metabolic rate per kilogram versus moderate and 
vigorous activity for the entire cohort. Assessment performed using Pearson’s correlation, 
significant result if p<0.01. The time spent in MVPA in minutes is plotted against the BMR/kg in 
kilojoule per kilogram per day.. Basal metabolic rate/kilogram is shown as BMR/kg and moderate & 
vigorous activity is shown as MVPA. 
 
 
 
 
 
 
 
 
 
  
r=0.325 
p=0.001 
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4.8.2 Gestational change in energy metabolism and total body 
skinfolds 
Univariate analysis was performed to assess the relationship between the 
absolute change in total body skinfolds and gestational changes in energy 
metabolism (table 4.2). There were no significant association with the increase 
in total body skinfolds seen during pregnancy and BMR/kg, NPRER or MVPA. 
Table 4.2 Univariate analysis of the association between gestational change in total body 
skinfolds to the gestational change in energy metabolism in entire cohort. Assessment 
performed using Pearson’s correlation, significant result if p<0.01. The basal metabolic 
rate/kilogram is shown as BMR/kg, non-protein respiratory exchange ratio shown as NPRER and 
moderate & vigorous activity shown as MVPA.  
 BMR/kg 
V1-V3 
NPRER 
V1-V3 
MVPA 
V1-V3 
V1-V3 total body skinfolds  
 
Pearson correlation 
P value 
 
 
0.195 
0.22 
 
 
-0.143 
0.37 
 
 
-0.113 
0.55 
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4.8.3 Gestational change in energy metabolism and upper body 
peripheral skinfolds 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in upper body peripheral skinfolds and 
components of energy metabolism (table 4.3). There was a trend for the 
increase in upper body peripheral skinfolds change to be associated with the 
change in NPRER during pregnancy. 
Table 4.3 Univariate analysis of the association between gestational change in upper body 
peripheral skinfolds and the gestational change in energy metabolism in the entire cohort. 
Analysis performed using Pearson’s correlation, significant result if p<0.01. The basal metabolic 
rate/kilogram is shown as BMR/kg, non-protein respiratory exchange ratio as NPRER and 
moderate & vigorous activity as MVPA.  
 BMR/kg 
V1-V3 
NPRER 
V1-V3 
MVPA 
V1-V3 
 
V1-V3 upper body peripheral 
skinfolds 
Pearson correlation 
P value 
 
 
0.228 
0.15 
 
 
-0.314 
0.046 
 
 
-0.004 
0.98 
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The relationship between upper body peripheral skinfolds and NPRER was 
explored. The change in UBPS and the change in NPRER were plotted (figure 
4.15). If there is an increase in NPRER across gestation this indicates a move to 
more carbohydrate oxidation, a decrease in the NPRER suggests more fat 
oxidation. Therefore, a large increase in UBPS is related to a higher proportion 
of fat metabolism, whereas a small increase in UBPS is related to a higher 
degree of carbohydrate metabolism. 
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Figure 4.15 Relationship between the change in upper body peripheral skinfolds and the 
change in NPRER for the entire cohort. Assessment performed using Pearson’s correlation, 
significant result if p<0.01. The change in UBPS is plotted against the change observed in NPRER 
during pregnancy for the entire cohort. Upper body peripheral skinfolds is shown as UBPS. 
 
 
 
 
 
 
  
r=-0.314 
p=0.046 
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4.8.4 Gestational change in energy metabolism and abdominal 
skinfolds 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in abdominal skinfolds and 
components of energy metabolism. No significant associations were found. 
Table 4.4 Univariate analysis of the association between gestational change in abdominal 
skinfolds and the gestational change in energy metabolism in the entire cohort. Analysis 
performed using Pearson’s correlation, significant result if p<0.01. The basal metabolic 
rate/kilogram is shown as BMR/kg, non-protein respiratory exchange ratio as NPRER and 
moderate & vigorous activity as MVPA. 
 BMR/kg 
V1-V3 
NPRER 
V1-V3 
MVPA 
V1-V3 
 
V1-V3 abdominal skinfolds  
Pearson correlation 
P value 
 
0.038 
0.81 
 
0.190 
0.24 
 
-0.127 
0.50 
 
4.8.5 Gestational change in energy metabolism and lower body 
skinfolds 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in lower body skinfolds and 
components of energy metabolism. No significant associations were found. 
Table 4.5 Univariate analysis of the association between gestational change in lower 
skinfolds and the gestational change in energy metabolism in the entire cohort. Analysis 
performed using Pearson’s correlation, significant result if p<0.01. The basal metabolic 
rate/kilogram is shown as BMR/kg, non-protein respiratory exchange ratio as NPRER and 
moderate & vigorous activity as MVPA. 
 BMR/kg 
V1-V3 
NPRER 
V1-V3 
MVPA 
V1-V3 
 
V1-V3 lower body skinfolds 
Pearson correlation 
P value 
 
0.165 
0.30 
 
-0.161 
0.31 
 
-0.217 
0.25 
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4.9 Discussion 
In our study, there was a significant rise in basal metabolic rate during 
pregnancy and OW/OB women had higher rates of BMR than lean women. This is 
consistent with the current literature (Forsum and Lof, 2007, Lof et al., 2005).  
Although we found the increase in BMR continuous from 15 weeks’ gestation, 
other reports regarding the timing of increases in BMR differ. Some authors have 
reported that BMR only rises significantly after 32 weeks’ gestation (Forsum and 
Lof, 2007, Lof et al., 2005). Others have detected a rise in BMR from conception 
and a further increase in the third trimester (Chihara et al., 2002). Our study 
cannot comment on pre-conceptual or early pregnancy changes, and our results 
suggest that BMR increases throughout pregnancy rather than just in the third 
trimester.  
 
In this study, the higher rates of BMR in the OW/OB group simply reflect the fact 
that these women are significantly heavier throughout pregnancy than the lean 
women. In order to correct for the impact of higher body mass, basal metabolic 
rate per kilogram (BMR/kg) was calculated.  Lean women had significantly higher 
BMR/kg throughout pregnancy compared to OW/OB women (p type<0.0001). 
There was also a trend towards a different pattern of change in BMR/kg between 
the groups (p=0.065). Across gestation, BMR/kg fell continuously in the lean 
group but stayed relatively stable in the OW/OB group. Other authors have not 
discussed BMR/kg (Forsum and Lof, 2007, Chihara et al., 2002) and differences in 
maternal body mass between different studies may underlie the disparity in 
reported changes of BMR during pregnancy. As lean and OW/OB women gained 
the same fat mass and total body weight during pregnancy the observed 
gestational decline in BMR/kg observed must be explained by another 
component of energy metabolism.  
 
During pregnancy, both groups show a significant fall in MVPA levels and by the 
third trimester lean women have similarly low MVPA levels to that observed in 
OW/OB women. Throughout pregnancy, lean women are on average 37.4% more 
active during pregnancy than OW/OB women, based on time spent in MVPA. 
Conversely there was a trend for OW/OB women to be more sedentary than lean 
women throughout pregnancy but this did not reach significance. In under-
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nourished maternal populations, a fall in activity as pregnancy progresses has 
been thought to relate to conservation of energy in the face of an increasing 
basal metabolic rate (Lawrence et al., 1987). In affluent mothers, the fall in 
MVPA has also been suggested to be as a result of physical restrictions in moving 
because of maternal habitus and avoidance of activity which is considered a risk 
to fetus (Melzer et al., 2009).  
 
Interestingly in the univariate analysis there were no strong associations 
between the change in fat mass or total body skinfolds and BMR/kg, NPRER and 
MVPA. However, because BMR/kg and MVPA were different between the groups 
it was tested whether higher rates of physical activity accounted for the higher 
BMR per kilogram in the lean group. Plotting all time points we found that there 
was a significant association between BMR/kg and MVPA (p=0.001), suggesting 
that more active women have a higher BMR/kg. In our cohort physical activity 
appears to be a major determinant of BMR in pregnancy (r=0.325).  
 
In this cohort, we found that there was no difference across gestation or 
between the groups in terms of total energy and macronutrient intake. Our data 
suggested that our participants had similarly diets. Previous studies on diets 
during pregnancy have found very little change in terms of the increase in high 
energy (cakes, biscuits, processed meats, white bread) diet components (Crozier 
et al., 2009). Other authors however, have found significant increases in the 
dietary energy density during pregnancy and that high energy diets were 
significantly associated with total gestational weight gain (Deierlein et al., 
2008). Published data also show that those with a high pre-pregnancy BMI tended 
to consume a diet with high glycaemic loads (Deierlein et al., 2008). These 
contradictory findings highlight the difficulties in collecting dietary information. 
In our study, both groups gain a similar amount of GWG and fat mass during 
pregnancy which suggests a lack of difference in dietary energy intake. This 
suggests that managing gestational weight gain in a Scottish population by diet 
alone may not be successful and guidance should include encouraging OW/OB 
women to increase their physical activity prior and during pregnancy. It would 
be interesting to explore associations between insulin resistance and visceral fat 
accretion and gestational changes in BMR/kg and MVPA to see if this advice 
would lead to an improved metabolic profile. 
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As discussed above, there were no associations between the change in fat mass 
or total body skinfolds and measurements of energy metabolism. It cannot be 
ruled out that there is an element of fat mass not being assessed which is 
affected by MVPA; this may be the visceral compartment. Unfortunately the 
visceral compartment was not measured thus there is no information on this 
association in the current study. There is an abundance of data which indicates 
the association between physical activity and visceral fat in the adult non-
pregnant population. In inactive adults, prolonged bed rest is associated with an 
increase in visceral fat depots (Belavy et al., 2014). The converse of this is also 
true, a recent a meta-analysis showed that moderate and vigorous exercise 
programmes reduce visceral adiposity more than low-impact aerobic regimens in 
obese men and women (Vissers et al., 2013). Published data in an overweight 
and obese pregnant population found that women with the largest fall in MVPA 
across gestation had higher levels of plasma insulin and triglycerides and worse 
insulin sensitivity in late pregnancy (van Poppel et al., 2013). Although not 
examined in this cohort further analysis of this data could assess whether this 
association exists and if there are differences in any associations in lean 
pregnancies. Therefore, in an obstetric population whether lean or OW/OB, 
sedentary lifestyle may be a risk factor for increased deposition of visceral fat.  
 
Carbohydrate oxidation was on average 20% higher in lean women when 
compared to OW/OB group. The rate of fat oxidation was on average 36% higher 
in OW/OB pregnancies. These differences in substrate utilisation are reflected in 
the OW/OB women having lower NPRER. An increased fat oxidation may lead to 
a ‘switching off’ of glucose oxidation (Randle et al., 1963). However, in obesity 
the capacity of tissue, primarily muscle, to utilise fat is also diminished and this 
further enhances the development of insulin resistance (McGarry, 2002). OW/OB 
women have been found to be more insulin resistant during pregnancy and their 
increase in fat oxidation may represent an imbalance in fat and glucose 
utilisation resulting in increasing insulin resistance. Our results would also 
suggest that lean women continue to utilise glucose as an energy source even in 
the third trimester. This may represent a more flexible metabolic response in 
which they can utilise both fat and carbohydrate utilisation because of relative 
insulin sensitivity compared to the OW/OB group. 
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In terms of fat distribution however there was a trend for the change in upper 
body peripheral skinfolds to be negatively associated with the change in NPRER. 
Therefore, an increase in UBPS was related to a larger contribution from fat 
metabolism as pregnancy progresses, whereas a decrease in UBPS was related to 
a larger contribution from carbohydrate oxidation. These results suggest that 
there may be a mechanism by which decreases carbohydrate metabolism is 
associated with a preferential storage in fat in the upper body peripheral 
depots. OW/OB women had lower contribution from carbohydrate metabolism 
and lower NPRER during pregnancy and accumulated more fat in this depot that 
lean women, especially in the latter part of pregnancy. This may be because of 
other depots such as lower body, truncal and visceral compartments being more 
replete or that this is the only remaining compartment which can undergo 
healthy expansion during pregnancy. In non-pregnant OW/OB adults, reduced 
capacity of a subcutaneous fat depot to expand (using capillary density and 
quantified capillary branch formation to represent a depots expansion 
potential), was associated with increased insulin resistance (Gealekman et al., 
2011). Therefore, this finding may also reflect changes in insulin sensitivity in 
different fat depots depending on their expansion during pregnancy. In general 
adult populations it is recognised that abdominal subcutaneous adipocytes 
behave differently than visceral adipocytes (Pou et al., 2007, Fried et al., 1998), 
and that lower body adipose tissue function is different yet again (Jensen, 2008) 
with gynoid adiposity may be protective to health (McCarty, 2003). In healthy 
pregnancy, visceral adipocytes are smaller, less lipolytic and more insulin 
resistant than abdominal subcutaneous fat in the third trimester (Huda et al., 
2014). Once again this suggests that any differences in fat distribution seen 
between the groups could have an impact on metabolic adaptation to 
pregnancy.  
 
The strength of this study is the comprehensive methodology. The indirect 
calorimetry measurement technique (Oxycon) employed for basal metabolic rate 
and substrate utilisation has been compared to the gold standard technique of 
the Douglas bag (Rosdahl et al., 2010), and is technically reliable and 
reproducible. Air displacement plethysmography was employed to assess total 
fat mass, this gives a more objective measurement of fat mass and which was 
also corrected for gestational changes seen in interstitial fluid and oedema 
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accumulation. The measurement of physical activity was objective and there 
were no differences found in the time each accelerometer was worn across 
gestation or between the groups. Accelerometry has been used by other authors 
during pregnancy (van Poppel et al., 2013), and our methodology was based on 
pregnancy-related validation studies for wear time and number of valid wear 
days (Kinnunen et al., 2011). Dietary analysis is notoriously difficult to optimise 
due to the potential of recall bias. However, our 24 hour recall dietary 
questionnaire method has been validated in British populations (Holmes et al., 
2008). In order to reduce bias in the recall data protocols from the Food 
Standard Authority’s Low Income Diet and Nutrition Survey were used and the 
questionnaire conveniently took only 15-20 minutes to complete.  
 
There were limitations to the study. Although a rigorously tested method, air 
displacement plethysmography is a two compartment model measuring only fat 
mass and fat free mass. It did not distinguish the fetal and placental 
compartment from the maternal compartment nor was it able to differentiate 
between visceral and subcutaneous fat or fat distribution. Skinfold thickness 
measurements also only assessed selected subcutaneous fat depots and not 
visceral depots. One element which was included but not quantified is the fetal 
contribution to metabolism and energy requirements which may, especially in 
late gestation, impact on both maternal energy metabolism and fat accretion. In 
addition, power calculations did not include the number needed to recruit in 
order to find a difference in physical activity. Therefore although a difference 
was found in MVPA, the lack of differences found in sedentary and light activity 
may be a result of this data being underpowered. 
 
In conclusion, during pregnancy both lean and OW/OB women exhibited a rise in 
BMR and a reduction in MVPA. There were no differences in dietary intake either 
during pregnancy or observed between the lean and OW/OB group. Therefore, 
both lean and OW/OB women have a similar response in their energy metabolism 
to pregnancy. During pregnancy, OW/OB women had higher BMR which is due to 
their heavier total body weight. Lean women have a decline in BMR/kg over 
gestation that can be explained at least in part by their reduced physical 
activity. Their higher MVPA and BMR/kg could potentially mean a lesser degree 
of visceral fat accumulation but we cannot conclude this from our data. Lean 
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women also start pregnancy with relatively high carbohydrate oxidation (possibly 
due to greater insulin sensitivity) and are more active than OW/OB women. 
OW/OB women gain fat in the upper body peripheral fat depots throughout 
pregnancy. The association between NPRER and upper body peripheral skinfolds 
may reflect preferential fatty acid storage at this site and a switch to increased 
fat metabolism associated which may be associated with insulin resistance in 
OW/OB women. Therefore in healthy pregnancy, despite differences in substrate 
utilisation, the impact of energy metabolism is similar between lean and OW/OB 
women and appears to have no impact on overall fat mass accumulation.  
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Chapter 5 - Gestational carbohydrate, lipid and 
inflammatory profiles in lean and OW/OB 
pregnancies 
5.1 Introduction  
During healthy pregnancy, there are dramatic changes in lipid and carbohydrate 
metabolism in order to meet the changing metabolic demands for both the 
mother and fetus. These changes have been well documented in the current 
literature. 
 
There is a gradual increase in total triglycerides (estimated 2-3 fold increase) 
which peaks at term and falls to pre-pregnancy levels by about 6 weeks 
postpartum. Total cholesterol concentrations increase more modestly reaching 
approximately 50-60% above pre-pregnancy levels. The rise in LDL levels is 
proportional to the increase in cholesterol and remains elevated until 8 weeks 
postpartum. HDL exhibits a unique pattern of fluctuation during pregnancy 
which show a peak concentration at around 20 weeks’ gestation before a fall in 
levels in the third trimester (Sattar et al., 1997). These changes in lipid profiles 
are thought to be, in part, an oestrogenic response (Salameh and Mastrogiannis, 
1994). Gestational changes in lipid metabolism initially allow the accumulation 
of maternal fat stores before a more lipolytic phase in which there is an 
increased utilisation of maternal NEFA during late pregnancy in order that the 
fetus can preferentially use amino acids and glucose as energy sources. Studies 
have suggested that fatty acids may be important in the endothelial dysfunction 
seen in pregnancies affected by pre-eclampsia (Robinson, 2009). 
 
Cross-sectional assessment in the third trimester showed that in maternal 
obesity there is an exaggerated dyslipidaemia (raised TG and lower HDL), 
hyperinsulinaemia and a low grade inflammatory response (CRP and IL6) 
compared to lean pregnant women. (Ramsay et al., 2002a). Further longitudinal 
assessment of lean and OW/OB pregnancies indicated that this pro-inflammatory 
response exists from the first trimester onwards (Stewart et al., 2007a). 
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The concept of adipose tissue as an endocrine organ is now firmly established 
and the dysregulation of adipokine production from fat can lead to the 
pathogenesis of the metabolic syndrome in the non-pregnant population (Hutley 
and Prins, 2005). Both visceral and subcutaneous fat have been independently 
associated with markers of inflammation including CRP and IL6 (Pou et al., 
2007).  
 
In current published literature, little has been reported on differences in the 
pattern of change of markers of lipid, carbohydrate and inflammatory pathways 
specifically with reference to changes in body fat distribution associated with 
pregnancy. This chapter assesses these profiles longitudinally and relates them 
to the anatomical changes seen in fat accumulation during pregnancy. 
 
5.2 Research Questions  
1. What are the gestational changes in plasma markers of carbohydrate, lipid 
and inflammatory profiles in lean and OW/OB pregnancies? 
2. What are the differences between lean women and OW/OB women in 
terms of gestational change in plasma markers of carbohydrate, lipid and 
inflammation? 
3. Does anatomical distribution of subcutaneous fat during pregnancy have 
an impact on any changes in these plasma markers in lean and OW/OB 
pregnancies? 
 
5.3 Methods 
Plasma collection and methodology have been detailed in section 2.5 of the 
General Methods Chapter 2. Further information regarding specific analytic 
techniques has been detailed in each section of this results chapter.  
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5.4 Gestational changes in plasma markers of 
carbohydrate metabolism 
5.4.1 Fasting glucose 
Fasting glucose was assessed across time and between groups (figure 5.1). There 
was a borderline increase in fasting glucose during pregnancy; mean visit 1 
4.6mmol/L (SEM 0.05) versus mean visit 3 4.7mmol/L ( SEM 0.07), p time=0.019.  
 
There was no difference between the groups (p type=0.25) and in the pattern of 
change in fasting glucose between the two groups, shown as the interaction 
term (p time x group=0.24). 
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Figure 5.1 Fasting glucose at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean fasting glucose (raw data) and standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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5.4.2  Fasting insulin 
Fasting insulin was assessed across time and between groups (figure 5.2). There 
was a significant rise in fasting insulin during pregnancy in both groups; mean 
visit 1 5.0mU/L (SEM 0.5) versus mean visit 3 11.2mU/L (SEM 1.6), p 
time<0.0001. OW/OB women had significantly higher levels of fasting insulin 
during pregnancy compared  to lean women; mean OW/OB 11.3mU/L (SEM 0.9) 
versus mean lean 5.7mU/L (SEM 0.9), p type<0.0001.  The pattern of change in 
this plasma marker was not different between the groups (p time x type=0.76).   
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Figure 5.2 Fasting insulin at each gestational time point in lean and OW/OB pregnancy.  
Illustrated is the mean fasting insulin (raw data) and standard error of the mean at each gestational 
time point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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5.4.3 Insulin resistance 
Insulin resistance was assessed using the Homeostasis Model Assessment (HOMA).   
Using the linear mixed model HOMA was assessed across time and between 
groups (figure 5.3). There was a significant rise in insulin resistance during 
pregnancy in both groups; mean visit 1 HOMA 1.0 (SEM 0.1) versus mean visit 3 
HOMA 2.5 (SEM 0.4), p time<0.0001. OW/OB women were significantly more 
insulin resistant than lean women during pregnancy; mean OW/OB HOMA 2.4 
(SEM 0.2) versus mean lean 1.2 (SEM 0.2), p type<0.0001.  
 
Both groups showed a linear relationship between gestation and HOMA thus 
there was no difference pattern of change (p time x type=0.77) in insulin 
resistance.  
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Figure 5.3 Insulin resistance (HOMA) at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean HOMA and standard error of the mean at each gestational time 
point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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5.5 Gestational changes in plasma markers of lipid 
metabolism 
5.5.1 Total cholesterol 
The concentration of cholesterol was assessed across time and between the 
groups (figure 5.4). This indicated that there was a significant increase in total 
cholesterol during pregnancy; mean visit 1 cholesterol 5.4mmol/L (SEM 0.1) 
versus visit 3 total cholesterol 6.8mmol/L (SEM 0.2), p time<0.0001. There was 
no difference observed between the groups (p type=0.46) or in the pattern of 
change in total cholesterol (p time x type=0.37).  
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Figure 5.4 Total cholesterol at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean total cholesterol concentration (raw data) and standard error of the mean at 
each gestational time point in lean and OW/OB pregnancy. Differences across gestation were 
expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in 
the variable between the groups as ‘p time x type’. 
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5.5.2 High density lipoprotein 
The plasma concentration of HDL was assessed across time and between the 
groups (figure 5.5). Gestation did not have an impact on HDL concentration (p 
time=0.57). Lean women had significantly higher levels of HDL than OW/OB 
women during pregnancy; mean lean HDL 2.0mmol/L (SEM 0.04) versus mean 
OW/OB HDL 1.7mmol/L (SEM 0.04), p type=0.007.  There was no difference in 
the pattern of change seen between the groups (p time x type=0.40).  
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Figure 5.5 HDL at each gestational time point in lean and OW/OB pregnancy. Illustrated is the 
mean HDL concentration (raw data) and standard error of the mean at each gestational time point 
in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between 
the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the groups 
as ‘p time x type’. 
 
 
 
 
  
p time =0.57 
p type =0.007 
p time x type = 0.40 
OW/OB 
lean 
Chapter 5  153 
5.5.3 Total triglycerides 
The total triglyceride concentration was assessed across time and between the 
groups (figure 5.6). There was a significant increase in total triglycerides during 
pregnancy; mean visit 1 1.4mmol/L (SEM 0.1) versus mean visit 3 2.6mmol/L 
(SEM 0.1), p time<0.0001. OW/OB women had borderline higher levels of total 
triglycerides compared to lean women; mean OW/OB 2.2mmol/L (SEM 0.1) 
versus lean 1.8mmol/L (SEM 0.1), p type=0.017. There was no difference 
between the groups in pattern of change (p time x type=0.12). 
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Figure 5.6 Total triglycerides at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean total triglyceride concentration (raw data) and standard error of the mean at 
each gestational time point in lean and OW/OB pregnancy. Differences across gestation were 
expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in 
the variable between the groups as ‘p time x type’. 
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5.5.4 Non-esterified fatty acids 
NEFA concentration was assessed across time and between groups (figure 5.7). 
The levels of NEFA did not change significantly over the course of pregnancy (p 
time=0.75). Lean women had borderline higher levels of NEFA than OW/OB 
women during pregnancy; mean lean NEFA 1.4mmol/L (SEM 0.06) versus OW/OB 
1.1 (SEM 0.07), p type=0.012.  
 
The pattern of change seen in OW/OB pregnancy was significantly different 
between the groups (‘p time x type’=0.008).  In lean pregnancy the mean NEFA 
level remained essentially static (1.3mmol/L [SEM 0.1], 1.4mmol/L [SEM 0.1], 
1.4mmol/L [SEM 0.1] at visit 1, 2 and 3 respectively). In OW/OB women there 
was a fall in NEFA levels (1.3mmol/L [SEM 0.1], 1.1mmol/L [SEM 0.1] and 
0.9mmol/L [SEM 0.1] at visit 1, 2 and 3 respectively).  
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Figure 5.7 NEFA at each gestational time point in lean and OW/OB pregnancy. Illustrated is 
the mean NEFA concentration (raw data) and standard error of the mean at each gestational time 
point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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5.6 Gestational changes in plasma markers of 
inflammation 
5.6.1 C-reactive protein  
CRP concentration was assessed across time and between the groups (figure 
5.9). Over the course of pregnancy CRP levels fell significantly; mean visit 1 CRP 
5.5mg/L (SEM 0.8) versus mean visit 3 CRP 4.2mg/L (SEM 0.5), p time=0.004. 
During pregnancy CRP was significantly higher in OW/OB women compared to 
lean women; mean OW/OB CRP 7.7mg/l (SEM 0.7) versus lean 3.5mg/L (SEM 0.4) 
p type<0.0001.  
 
In both groups although the levels of CRP fell during pregnancy, the pattern of 
change was significantly different (p time x type=0.003). In lean pregnancy CRP 
measurements were 3.5mg/L (SEM 0.7), 3.8mg/L (SEM 0.7) and 3.1mg/L (SEM 
0.5) at visit 1, 2 and 3 respectively. In OW/OB pregnancy CRP levels were 
8.9mg/L (SEM 1.4), 8.5mg/L (SEM 1.2) and 5.7mg/L (SEM 0.8) at each gestational 
time point. 
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Figure 5.8 CRP at each gestational time point in lean and OW/OB pregnancy. Illustrated is the 
mean CRP concentration (raw data) and standard error of the mean at each gestational time point 
in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between 
the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the groups 
as ‘p time x type’. 
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5.6.2 Interleukin 6  
The change in IL6 concentration was assessed across time and between the 
groups (figure 5.10). Over the course of pregnancy IL6 levels rose significantly; 
mean visit 1 IL6 0.8pg/mL (SEM 0.05) versus visit 3 IL6 1.5pg/mL (SEM 0.08), p 
time<0.0001.  
 
During pregnancy IL6 concentration was different between OW/OB women and 
lean women, although the overall mean for lean and OW/OB women was similar; 
lean 1.1pg/mL (SEM 0.06) versus OW/OB 1.1pg/mL (SEM 0.07), p type<0.0001.  
 
In both groups although the levels of IL6 rose during pregnancy, the pattern of 
change was significantly different (p time x type<0.0001). In lean pregnancy IL6 
measurements were 0.8pg/mL (SEM 0.06), 1.0pg/mL (SEM 0.08) and 1.6pg/mL 
(SEM 0.1) at visit 1, 2 and 3 respectively. In OW/OB pregnancy IL6 levels were 
1.0pg/mL (SEM 0.1), 1.1pg/mL (SEM 0.1) and 1.3pg/mL (SEM 0.1) at each 
gestational time point.  
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Figure 5.9 IL6 at each gestational time point in lean and OW/OB pregnancy. Illustrated is the 
mean IL6 concentration (raw data) and standard error of the mean at each gestational time point in 
lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, between the 
lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the groups as ‘p 
time x type’. 
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5.6.3 Tumour necrosis factor alpha  
TNFα concentration was assessed across time and between the groups (figure 
5.11). Over the course of pregnancy TNFα levels did not change significantly (p 
time=0.044).  
 
During pregnancy TNFα was significantly higher in OW/OB women compared to 
lean women; mean OW/OB 1.6pg/mL (SEM 0.1) versus lean 0.8pg/mL (SEM 0.1), 
p type<0.0001.  
 
The pattern of change in TNFα levels was not different between the groups (p 
time x type=0.24).   
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Figure 5.10 TNFα at each gestational time point in lean and OW/OB pregnancy. Illustrated is 
the mean TNFα concentration (raw data) and standard error of the mean at each gestational time 
point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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5.7 Summary of gestational changes seen in 
carbohydrate & lipid metabolism and inflammatory 
markers 
 
Figure 5.11 Summary of the gestational changes in carbohydrate, lipid and inflammation 
profiles observed in lean and OW/OB pregnancy. This figure summarises the gestational 
differences (previously expressed as ‘p time’), the differences between the groups (‘p type’) and the 
differences in the pattern of change (‘p time x type’) seen in lean and OW/OB pregnancy. 
 
During pregnancy there are gestational changes which are the same for both 
lean and OW/OB pregnancy: an increase in insulin, HOMA, total cholesterol, 
total triglycerides and IL6. Interestingly, CRP falls during pregnancy in both 
groups. OW/OB women have higher levels of insulin, HOMA, CRP and TNFα and 
lean women have higher levels of HDL and IL6. From the above analysis the 
gestational pattern of NEFA, CRP and IL6 change in pregnancy is different 
between lean and OW/OB pregnancy. 
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5.8 Gestational pattern of change in plasma markers 
From the above analysis, it would appear that there are differences in the 
pattern of change seen in NEFA, CRP and IL6 in the lean and OW/OB groups.  
Post hoc analysis was carried out to assess the change in each variable across 
gestation using repeated measures ANOVA and post hoc Tukey test. This analysis 
was performed separately in the lean and OW/OB groups. All analysis was 
performed in Minitab vs16 and significance was considered as p<0.01.  
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5.8.1 Non-esterified fatty acids 
There was no significant change in NEFA concentration across gestation in lean 
pregnancy (figure 5.11).  
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Figure 5.12 Temporal changes in NEFA levels in lean pregnancy. Gestational time points are 
illustrated on the x axis and raw values are quotes on the y axis. Analysis performed on raw values 
following Ryan-Joiner normality testing. Analysis performed using repeated measures ANOVA, 
significant result if p<0.01. Data with different superscript levels are significantly different from each 
other. As each of the means is denoted by  
a 
 this indicates there is no difference between the 
mean values at each gestational time point.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  a              a              a            p=0.54 
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OW/OB women showed a significant fall in NEFA levels, (p=0.006), although 
there was wider variation in the concentration of NEFA in this group as 
pregnancy progressed Figure 5.12. Post hoc analysis suggested that there was a 
fall across the entire gestational period rather than at a specific time during 
pregnancy in OW/OB women.   
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Figure 5.13 Temporal changes in NEFA levels in OW/OB pregnancy. Gestational time points 
are illustrated on the x axis and raw values are quotes on the y axis. Analysis performed on raw 
values following Ryan-Joiner normality testing. Analysis performed using repeated measures 
ANOVA, significant result if p<0.01. Data with different superscript levels are significantly different 
from each other. As each of the means is denoted by  
a, ab, b 
 this indicates there is no difference 
between the mean values at 15 weeks and 25 weeks and between 25 weeks and 35 weeks. 
However there was a significant difference between 15 weeks and 35 weeks.   
 
Therefore the interaction between the group and time observed (‘p time x 
type’) in Figure 5.7 is explained by the fact that NEFA concentration remains 
stable in lean women but fall in OW/OB women during pregnancy.  
 
 
 
 
  
  a              ab              b            p=0.006 
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5.8.2 C-reactive protein 
Lean women did not show a significant change in CRP levels during pregnancy 
(p=0.31), Figure 5.13.  
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Figure 5.14 Temporal changes in CRP levels in lean pregnancy. Gestational time points are 
illustrated on the x axis and logged values are quotes on the y axis. Analysis performed on logged 
values following Ryan-Joiner normality testing. Analysis performed using repeated measures 
ANOVA, significant result if p<0.01. Data with different superscript levels are significantly different 
from each other. As each of the means is denoted by  
a 
 this indicates there is no  difference 
between the mean values at each gestational time point. 
 
 
 
 
 
 
 
  
  a              a              a            p=0.31 
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OW/OB women had a significant fall in CRP levels as pregnancy progressed 
(p<0.0001), Figure 5.14, and post hoc analysis indicated that the fall in CRP was 
significant between 25 weeks and 35 weeks.  
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Figure 5.15 Temporal changes in CRP levels in OW/OB pregnancy. Gestational time points are 
illustrated on the x axis and logged values are quoted on the y axis. Analysis was performed on 
logged data after a Ryan-Joiner test showed a non-normal distribution. Analysis was performed 
using repeated measures ANOVA, significance level was p<0.01. Data with different superscript 
levels 
a,b
 are significantly different from each other. There was no difference between the mean 
CRP at 15 weeks and 25 weeks. Between 15 weeks and 35 weeks and between 25 weeks and 35 
weeks there was a significant fall in CRP level.   
 
 
Therefore the interaction between the group and time observed (‘p time x 
type’) in Figure 5.8 is explained by the fact that CRP levels remains stable in 
lean women but fall in OW/OB women during late pregnancy.  
 
 
 
 
 
  
  a              a              b            p<0.0001 
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5.8.3 Interleukin-6 
Lean women showed a continual significant rise in IL6 levels during pregnancy 
(p<0.0001), Figure 5.15 which was not specific to either early or late pregnancy.  
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Figure 5.16 Temporal changes in IL6 levels in lean pregnancy. Gestational time points are 
illustrated on the x axis and logged values are quoted on the y axis. Analysis was performed on 
logged data after a Ryan-Joiner test showed a non-normal distribution. Analysis was performed 
using repeated measures ANOVA, significance level was p<0.01. Data with different superscript 
levels 
a,b,c
 are significantly different from each other. There was a significant increase in IL6 
between 15 weeks and 25 weeks, and between 25 weeks and 35 weeks, and between 15 weeks 
and 35 weeks.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  a              b              c            p<0.0001 
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OW/OB women also showed a significant rise in IL6 levels as pregnancy 
progressed (p=0.005), Figure 5.16. Post hoc analysis indicates that this rise in IL6 
occurs throughout pregnancy rather than a specific gestational time period.   
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Figure 5.17 Temporal changes in IL6 levels in OW/OB pregnancy. Gestational time points are 
illustrated on the x axis and logged values are quoted on the y axis. Analysis was performed on 
logged data after a Ryan-Joiner test showed a non-normal distribution. Analysis was performed 
using repeated measures ANOVA, significance level was p<0.01. Data with different superscript 
levels 
a,b
 are significantly different from each other. There was no difference in IL6 concentration 
between 15 weeks and 25 weeks or between 25 weeks and 35 weeks. However, between 15 
weeks and 35 weeks IL6 did increase significantly.  
 
 
Therefore, both lean and OW/OB women show a rise in IL6 during pregnancy. 
The significant interaction term in the linear mixed model analysis is explained 
by there being a greater increase in IL6 in the lean group compared to the 
OW/OB group. 
 
 
 
  
   a             ab             b            p=0.005 
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5.9 Associations between the increase in total fat mass, 
anatomical fat distribution and plasma markers of 
carbohydrate & lipid metabolism and inflammatory 
profiles  
Having assessed how plasma markers change in lean and OW/OB pregnancy, 
further analysis was performed to look for associations between changes in total 
fat mass and changes in anatomical location of subcutaneous adipose tissue 
(total body, upper body peripheral and lower body skinfolds) and changes in 
carbohydrate, lipid or inflammatory plasma markers. Where there were no 
interactions between group and gestation in the initial analysis described above 
(fasting glucose, total cholesterol, total triglycerides, fasting insulin, TNFα, and 
HDL), the lean and OW/OB groups were combined as a single cohort to analyse 
relationships between changes in body fat distribution and changes in plasma 
biomarkers. Where an interaction between lean and OW/OB group and gestation 
existed i.e. for NEFA, CRP and IL6, associations between changes in total fat 
mass and grouped skinfolds with changes in plasma biomarkers was assessed 
separately for each group.  
 
Univariate analysis was performed using Pearson’s correlations, and significance 
level was set at p<0.01 to mitigate for multiple testing. If a significant univariate 
association was found, multivariate analysis was performed using the General 
Linear Model (significance p<0.05). The anthropometric measures included in 
this analysis were fat mass, total body skinfolds, upper body peripheral skinfolds 
and lower body peripheral skinfolds.  
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As shown in Table 5.1, there were no significant correlations between the 
absolute change in plasma markers and absolute change in fat mass and 
anatomical skinfold groups using the whole cohort. There were trends for 
negative associations between change in LBS and change in total cholesterol, 
total triglyceride and a positive association with plasma glucose but these did 
not reach significance. As there were no significant univariate associations, no 
further analysis was performed. 
Table 5.1 Univariate analysis of the association between the gestational change in fat mass 
and skinfolds and the change in carbohydrate, lipid and inflammatory profiles. The table 
shows Pearson correlation and p values for plasma markers which changed significantly across 
gestation or between the groups. Significant result if p<0.01. Total body skinfolds shown as TBS, 
upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
Plasma marker 
V1-V3 
Fat mass  
V1-V3  
TBS V1-V3 
 
UPBS V1-V3  LBS V1- V3 
 
     
Total 
cholesterol  
Pearson’s 
correlation 
p value 
 
 
 
0.082 
0.62 
 
 
 
-0.027 
0.87 
 
 
 
0.254 
0.11 
 
 
 
-0.322 
0.043 
 
Total 
triglycerides  
Pearson’s 
correlation 
p value 
 
 
 
 
0.167 
0.31 
 
 
 
 
-0.125 
0.44 
 
 
 
 
0.032 
0.84 
 
 
 
 
-0.297 
0.063 
 
HDL 
Pearson’s 
correlation 
p value 
 
 
 
 
-0.044 
0.79 
 
 
 
0.046 
0.78 
 
 
 
0.074 
0.65 
 
 
 
0.076 
0.64 
Fasting glucose 
Pearson’s 
correlation 
p value 
 
 
0.133 
0.42 
 
 
0.269 
0.093 
 
 
0.029 
0.86 
 
 
0.297 
0.062 
 
Fasting insulin 
Pearson’s 
correlation 
p value 
 
 
 
0.143 
0.39 
 
 
 
0.013 
0.94 
 
 
 
-0.150 
0.36 
 
 
 
0.061 
0.71 
 
TNFα 
Pearson’s 
correlation 
p value 
 
 
 
-0.078 
0.65 
 
 
 
0.158 
0.34 
 
 
 
0.234 
0.16 
 
 
 
-0.010 
0.95 
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5.9.1 Association between gestational change in obesity 
measures and gestational change in NEFA 
5.9.1.1 Lean pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in NEFA and change in fat mass, total body, 
upper body peripheral and lower body skinfolds (Table 5.2). There were no 
significant correlations found in this analysis. 
Table 5.2 Univariate analysis of the association between the gestational change in NEFA 
and the gestational change in anatomical and total fat in lean pregnancy. Analysis was 
performed using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as 
TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
 
UPBS 
V1-V3  
 
LBS 
V1-V3 
 
V1-V3 NEFA 
Pearson correlation 
P value 
 
-0.103 
0.63 
 
-0.277 
0.18 
 
-0.050 
0.81 
 
-0.187 
0.14 
 
5.9.1.2 OW/OB pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in NEFA and change in fat mass, total 
body, upper body peripheral and lower body skinfolds (Table 5.3). There were 
no significant relationships between the change in NEFA and the change in fat 
mass total or grouped skinfolds. 
Table 5.3 Univariate analysis of the association between the gestational change in NEFA 
and the gestational change in anatomical and total fat in OW/OB pregnancy. Analysis was 
performed using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as 
TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
 
UPBS 
V1-V3  
 
LBS 
V1-V3 
 
V1-V3 NEFA 
Pearson correlation 
P value 
 
-0.084 
0.77 
 
-0.069 
0.81 
 
0.290 
0.30 
 
-0.330 
0.23 
 
  
Chapter 5  169 
5.9.2 Association between gestational change in obesity 
measures and gestational change in CRP 
5.9.2.1 Lean pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in CRP and fat mass, total body, upper 
body peripheral, abdominal and lower body skinfolds (Table 5.4). There were no 
significant associations between the grouped skinfolds and the change seen in 
CRP. 
Table 5.4 Univariate analysis of the association between the gestational change in CRP and 
the gestational change in anatomical and total fat in lean pregnancy. Analysis was performed 
using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as TBS, upper 
body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
UPBS 
V1-V3  
LBS 
V1-V3 
V1-V3 CRP 
Pearson correlation 
P value 
 
0.145 
0.50 
 
0.303 
0.14 
 
0.345 
0.091 
 
0.229 
0.27 
 
5.9.2.2 OW/OB pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in CRP and the change in fat mass, 
total body, upper body peripheral and lower body skinfolds (Table 5.5). There 
were no significant relationships between the change in CRP and the change in 
fat mass total or grouped skinfolds. 
Table 5.5 Univariate analysis of the association between the gestational change in CRP and 
the gestational change in anatomical and total fat in OW/OB pregnancy. Analysis was 
performed using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as 
TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
UPBS 
V1-V3  
 
LBS 
V1-V3 
 
V1-V3 CRP 
Pearson correlation 
P value 
 
0.359 
0.19 
 
0.021 
0.94 
 
-0.148 
0.60 
 
0.045 
0.88 
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5.9.3 Association between gestational  change in obesity 
measures and gestational change in IL6 
5.9.3.1 Lean pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in IL6 and fat mass, total body, upper 
body peripheral and lower body skinfolds (Table 5.6). There were no significant 
associations between gestational change in IL6 and grouped skinfolds in lean 
pregnancy. 
Table 5.6 Univariate analysis of the association between the gestational change in IL6 and 
the gestational change in anatomical and total fat in lean pregnancy. Analysis was performed 
using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as TBS, upper 
body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
UPBS 
V1-V3  
 
LBS 
V1-V3 
 
V1-V3 IL6 
Pearson correlation 
P value 
 
0.356 
0.088 
 
0.289 
0.16 
 
0.087 
0.68 
 
0.113 
0.59 
 
5.9.3.2 OW/OB pregnancy 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the absolute change in IL6 and change in fat mass, total 
body, upper body peripheral and lower body skinfolds (Table 5.7). There were 
no significant relationships between the change in IL6 and the change in fat mass 
total or grouped skinfolds in OW/OB pregnancy. 
Table 5.7 Univariate analysis of the association between the gestational change in IL6 and 
the gestational change in anatomical and total fat in OW/OB pregnancy. Analysis was 
performed using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown as 
TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 Fat mass 
V1-V3 
 
TBS 
V1-V3 
UPBS 
V1-V3  
 
LBS 
V1-V3 
V1-V3 IL6 
Pearson correlation 
P value 
 
-0.068 
0.81 
 
0.133 
0.64 
 
0.040 
0.89 
 
0.011 
0.97 
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5.10 Discussion 
There were no associations between the increase in total fat mass, total 
skinfolds and upper body peripheral skinfolds and changes in plasma biomarkers. 
There was a trend for the increase in lower body subcutaneous adipose depots to 
be inversely associated with the change in total cholesterol and total 
triglycerides, although this did not reach significance. These results may suggest 
that those women who gain more fat in lower body depots during pregnancy 
have an adverse lipid response to pregnancy, but this would require to be 
verified in a larger sample size study. Published data from the general adult 
population show that lower body fat is more insulin sensitive (Jensen, 2008) and 
smaller thigh fat depots are considered a risk factor for high levels of plasma 
triglyceride, low plasma HDL concentration and hyperglycaemia (Snijder et al., 
2005).  
 
The gestational increases in both total cholesterol and total triglycerides were as 
expected and have been observed before (Salameh and Mastrogiannis, 1994). 
The rise in total triglycerides and fall in plasma HDL is a likely response to the 
developing gestational insulin resistance secondary to rising levels of pregnancy 
related hormones (Emet et al., 2013, Salameh and Mastrogiannis, 1994) and 
patterns of change in HOMA, TG and HDL suggest that obese women have a shift 
towards a metabolic syndrome profile at all gestational time points. There was a 
significant rise in total triglycerides across gestation with a trend for the OW/OB 
group to have higher levels (p=0.017). However, the maximum concentrations 
reached by 35 weeks were very similar (lean 2.5mmol/L versus OW/OB 
2.68mmol/L) in the groups confirming previous observations (Meyer et al., 
2013). This suggests that a similar limiting factor, possibly lipoprotein lipase 
concentration or VLDL secretion rate, in the third trimester limits the maximum 
plasma triglyceride concentration reached. High plasma triglycerides 
concentrations are linked with greater oxidative stress and the production of 
small, dense LDL which are easily oxidised. High concentrations of oxidised lipids 
are associated with vascular damage (Norata et al., 2003). Current literature has 
found that in approximately a third of obese mothers there are increased levels 
of LDL-III in the third trimester (Meyer et al., 2013). It will be interesting to 
assess small, dense LDL-III levels in the present study and aliquots of plasma 
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have been retained for future ascertainment.  The low HDL and high 
triglycerides exhibited by the OW/OB women in the current study suggest they 
have metabolic syndrome but  that they are not in the subset of women most at 
risk of vascular damage through higher levels of LDL-III.  
 
Total cholesterol increased by approximately 25% and interestingly there were 
no lean/OW/OB group differences as observed for triglycerides. This might 
suggest that gestational cholesterol mobilisation is not related to gestational 
insulin resistance. The magnitude of the increase in plasma cholesterol is smaller 
than that of plasma triglyceride, suggesting a lower extent of cholesterol 
mobilisation or greater cholesterol utilisation than that for triglycerides by the 
mother and/or fetus.  
 
Lean women in this study had higher levels of HDL than OW/OB women, which is 
consistent with the current literature (Scifres et al., 2014, Stewart et al., 2007a, 
Ramsay et al., 2002a). A large recent study (n=225) (Scifres et al., 2014), has 
shown, similarly to the current data, that there was a peak in HDL concentration 
at 25 weeks’ gestation and then a fall in the third trimester in all pregnancies. 
This adds significant support to this finding of a peak HDL concentration mid-
gestation. HDL has been shown to offer vascular protection via a number of 
mechanisms including increased  production of NO via upregulation of eNOS 
expression (Mineo et al., 2006, Besler et al., 2012), preventing the formation of 
toxic oxidised lipid species (Mackness et al., 1993) and acting as an antioxidant 
(Besler et al., 2011). These properties suggest that HDL might confer significant 
protection to the maternal vascular endothelium in the face of the developing 
gestational hyperlipidaemia. The synthesis of HDL is determined by the 
production and secretion of apolipoprotein-A1 (Apo-A1), the main protein in 
HDL. However, the alterations in HDL concentration and function in pregnancy 
have not been fully investigated (Besler et al., 2012). An impaired improvement 
in endothelial function is a feature of obese pregnant women (Stewart et al., 
2007a). In the current study, although HDL concentrations were significantly 
higher in lean women, the pattern of change across pregnancy was the same. 
This suggests that the signal that determines HDL production in pregnancy are 
the same in both groups, i.e. the biosynthesis of apo-A1 regulated by oestrogens 
rather than an obesity-driven effect such as the negative impact of 
Chapter 5  173 
hypertriglyceridaemia on plasma HDL concentration. The higher levels of HDL 
found in the lean cohort may result in a more pronounced protective effect of 
HDL on vascular function than that in obesity where lower levels of HDL may 
lead to an increased susceptibility to vascular damage. This would be an 
interesting hypothesis to test in this data set at a later date. 
 
There was no significant association of plasma biomarkers with subcutaneous 
adipose depots. A possible explanation for the lack of association may be that 
there is an unmeasured fat depot unaccounted for in the present analysis having 
a confounding impact on these metabolic parameters. Changes in the visceral fat 
compartment or gluteal skinfolds were not assessed. Recent published data has 
suggested that gluteal but not abdominal subcutaneous adipose tissue have 
higher rates of gene expression involved in adipocyte differentiation (Divoux et 
al., 2014). Data presented in Chapter 3 suggest that there may be a contribution 
from the visceral compartment which cannot be measured using skinfold analysis 
or air displacement plethysmography. Alternatively the observed trends may not 
reach significance because of the small sample size.  
 
Where there was a significant interaction between the lean and OW/OB group 
then analysis was performed separately within each group, this was performed 
for CRP, IL6 and NEFA There were no significant associations between total fat 
mass, total skinfolds and fat distribution with the changes seen in these markers 
in either lean or OW/OB women suggesting that there is no innate differences in 
subcutaneous fat mass accumulation between lean and OW/OB women that 
account for the differences in these plasma markers. However, by separating the 
lean and OW/OB women for this analysis the sample size did become smaller and 
differences are more difficult to evaluate.  
  
The majority of the gestational changes (increases in total cholesterol, total 
triglycerides, fasting insulin, HOMA, and IL6 and fall in CRP) and group 
differences (higher HOMA, fasting insulin, CRP and TNFα, and lower HDL) in 
OW/OB pregnancies in plasma biomarkers observed in this study are similar to 
those previously observed by others (Catalano et al., 1991, Catalano et al., 
1999, Salameh and Mastrogiannis, 1994, Meyer et al., 2013, Ramsay et al., 
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2002a, Scifres et al., 2014, Stewart et al., 2007a).There are however some 
interesting findings worth exploring in more detail.  
 
Throughout pregnancy, TNFα remained significantly higher in the OW/OB group 
but its concentration did not change significantly across gestation. Current 
literature suggests that during gestation, TNFα rises and peaks in the second 
trimester (Beckmann et al., 1997) and that this plasma marker correlates 
significantly with insulin sensitivity in non-diabetic healthy pregnancies (Kirwan 
et al., 2002). In our study, we did not find a significant association between the 
change in TNFα and the change in insulin resistance (r=0.016, p=0.92), as TNFα 
remains stable during pregnancy whereas HOMA increases significantly. This 
could suggest that in the current study TNFα  may not be contributing as much 
to insulin resistance as in other cohorts (Hotamisligil et al., 1996).  
 
As expected CRP levels were significantly higher in the OW/OB group than the 
lean group throughout pregnancy (p<0.0001). However, the pattern of change in 
CRP concentration was different between the groups (p time x type=0.003). 
When the groups were assessed separately CRP fell significantly in the OW/OB 
group (p<0.0001) but not the lean group (p=0.57). Consistent with our findings, 
other authors have seen a fall in CRP during gestation, (Stewart et al., 2007a). It 
is possible that, in the relatively healthy OW/OB women studied here, in late 
pregnancy the increase in lipolysis from adipose tissue may relieve the 
inflammation at the fat depot, and potentially the liver, leading to a fall in 
plasma CRP. CRP is also known to be produced in the placenta (Malek et al., 
2006). The observed fall in plasma CRP in OW/OB women could alternatively 
represent a reduction in the placental production of CRP in healthy OW/OB 
pregnancies which may ameliorate any potential for placenta complications in 
this healthy OW/OB group.  
 
During pregnancy IL6 plasma levels rose significantly (p<0.0001), and were 
higher in lean women. Previous authors have found IL6 to be significantly higher 
in obese women throughout pregnancy and compared to published data our 
OW/OB women had relatively low levels of IL6 (Stewart et al., 2007a) again 
indicating they were healthy OW/OB individuals. Interestingly, in the linear 
mixed model analysis there was a significant difference in the pattern of change 
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in IL6 concentrations between the lean and OW/OB group. This was because the 
lean women have a significant rise in IL6 concentrations between all gestational 
time point (15, 25 and 35 weeks) but the OW/OB group the increase was more 
gradual and the significant increase was only seen between 15 weeks and 35 
weeks. On inspection of Figure 5.9, the actual concentrations of IL6 are very 
similar between the groups. In healthy pregnancies, there is significant 
remodelling of adipose tissue undergoing both hyperplasia, where pre-adipocytes 
are recruited to make new adipocytes, and a degree hypertrophy of existing 
adipocytes (McLaughlin et al., 2007) with a concurrent rise in serum 
inflammatory markers including IL6. The increase in adipokine secretion is 
considerably enhanced in obese individuals where excessive adipocyte 
hypertrophy takes place leading to hypoxic areas of adipose tissue, infiltration of 
macrophages and an inflammatory response.  IL6 is also thought to play a part in 
the development of gestational physiological insulin resistance through the 
inhibition of the action of insulin at muscle, liver and adipocyte (Hutley and 
Prins, 2005). The fact that lean healthy women show an increase in IL6 suggests 
that IL6 may play a role in healthy pregnancy perhaps to generate the 
gestational insulin resistance, although little published data exists to support 
this. 
 
The trend for lean women to have higher levels of NEFA and the decrease in 
concentration of NEFA in the OW/OB group was not expected. In the current 
lean cohort, measured NEFA levels were higher than in other studies (Meyer et 
al., 2013). Different methodologies were employed by different studies; the 
current analysis was performed by autoanalyser compared to the manual method 
employed by other authors (Meyer et al., 2013) which may account for the 
difference in concentrations.  
 
Our observations on NEFA concentration were a ‘snap shot’ at different time 
points. Figure 5.18 illustrates the various sources of NEFA as well as the various 
outputs which contribute to plasma NEFA concentrations. The data presented 
here suggest that OW/OB women have either decreased production (lipolysis), or 
increased utilisation (placental transport) or increased storage either in adipose 
tissue or ectopically in liver or placenta by the third trimester. Placentae from 
obese mothers at term have been found to have significantly more lipid content 
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than those from lean women (Saben et al., 2014). As well as placental storage, 
the fetus requires NEFA for many aspects of development. Longitudinal studies 
have found that the offspring of obese mothers have greater percentage body 
fat levels compared to babies of lean mothers (Catalano et al., 2009) often 
referred to as the “overnutrition hypothesis”. Increased deposition of fatty acids 
into each of these ‘depots’ may account for lower levels of plasma NEFA in 
OW/OB pregnancies.  
 
5.18 The inputs and outputs demand to the plasma NEFA compartment. The figure represents 
the various inputs and output pathways which can lead to a raised or decreased NEFA 
concentration in the maternal circulation, illustrating the difficulties in interpretation of steady state 
NEFA concentration during pregnancy. 
 
The timing of sample collection may also have had an impact on the NEFA 
concentrations. All samples were collected from study participants after an 
overnight fast. OW/OB individuals have greater basal metabolic demands purely 
based on increased weight as shown in Chapter 4. Fat oxidation was on average 
35.6% higher in OW/OB pregnancies (p type<0.0001, Chapter 4, section 4.4.4, 
Figure 4.4) and fat oxidation increased in OW/OB women as pregnancy 
progressed (Figure 4.4). These results may reflect the predominant utilisation of 
fat as an energy source by OW/OB women which would be more pronounced in 
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the fasting state leading to lower fasting NEFA levels than lean women which fall 
as pregnancy progresses.  
 
As highlighted above, the amount of total fat accretion and site of subcutaneous 
fat storage has little impact on the gestational response of plasma biomarkers. 
In fact, healthy lean and OW/OB pregnancies show many similarities in this 
response. Both lean and OW/OB women have similar concentrations of IL6, total 
triglyceride and total cholesterol at the end of pregnancy despite the OW/OB 
group exhibiting more insulin resistance and some aspects of inflammation (CRP 
and TNFα). Lean women have higher levels of HDL. It is likely that our OW/OB 
women were relatively healthy leaving the groups too similar to tease out all 
metabolic differences associated with maternal obesity or their association with 
fat distribution in pregnancy. This may indicate that our OW/OB group is 
different to those studied by other authors as they are non-smokers, have higher 
socioeconomic scores and include some overweight rather than obese 
individuals. This suggestion is supported by the demographic differences 
between our OW/OB cohort and other obese populations. In Stewart et al, 40% 
of the obese women were smokers, no women in either lean or OW/OB group 
smoked in the present study. The OW/OB group presented here was well 
educated (88% of lean women and 75% of OW/OB women attended university) 
and came from high socioeconomic classes (73% of lean women and 44% of 
OW/OB women were in upper half of 2009 SMID [Scottish multiple index of 
deprivation] decile for social deprivation). The demographics of the Stewart et 
al cohort indicated that only 43% of the non-obese group and 41% of the obese 
group were in either affluent or intermediate DEPCAT deprivation score 
categories. Methodology for assessing social deprivation has changed between 
these two studies therefore direct comparison is difficult, however this may be a 
factor explaining the metabolic differences with previous data in obese women 
published from this laboratory. Plasma markers of inflammation (IL6 and CRP) 
have been found to be associated with poorer socioeconomic backgrounds 
(Packard et al., 2011). In addition, in the study published by Stewart et al, the 
obese group was heavier than our group with a mean BMI of 34.2 kg/m2 (SD4.5) 
compared to a mean BMI of 31.5 kg/m2 (SD2.7) in the present study.  
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The strength of the current study is a consistency in methodology across all 
gestational time points. A breadth of markers for carbohydrate, lipid and 
inflammatory profiles were studied which gave a comprehensive analysis.  
There were limitations to the study. Assessment of adiposity by skinfold 
thickness does not assess functionality of adipose tissue which may be more 
important than the actual size of the depot. The more atherogenic LDL-III that 
has been used to identify an atherogenic lipoprotein phenotype was not 
measured, although samples are available for future analysis. In addition, the 
OW/OB group recruited includes women who are apparently healthy and this 
may account for some of the unexpected data. Finally gestational changes were 
assessed as the absolute concentration at 35 weeks minus the concentration at 
15 weeks. This may be too simple a measure of gestational adaptation and 
further analysis of the data could assess gestational changes using incremental 
area under curve to try and convey how these plasma markers change during 
pregnancy. 
 
In conclusion, the majority of gestational carbohydrate, lipid and inflammatory 
profiles observed in this study support current published data. Some of the 
differences been between the lean and OW/OB women were anticipated with 
the OW/OB group were more insulin resistant and pro-inflammatory (CRP and 
TNFα) than lean women and lean women having higher concentration of plasma 
HDL. This suggests that these OW/OB women exhibit a degree of metabolic 
syndrome. However, in the lean group the higher levels of inflammation (IL6) 
which may reflect a physiological rather than pathological process. The observed 
differences in lean and OW/OB women in plasma NEFA concentration was 
difficult to explain and may be multifactorial. The presented data showed that 
in both lean and OW/OB pregnancies the studied subcutaneous adipose depots 
did not contribute to the gestational changes in markers of carbohydrate, lipid 
and inflammatory profiles, but that there is accepted limitations to the above 
cohort which may be the reason for the lack of associations. Further exploration 
of the data and inclusion of other depots may yield different results. Therefore 
the results of this chapter suggest that central subcutaneous fat depots may not 
be important in the development of adverse metabolic profiles. These findings 
therefore do not support the hypothesis that OW/OB women gain subcutaneous 
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fat in the central compartments and that this leads to the carbohydrate, lipid 
and inflammatory profiles observed in the gestational metabolic syndrome. 
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Chapter 6 - Gestational measures of microvascular 
function, oxidative stress and lipotoxicity in lean 
and OW/OB pregnancies 
6.1 Introduction  
Pregnancy is a time of immense physiological stress and involves adaptation of 
the maternal cardiovascular system. The main adaptation seen is peripheral 
vasodilatation thought to be mediated through endothelium-dependent factors 
upregulated by oestradiol and prostaglandins.  
 
Published data have shown that, in the third trimester, obese women have a 
poorer microvascular response to ACH iontophoresis than lean women, indicating 
poorer endothelium-dependent vasodilatation (Ramsay et al., 2002a). It has 
been proposed that in maternal obesity the reduced improvement in endothelial 
function is related to a pathological pathway involving increased plasma lipids 
with the promotion of oxidative stress (Vincent and Taylor, 2005). There are a 
number of biomarkers which have been linked to endothelial dysfunction through 
the process of oxidative stress and these have been detailed in Chapter 1 
including GGT, pro-inflammatory lipoproteins such as oxLDL, superoxide species 
and more novel markers such as urinary isoprostanes. Endothelial dysfunction 
can also be assessed by measuring in vivo markers of endothelial activation such 
as sVCAM-1 and sICAM-1 which have been found to be elevated in pregnancies 
complicated by pre-eclampsia (Chaiworapongsa et al., 2002) where endothelial 
damage is a hallmark of the disease. Interestingly, little research has looked at 
the gestational changes in these markers of lipotoxicity and their impact on 
microvascular function in pregnancy. The following chapter assesses 
microvascular function and lipotoxicity markers during pregnancy in lean and 
OW/OB women. The relationships of microvascular function and lipotoxicity to 
anatomical fat distribution and accumulation was also studied.  
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6.2 Research Questions 
1. During pregnancy, are there changes in peripheral microvascular function and 
the concentration of plasma and urinary markers of lipotoxicity and oxidative 
stress? 
2. Are there differences between lean women and OW/OB women in terms of 
microvascular function and plasma and urinary markers of lipotoxicity and 
oxidative stress?  
3. Are there differences in the pattern of change in concentration in these 
markers during pregnancy between lean and OW/OB pregnancies? 
4. Does anatomical distribution of subcutaneous fat during pregnancy have an 
impact on the change in peripheral microvascular function and the change in 
concentrations of plasma and urinary markers of lipotoxicity and oxidative 
stress in lean and OW/OB pregnancies? 
 
6.3 Methods 
Peripheral vascular function assessment and plasma collection and methodology 
have been detailed in section 2.4 and 2.5 respectively of the General Methods 
Chapter 2. Further information regarding specific analytic techniques has been 
detailed in each section of this chapter. Throughout pregnancy blood volume 
changes. Before analysis was performed on this data, a haematocrit and 
haemoglobin (Quantichrom, BioAssay Systems, Universal Biologicals Ltd 
Cambridge, UK) were measured for each sample and the blood volume was 
corrected as per the method used by Dill and Costill (Dill and Costill, 1974). 
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6.4 Gestational changes in microvascular function 
6.4.1 Endothelium-dependent microvascular function 
The gestational response in endothelium-dependent microvascular function 
(EDMVF) was assessed across time and between groups (Figure 6.1). During 
pregnancy there was a significant improvement in EDMVF, ‘p time’=0.010; mean 
visit 1 log perfusion response was 2.78 PU MΩ/min (standard error of the mean 
0.46) and mean visit 3 log perfusion response was 4.61 PU MΩ/min (0.57). 
 
There was no difference between the groups (‘p type’) or in the pattern of 
change in EDMVF response between the two groups, shown as the interaction 
term (‘p time x group’).  
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Figure 6.1 EDMVF response at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean EDMVF response (logged data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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6.4.2  Endothelium independent microvascular function 
The gestational response seen in endothelium independent microvascular 
function (EIMVF) was assessed across time and between groups (Figure 6.2). 
There was no significant change in EIMVF response during pregnancy (‘p time’) 
and there was no difference observed between lean and OW/OB women (‘p 
type’). The pattern of change in EIMVF response was not different between the 
groups (‘p time x type’).   
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Figure 6.2 EIMVF response at each gestational time point in lean and OW/OB pregnancy. 
Illustrated is the mean EIMVF response (logged data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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6.5 Plasma markers of vascular function and lipotoxicity 
6.5.1 Soluble intercellular adhesion molecule-1 
The change in plasma sICAM-1 was assessed across time and between the groups 
(Figure 6.3). Over the course of pregnancy sICAM-1 levels did not change (‘p 
time’=0.57). There was a no difference between the two groups (‘p type’=0.94). 
The pattern of change was not different between the two groups (‘p time x 
type’=0.82).   
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Figure 6.3 sICAM-1 at each gestational time point in lean and OW/OB pregnancy. Illustrated is 
the mean sICAM-1 concentration (raw data) and the standard error of the mean at each gestational 
time point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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6.5.2 Soluble vascular cell adhesion molecule-1  
Using the linear mixed model plasma sVCAM-1 was assessed across time and 
between groups (Figure 6.4).  
 
The concentration of sVCAM-1 increased significantly across gestation (‘p 
time’<0.0001); mean visit 1 concentration was 641ng/mL (SEM 20) compared 
with mean visit 3 concentration 757ng/mL (29). 
  
There was a trend for lean women to have higher concentrations of sVCAM-1 
during pregnancy (‘p type’=0.028), mean lean concentration 694ng/mL versus 
OW/OB 629ng/mL. There was no difference pattern of change (‘p time x group’) 
in sVCAM-1 levels.  
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Figure 6.4 sVCAM-1 at each gestational time point in lean and OW/OB pregnancy. Illustrated 
is the mean sVCAM-1 concentration (raw data) and the standard error of the mean at each 
gestational time point in lean and OW/OB pregnancy. Differences across gestation were expressed 
as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable 
between the groups as ‘p time x type’. 
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6.5.3 Oxidised low density lipoprotein 
The concentration of oxLDL was assessed across time and between the groups 
(Figure 6.5).  
 
There was a significant rise in oxLDL during pregnancy (‘p time’<0.0001); mean 
visit 1 concentration was 58.6U/L (SEM 2.6) and visit 3 concentration was 
82.7U/L (3.5). However there were no significant differences between groups or 
in the pattern of change.  
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Figure 6.5 oxLDL at each gestational time point in lean and OW/OB pregnancy. Illustrated is 
the mean oxLDL concentration (raw data) and the standard error of the mean at each gestational 
time point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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6.5.4 Gamma-glutamyl transferase 
The change in GGT concentration was assessed across time and between the 
groups (figure 6.6). The levels of GGT did not change significantly over the 
course of pregnancy (p time=0.98). There was no differences between the 
groups (p time=0.37) or in the pattern of change in GGT (p time x type=0.093). 
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Figure 6.6 GGT at each gestational time point in lean and OW/OB pregnancy. Illustrated is the 
mean GGT concentration (raw data) and the standard error of the mean at each gestational time 
point in lean and OW/OB pregnancy. Differences across gestation were expressed as ‘p time’, 
between the lean and OW/OB groups as ‘p type’ and pattern of change in the variable between the 
groups as ‘p time x type’. 
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6.5.5 Urinary isoprostanes 
Concentration of urinary isoprostanes was assessed across time and between the 
groups (Figure 6.7).  
 
There was a trend for the concentration of urinary isoprostanes to rise during 
pregnancy; mean visit 1 concentration 8.2ug/mmol (SEM 0.9) versus mean visit 3 
concentration 9.5ug/mmol (0.7), but this did not reached significance 
(‘p time’=0.029).  
 
There was no significant difference between the lean and OW/OB women and 
the pattern of change in the level of this urinary metabolite, was similar (‘p 
time x type’=0.97). 
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Figure 6.7 Urinary isoprostanes at each gestational time point in lean and OW/OB 
pregnancy. Illustrated is the mean urinary isoprostanes concentration (raw data) and the standard 
error of the mean at each gestational time point in lean and OW/OB pregnancy. Differences across 
gestation were expressed as ‘p time’, between the lean and OW/OB groups as ‘p type’ and pattern 
of change in the variable between the groups as ‘p time x type’. 
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6.5.6 Plasma superoxide concentration 
Plasma superoxide concentrations were measured in whole blood. Data was 
corrected for changes in blood volume as per the method used by Dill and Costill 
(Dill and Costill, 1974). 
 
Plasma superoxide concentration was assessed across time and between the 
groups (figure 6.8). There was no significant change in superoxide levels during 
pregnancy (‘p time’=0.48).There was no significant difference between the lean 
and OW/OB women and the pattern of change in the level of this plasma 
metabolite was similar. 
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Figure 6.8 Plasma superoxide concentration at each gestational time point in lean and 
OW/OB pregnancy. Illustrated is the mean plasma superoxide concentration (raw data) and the 
standard error of the mean at each gestational time point in lean and OW/OB pregnancy. 
Differences across gestation were expressed as ‘p time’, between the lean and OW/OB groups as 
‘p type’ and pattern of change in the variable between the groups as ‘p time x type’. 
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6.6 Summary of gestational changes seen in 
microvascular function and markers of lipotoxicity 
 
Figure 6.9 Summary of evidence found for endothelial function, activation and lipotoxicity in 
lean and OW/OB pregnancy. The above figure indicates that there are only gestational changes 
in vascular function and lipotoxic markers during pregnancy but there are no differences observed 
between the groups or any differences in the pattern of changes between the groups (interaction 
differences) for these markers. 
 
During pregnancy there were gestational changes which were the same for both 
lean and OW/OB pregnancy: both show an improvement in EDMVF and an 
increase in sVCAM-1 and oxidised LDL concentrations. There were no significant 
differences between lean and OW/OB women in microvascular function (EDMVF 
or EIMVF) or any of the markers of lipotoxicity measured. From the above 
analysis there was no difference in the pattern of change seen in endothelial 
function and markers of lipotoxicity in the lean and OW/OB pregnancies studied. 
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6.7 The relationship between anatomical fat distribution, 
endothelial function and markers of lipotoxicity in 
healthy pregnancy 
From the above analysis, no differences were found between lean and OW/OB 
pregnancies in terms of endothelial function or markers of lipotoxicity.  
Therefore further analysis on the impact of anatomical fat distribution was 
performed on the entire cohort, with and without BMI as a covariate in the 
analysis.  
 
Further analysis looked at EDMVF response, but not EIMVF response as there was 
no change in this across pregnancy. Plasma oxLDL, sVCAM-1 increased during 
pregnancy and were assessed. There was a trend for urinary isoprostanes to 
increase during pregnancy and this was included in the analysis. 
 
Univariate analysis was performed using Pearson’s correlation, and significance 
was p<0.01. If significant results were found multivariate analysis was performed 
using the General Linear Model (significance p<0.05). The anthropometric 
measures included in this analysis were fat mass, total body skinfolds, upper 
body peripheral skinfolds and lower body peripheral skinfolds.  
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6.7.1 EDMVF response 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in EDMVF response and change in fat mass, 
total body, upper body peripheral and lower body skinfolds (Table 6.1). There 
were no significant correlations found in this analysis.  
Table 6.1 Univariate analysis of the associations between the gestational change in EDMVF 
response and the gestational change seen in anatomical and total fat mass in entire cohort. 
Analysis was performed using Pearson’s correlation, significant result if p<0.01. Total body 
skinfolds shown as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as 
LBS. 
 fat mass 
V1-V3 
TBS 
V1-V3 
UBPS 
V1-V3 
LBS 
V1-V3 
 
V1-V3 EDMVF response 
Pearson correlation 
P value 
 
-0.233 
0.15 
 
-0.187 
0.25 
 
-0.161 
0.32 
 
-0.167 
0.30 
 
 
6.7.2 Oxidised LDL 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in oxLDL and change in fat mass, total body, 
upper body peripheral and lower body skinfolds (Table 6.2). There were no 
significant correlations found in this analysis.  
Table 6.2 Univariate analysis of the associations between the gestational change in oxLDL 
and the gestational change seen in anatomical and total fat mass in entire cohort. Analysis 
was performed using Pearson’s correlation, significant result if p<0.01. Total body skinfolds shown 
as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as LBS. 
 fat mass 
V1-V3 
 
TBS 
V1-V3 
 
UBPS 
V1-V3 
 
LBS 
V1-V3 
 
V1-V3 oxLDL 
Pearson correlation 
P value 
 
0.003 
0.99 
 
-0.089 
0.59 
 
0.064 
0.70 
 
-0.252 
0.12 
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6.7.3 sVCAM-1 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in sVCAM-1 and change in fat mass, total body, 
upper body peripheral and lower body skinfolds (Table 6.3). There were no 
significant correlations found in this analysis.  
Table 6.3 Univariate analysis of the associations between the gestational change in    
sVCAM-1 and the gestational change seen in anatomical and total fat mass in entire cohort. 
Analysis was performed using Pearson’s correlation, significant result if p<0.01. Total body 
skinfolds shown as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as 
LBS. 
 fat mass 
V1-V3 
 
TBS 
V1-V3 
 
UBPS 
V1-V3 
 
LBS 
V1-V3 
 
V1-V3 sVCAM-1 
Pearson correlation 
P value 
 
-0.111 
0.50 
 
-0.270 
0.092 
 
0.181 
0.27 
 
-0.281 
0.079 
 
 
6.7.4 Urinary Isoprostanes 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in urinary isoprostanes and change in fat mass, 
total body, upper body peripheral and lower body skinfolds (Table 6.4). There 
were no significant correlations found in this analysis.  
Table 6.4 Univariate analysis of the associations between the gestational change in urinary 
isoprostanes and the gestational change seen in anatomical and total fat mass in entire 
cohort. Analysis was performed using Pearson’s correlation, significant result if p<0.01. Total body 
skinfolds shown as TBS, upper body peripheral skinfolds as UPBS and lower body skinfolds as 
LBS. 
 fat mass 
V1-V3 
 
TBS 
(V1-V3) 
UBPS 
V1-V3 
 
LBS 
V1-V3 
 
V1-V3 urinary isoprostanes  
Pearson correlation 
P value 
 
0.106 
0.53 
 
0.168 
0.31 
 
0.204 
0.21 
 
0.139 
0.40 
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6.8 EDMVF and other biomarkers 
There was no significant impact of the change in fat mass or anatomical fat 
distribution on EDMVF or biomarkers of lipotoxicity. However, further analysis 
was performed to assess the impact of energy metabolism, carbohydrate, lipid 
and inflammatory profiles and markers of lipotoxicity on EDMVF response. This 
was performed using univariate analysis.  
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6.8.1 EDMVF response and parameters of energy metabolism 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in EDMVF response and change in energy 
metabolism parameters (Table 6.5). There were no significant correlations found 
in this analysis.  
 
Table 6.5 Univariate analysis of the change in EDMVF response and the changes in 
parameters of energy metabolism 
Energy parameter V1-V3 EDMVF response V1-V3 
 
BMR 
Pearson correlation 
P value 
BMR/kg 
Pearson correlation 
P value 
NPRER 
Pearson correlation 
P value 
Fat oxidation 
Pearson correlation 
P value 
Carbohydrate oxidation 
Pearson correlation 
P value 
Sedentary activity 
Pearson correlation 
P value 
Light activity 
Pearson correlation 
P value 
MVPA 
Pearson correlation 
P value 
Daily energy intake 
Pearson correlation 
P value 
Fat intake 
Pearson correlation 
P value 
Carbohydrate intake 
Pearson correlation 
P value 
Protein intake 
Pearson correlation 
P value 
 
-0.250 
0.12 
 
-0.249 
0.13 
 
0.055 
0.74 
 
-0.118 
0.48 
 
0.005 
0.98 
 
0.097 
0.62 
 
-0.041 
0.83 
 
-0.204 
0.29 
 
-0.213 
0.19 
 
-0.190 
0.25 
 
-0.131 
0.43 
 
0.15 
0.38 
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6.8.2 EDMVF response and carbohydrate, lipid and inflammatory 
profiles 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in EDMVF response and the change in the 
plasma concentrations of markers of carbohydrate, lipid and inflammatory 
profiles (Table 6.6).There was a trend for IL6 to be positively associated with 
the improvement seen in EDMVF response (p=0.047). 
Table 6.6 Univariate analysis of the change in EDMVF response and the change in plasma 
concentrations of markers of carbohydrate, lipid and inflammatory profiles 
Plasma marker V1-V3 EDMVF response V1-V3 
 
Fasting glucose 
Pearson correlation 
P value 
Insulin 
Pearson correlation 
P value 
HOMA 
Pearson correlation 
P value 
Total cholesterol 
Pearson correlation 
P value 
Total triglycerides 
Pearson correlation 
P value 
HDL 
Pearson correlation 
P value 
NEFA 
Pearson correlation 
P value 
CRP 
Pearson correlation 
P value 
IL6 
Pearson correlation 
P value 
TNFα 
Pearson correlation 
P value 
 
-0.020 
0.90 
 
-0.088 
0.60 
 
-0.084 
0.62 
 
-0.140 
0.40 
 
-0.034 
0.84 
 
-0.18 
0.29 
 
0.013 
0.94 
 
-0.010 
0.95 
 
0.324 
0.047 
 
0.021 
0.90 
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6.8.3 EDMVF response and markers of lipotoxicity 
Univariate analysis was performed using Pearson correlation to assess the 
relationship between the change in EDMVF response and change in markers of 
lipotoxicity (Table 6.7). There were no significant correlations found in this 
analysis.  
Table 6.7 Univariate analysis of the change in EDMVF response and the change in markers 
of lipotoxicity 
Plasma marker V1-V3 EDMVF response V1-V3 
 
sICAM-1 
Pearson correlation 
P value 
sVCAM-1 
Pearson correlation 
P value 
oxLDL 
Pearson correlation 
P value 
GGT 
Pearson correlation 
P value 
Urinary isoprostanes 
Pearson correlation 
P value 
superoxides 
Pearson correlation 
P value 
 
-0.120 
0.48 
 
0.075 
0.66 
 
-0.050 
0.77 
 
-0.006 
0.97 
 
-0.184 
0.28 
 
-0.093 
0.62 
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6.9 Discussion 
As pregnancy progressed there was a significant improvement in the endothelium 
dependent microvascular function (EDMVF) response and increases in plasma 
concentrations of sVCAM-1 and oxidised LDL. These gestational changes were 
similar in both the lean and the OW/OB group. Previous studies have indicated 
that although all women exhibit an improvement in EDMVF during pregnancy, 
obese women show less improvement than lean women (Stewart et al., 
2007a).This was not found in the current study. However, as discussed in chapter 
5, this cohort was overall healthier and more affluent than previous populations 
which may account for the different findings. Higher deprivation scores have 
been linked to higher risk of cardiovascular mortality in both diabetic and non-
diabetic populations (Jackson et al., 2012). In addition, markers of chronic 
inflammation and endothelial activation (CRP, IL6 and sICAM-1) have been found 
to be significantly associated with poorer childhood living conditions and 
paternal manual occupations (Packard et al., 2011). There is also the obvious 
impact that smoking has on endothelial function (Ambrose and Barua, 2004), and 
in this study none of the participants smoked compared to previous study 
cohorts (Stewart et al., 2007a). The demographic similarities between the lean 
and OW/OB groups in our cohort may account for why no difference was seen in 
vascular function between our lean and OW/OB groups.  
 
In healthy pregnancy, sVCAM-1 has been found to increase significantly as 
pregnancy progresses (Beckmann et al., 1997). In the present study sVCAM-1 
increased significantly during gestation and these findings are consistent with 
published data in both lean and obese women (Stewart et al., 2007a). In the 
comprehensive study performed by Stewart et al, sVCAM-1 concentrations in 
both lean and OW/OB women were lower than our findings throughout 
pregnancy. In addition, Stewart et al did not find any differences between lean 
and obese women in each trimester in sVCAM-1. There are no reference 
standards so it is difficult to compare our findings to previous published data. 
 
In the present study plasma IL6 concentration was higher in lean women 
compared to OW/OB participants. This may be a result of up-regulation of IL6 
production by adipocytes in lean pregnancy if their adipose tissue has a greater 
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potential to undergo differentiation from pre-adipocytes to functional 
adipocytes compared to the adipose tissue of OW/OB individuals. In the mouse 
model, it has been suggested that IL6 plays a role in pulmonary vascular 
remodelling in pulmonary hypertension (Savale et al., 2009). Although this is an 
example of a pathological process, it does provide a potential explanation of 
higher IL6 levels as gestation advanced in this study. There does not appear to 
be any published data examining the role of IL6 in vascular remodelling in 
pregnancy. However, in our study, there was a trend for the increase in IL6 to be 
positively correlated with the improvement in EDMVF response (r=0.324, 
p=0.047). 
 
Previous authors have shown that plasma oxLDL levels are higher in pregnant 
women than in non-pregnant controls (Makedou et al., 2011). In healthy human 
pregnancy, gestational changes in LDL profile favours smaller species, which is 
thought to be a result of the increase in plasma triglyceride concentrations. This 
preference for smaller species of LDL is associated with an increased level of 
oxidised LDL (Belo et al., 2004). Lean and OW/OB women showed a significant 
increase in oxLDL during pregnancy in the present study, but there were no 
difference between the groups. Other authors have shown that although LDL-III 
concentration is higher in OW/OB pregnant women, only a proportion of the 
obese subjects exhibited oxLDL-III in a high enough concentration to have an 
atherogenic lipoprotein phenotype (Meyer et al., 2013), which is an indicator of 
metabolic pathology (Anber et al., 1996). In the current study, the OW/OB 
mothers may not be in this subset of high risk women who develop an 
atherogenic lipoprotein phenotype which would lead to a larger amount of small 
dense LDL that could be easily oxidised. If this is true then the current OW/OB 
cohort could be considered low risk as they exhibit a similar improvement in 
their EDMVF response compared to the lean group. The absolute change in 
oxidised LDL was not significantly correlated with the improvement in the EDMVF 
response for the entire cohort (Pearson’s correlation -0.050. p=0.77), which 
supports the theory that the OW/OB cohort did not include women with an 
atherogenic lipoprotein profile. In Meyer et al, the mean BMI of the obese group 
was 33.7kg/m2 (SD 4.2), and in the current OW/OB group this was 31.5 kg/m2 
(SD2.7). As the current OW/OB group had a lower BMI than the Meyer et al 
study, this may explain the lack of differences in oxLDL as well as in EDMVF 
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response and the other markers of lipotoxicity. Therefore, in order to see an 
effect of oxLDL concentration on EDMVF response, inclusion of women with 
higher BMI or perhaps greater central obesity may be required. 
 
Isoprostanes are markers of oxidative stress, which are produced as a result of 
the non-enzymatic peroxidation of arachidonic acid (Vincent et al., 2007). 
Previous authors have noted that both urinary and plasma measurements of 
these compounds can be used as biomarkers  in the estimation of lipid 
peroxidation (Cracowski et al., 2002). Published data have shown that in women, 
BMI significantly correlated with levels of urinary isoprostanes (8-iso-PGF2α) 
(Il'yasova et al., 2007, Keaney et al., 2003), and that in pregnancy women have 
elevated levels of both plasma and urinary isoprostanes (Ishihara et al., 2004). In 
the current analysis, there was some evidence that urinary isoprostanes rose 
during pregnancy (p=0.029) but there was no difference seen between lean and 
OW/OB women. Current literature suggests that plasma levels of isoprostanes 
are elevated in pre-menopausal women with increased central obesity (Crist et 
al., 2009). In the current study anthropometric differences were observed, but 
these findings related to upper body peripheral subcutaneous fat depots rather 
than either groups having preponderance for centrally accumulated 
subcutaneous adipose tissue. None the less, assessing plasma isoprostanes levels 
in both groups or stratifying the data based on waist hip ratio may be useful to 
assess the impact of lipid peroxidation and oxidative stress during pregnancy. 
Currently there is ongoing analysis of plasma samples from this cohort to 
ascertain the concentration of plasma isoprostanes. 
 
The initial analysis of microvascular function and markers of lipotoxicity did not 
find any differences between lean and OW/OB women in this cohort. For this 
reason, further analysis of the impact of anatomical fat depots on the EDMVF 
response and lipotoxic biomarkers were performed on the entire cohort. In this 
univariate analysis no significant associations were found. Therefore, for this 
cohort during pregnancy there was no impact of an increase in either total fat 
mass or anatomical fat depots on the gestational change in endothelial function 
or markers of lipotoxicity. This result may also indicate that these specific 
subcutaneous fat depots do not have a detrimental impact on endothelial 
function or promote lipotoxicity during healthy pregnancy.  
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Further analysis explored associations between the improvement in EDMVF 
response and gestational changes in direct measurements of energy metabolism, 
plasma markers of carbohydrate, lipid and inflammatory profiles and markers of 
lipotoxicity. There were no significant associations found in this analysis.  
 
A key strength of this present study was the use of laser Doppler imaging to 
assess microvascular function during pregnancy. The laboratory where the study 
was performed had experience of the technique (Ramsay et al., 2002a, Stewart 
et al., 2007a) and expertise in the methodology which was utilised by the 
researcher during the study (Ramsay et al., 2002b). The technique used to assess 
superoxide in whole blood, electron paramagnetic resonance (EPR), is an 
advanced objective technique performed by investigators experienced with the 
measurement. This analysis has included a comprehensive panel of vascular 
function and markers of lipotoxicity and all data was rigorously corrected prior 
to analysis in order to account for changes in blood volume and glomerular 
filtration rate during pregnancy. 
 
The limitations of our study are that our OW/OB group had a lower mean BMI 
and appeared to be a particularly healthy cohort. It is likely that the selection 
protocol resulted in OW/OB women being recruited who were extremely healthy 
and not at risk of developing an adverse obstetric outcome. Therefore we have 
missed out on recruiting women within the 30% of the obese maternal population 
who are at risk of pregnancy complications (Figure 1.2). 
 
In conclusion, in the current study both lean and OW/OB women exhibited 
similar endothelial microvascular function improvement and increases in 
lipotoxic markers. Analysis of this data has shown that in healthy lean and 
OW/OB pregnancy, although there was an increase in markers of lipotoxicity, 
this had no detrimental effect on the improvement seen in EDMVF. In addition, 
the increase in the studied subcutaneous fat depots, changes in direct 
measurements of energy metabolism and plasma markers of carbohydrate, lipid 
and inflammation do not have an impact on the improvement seen in EDMVF. 
Therefore in OW/OB pregnancy there appear to be some women for whom their 
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obesity could be thought of as ‘benign’ as they exhibit the same gestational 
vascular improvement in pregnancy as lean women.  
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Figure 6.10 Summary of finding of chapter 6. In the cohort studied, lean and OW/OB women 
both exhibited an improvement in vascular function and increased endothelial activation and 
increased lipotoxicity (as measured by oxLDL). Findings suggest that OW/OB women could be 
considered as either metabolically healthy therefore responding to pregnancy in a similar way to 
lean women or unhealthy where they have poorer vascular improvement in pregnancy. 
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Chapter 7 General Discussion & Future Research 
7.1 General Discussion 
In the wider non-pregnant population Jensen et al (Jensen, 2008) have described 
in detail how different subcutaneous adipose tissue depots differ in terms of 
their function and their role in whole body fatty acid metabolism. Previous 
studies in pregnancy have suggested that there are differences in the 
distribution of adipose tissue accumulated during pregnancy, with obese women 
tending to have a propensity to central subcutaneous fat accretion, while lean 
women, tend to gain fat in the lower body compartment (Taggart et al., 1967, 
Soltani and Fraser, 2000). The work presented in this thesis was designed to test 
the hypothesis that the increased risk of adverse pregnancy outcomes for obese 
women was the result of the inadequate adipose tissue storage of fatty acids and 
the subsequent lipotoxicity leading to reduced vascular function during 
pregnancy (Jarvie et al., 2010).  
In this thesis, the idea of functional adipose tissue depots in pregnancy was 
explored. One objective of this thesis was to ascertain whether OW/OB women 
gained gestational fat in the central subcutaneous fat compartment (measured 
using suprailiac and costal skinfolds), while lean women gained gestational fat in 
the lower body subcutaneous compartments (measured by midthigh and 
suprapatellar skinfolds). In this study, it was observed that lean and OW/OB 
women gain similar amounts of total body weight and fat mass during pregnancy, 
and all fat depots increased during pregnancy. The findings in this thesis were 
that in OW/OB pregnancy there was no preference in anatomical location of 
adipose tissue accumulation during pregnancy. In contrast lean women did have 
an anatomical depot-specific deposition of subcutaneous adipose tissue during 
pregnancy however this was not in the lower compartment. The primary location 
for gestational fat deposition in lean women was the upper peripheral 
subcutaneous fat stores (measured by biceps and triceps skinfolds) but this 
specific to gestational age. This preferential accumulation appeared only to 
increase in the second trimester (from 15 to 25 weeks). This may suggest that 
lean women are able to switch easily from a lipogenic to a lipolytic profile in 
later pregnancy when the fetal energy demands are greatest and the body is also 
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preparing for labour and breastfeeding energy demands. In contrast the finding 
that the OW/OB group did not show a gestational time or anatomical site 
preference for subcutaneous fat deposition throughout pregnancy may indicate a 
lack of metabolic flexibility due to a continued lipogenic profile within the 
adipose tissue in OW/OB pregnancy. 
In this study OW/OB women were not of a particularly extreme BMI and in fact, 
as stated earlier, the OW/OB women did include some women who were classed 
as overweight. Thus it is not possible to conclude the pattern of subcutaneous 
fat accumulation observed in the OW/OB group under study here is the same as 
in obese pregnancies of much higher BMI. This makes it difficult to relate the 
present findings to obese women ‘at risk’ of an adverse outcome. Such women 
of extreme obese phenotype may show a propensity to central adipose tissue 
accretion. Furthermore, the visceral compartment was not measured and it is 
possible that in the OW/OB group in the current study, fat was accumulated in 
that depot initially. Once this storage site is replete then fat accumulated in 
subcutaneous sites, without preference for location as all grouped (upper body 
truncal, upper body peripheral and lower body) skinfolds increased throughout 
pregnancy. However, the present observations do give a comprehensive picture 
of how subcutaneous fat depots change in a group of healthy pregnant women 
(both lean and obese). This is important because, as highlighted above, in the 
non-pregnant population, location of fat stores is associated with increased 
inflammatory profiles and insulin resistance.  
The next aim was to explore whether any differences in gestational fat 
accumulation between lean and OW/OB women could be explained by direct 
measurements of energy metabolism. These included basal metabolic rate, 
physical activity and dietary energy intake and observations were related to 
gestational fat gain and anatomical location of its storage. These were important 
variables to assess longitudinally as they have a major impact on total body and 
fat mass gain in the general adult population, and therefore gestational changes 
in energy metabolism could impact on gestational fat accumulation. In this study 
both groups responded to pregnancy similarly with a gestational rise in BMR, a 
decline in MVPA and a similar change in their macronutrient intake. These 
findings support current published data in lean pregnancy populations (mean BMI 
24), where basal metabolic rate increased during pregnancy and physical activity 
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levels were maintained until 32 weeks where after they decreased (Lof and 
Forsum, 2006). 
The results of this study observed some expected differences between lean and 
OW/OB women; OW/OB women had higher BMR, related to their higher body 
mass, and were less active than lean women throughout pregnancy. BMR is 
related to body mass, and in the non-pregnant obese population, BMR has been 
found to rise with increased levels of obesity (Elbelt et al., 2010). Thus because 
body mass was very different between lean and OW/OB women, BMR was 
corrected for this using BMR/kg. However, in the present study even when 
corrected for this there was no relationship between the change in BMR/kg and 
the increase in gestational fat mass. The lean and OW/OB group gained similar 
amounts of fat mass during pregnancy, which would indicate that they have a 
similar overall energy intake/energy expenditure balance. Published data has 
indicated that physical activity (both non-exercise and activity induced) plays an 
important part in basal metabolic rate and total energy expenditure 
(Westerterp, 2008). During pregnancy, increased MVPA was directly correlated 
with an increase in BMR/kg. Therefore the overall higher BMR/kg and physical 
activity in lean women compared to OW/OB women and the higher absolute 
rates of BMR in the OW/OB group could explain why, despite different activity 
levels and similar diets, both groups gain similar amounts of weight and fat. 
 
In this study, there were no gestational differences observed in diet of the 
entire cohort during pregnancy or between the lean and OW/OB groups. In a 
more in depth analysis of the dietary data performed on the present study 
population (but not reported in this thesis) it was found that both lean and 
OW/OB women were not consuming enough vitamin D and folic acid, and 
although this did improve with vitamin supplementation, 20% of OW/OB women 
were still not achieving their recommended intake of vitamin D. In current 
published literature there is interest in the role of vitamin D deficiency and its 
impact on pregnancy and birth outcomes (Aghajafari et al., 2013, Rodriguez et 
al., 2014), although the association at this time remains contentious. 
 
Strategies during pregnancy to try and improve pregnancy outcomes in obese 
women have focused on diet and exercise. Recent data indicates that while both 
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diet and activity modification can reduce the risk of PET and GDM compared to 
controls, dietary changes are most effective at reducing gestational weight gain 
(Thangaratinam et al., 2012). Other data suggests that a combination of dietary 
and activity advice did not improve maternal outcomes including GDM and PET in 
obese and overweight pregnancies (Dodd et al., 2014a), although antenatal 
advice did improve maternal activity levels and diet (Dodd et al., 2014b). Pilot 
data from the UPBEAT trial has indicated that there is more scope for changing 
diet than physical activity during obese pregnancies (Poston et al., 2013). The 
UPBEAT trial is currently being undertaken to further evaluate the impact of 
these interventions on maternal outcome in obese pregnancies (Briley et al., 
2014). The different conclusions reported in the literature highlights the 
complex interactions of diet and activity on weight gain and maternal outcomes.  
 
These findings have important implications on adapting behaviour during 
pregnancy. In this Scottish population, trying to change the dietary habits of the 
OW/OB group may be difficult when it appears there is no difference between 
lean and OW/OB diets during the antenatal period. Physical activity in pregnancy 
would also be difficult to maintain if, as these results suggest, all women 
become less active during gestation. Any intervention that attempts to improve 
maternal health is extremely important. Any positive change would be beneficial 
to both mother and the fetus (either via fetal programming or by reducing 
gestational over-nutrition), because it will reduce the metabolic risk for the next 
generation. An important question is when is the most effective time to 
intervene? As discussed above the results of the UPBEAT trial will help to answer 
how diet and exercise modifications during pregnancy can improve perinatal 
outcomes. Targeting obese women before conception may be another 
possibility. However targeting the pre-conceptual population would require a 
much wider public health approach and cannot be addressed by obstetrics alone. 
The focus for trying to reduce the risk of adverse metabolic and vascular 
complications needs to be two fold, with pre-pregnancy (and inter-pregnancy) 
counselling and optimising of healthy lifestyle in obese women prior to 
conception and during pregnancy providing additional support by means of an 
intervention strategy to improve  physical activity and diet. 
Across the entire cohort, increases in subcutaneous adipose tissue depots were 
not related to any changes in the measured variables of energy metabolism. This 
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suggests that in the specific depots assessed in the current study, their 
gestational increase is not driven by changes seen in energy metabolism and may 
be hormonally driven. Unfortunately, the inability to assess the visceral fat 
compartment does not allow one to gain a complete picture of the impact of 
energy parameters on gestational fat gain. 
 
The third aim was to explore whether anatomical location of gestationally-
acquired fat influenced the maternal metabolic adaptation to pregnancy building 
on the work of Jensen et al which showed that the location of storage of fat in 
the non-pregnant population influences metabolic profile. Plasma markers of 
lipid and carbohydrate metabolism and inflammation were examined to 
determine whether any differences in fat distribution was associated with the 
adverse metabolic profile. In the current study the changes in gestational 
carbohydrate, lipid and inflammatory profiles observed are broadly similar to 
current published data. There were some unexpected observations in biomarkers 
of inflammation and adipocyte fatty acid metabolism. Lean women had higher 
concentrations of IL6 and NEFA during pregnancy than OW/OB women, and 
OW/OB women had a greater gestational decrease in CRP than lean women. 
These findings were not anticipated and are difficult to explain. 
 
Previous authors have commented that even in healthy pregnancy there is a rise 
in plasma IL6 levels (Freeman et al., 2004), suggesting that an increase in this 
inflammatory marker may reflect a physiological rather than pathological 
process. Two possible explanations could be suggested. Firstly a gestational 
increase in IL6 could be the result of increased secretion from adipocytes 
secondary to hyperplasia of functional preadipocytes in lean pregnancy. In obese 
pregnancy adipocytes may either not mature or there may be a hypertrophic 
rather than hyperplasic fat cell response (McLaughlin et al., 2007).  
Alternatively there may be a role for IL6 in vascular remodelling as has been 
examined in animal models. It has been shown that under hypoxic conditions, IL6 
receptor levels are increased and may play a role in pulmonary vascular 
remodelling in mice (Savale et al., 2009). It was also observed that the sVCAM-1 
levels were higher in the lean group than the OW/OB group. As mentioned in 
chapter 6, higher sVCAM-1 levels have been found during physiological vascular 
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remodelling in endometrial spiral arterioles (Craven et al., 1998) and during in 
vitro small vessel inflammation experiments (Ohanian et al., 2012). If plasma 
increases in IL6 and sVCAM-1 reflect an increased vascular remodelling process, 
this would suggest that lean pregnant women have a better remodelling 
potential than OW/OB women and may explain a better vascular response in 
pregnancy. This observation may reflect not just an ability to adapt during 
pregnancy but the remodelling potential in the post natal period and subsequent 
pregnancies. 
 
The final aim was to look for evidence of development of lipotoxicity using 
plasma and urine biomarkers in both lean and OW/OB pregnancy and to relate 
this to endothelial function. The hypothesis was that a gestational subcutaneous 
fat distribution could explain poorer maternal vascular response seen in obese 
pregnancies (Stewart et al., 2007a, Ramsay et al., 2002a). In the current study, 
no differences in endothelial function and lipotoxicity between lean and OW/OB 
women were observed. Both groups showed a significant improvement in EDMVF 
response as pregnancy progressed. In addition, no differences in the 
concentrations of markers of lipotoxicity were noted between the lean and 
OW/OB group. When the entire cohort was assessed, the gestational increases in 
the studied anatomical subcutaneous fat depots were not related to endothelial 
function or markers of lipotoxicity. Therefore the initial hypothesis that 
pregnant OW/OB women gain fat during pregnancy in the central subcutaneous 
adipose tissue depots leading to NEFA overflow with subsequent lipotoxicity and 
endothelial dysfunction was not supported. 
There are a number of reasons why there was no evidence of lipotoxicity in the 
OW/OB women. In this study it was observed that the lean women had the 
metabolic and vascular response to pregnancy which was anticipated from 
previous literature. However, as discussed previously, while there was some 
evidence that the OW/OB group exhibited some of the abnormal metabolic 
adaptations this was not as pronounced as expected. When the current OW/OB 
cohort was compared to previous studies (Stewart et al., 2007a, Ramsay et al., 
2002a), it became evident that the OW/OB cohort recruited here was relatively 
healthy and their metabolic response to pregnancy was more similar to that of 
lean women than that of previously studied obese groups. When the 
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demographic characteristics of the present OW/OB cohort were compared to 
those of a previous obese cohort that had a poorer metabolic and vascular 
response to pregnancy (Stewart et al., 2007a) it became obvious that the current 
group were all non-smokers (compared with 40% smokers), were of higher 
socioeconomic status and had a lower mean BMI. Thus it would appear that the 
current OW/OB cohort have ‘benign’ obesity. Therefore it is not surprising that 
there were no significant differences in vascular response and markers of 
lipotoxicity between these lean and OW/OB women. 
In the non-pregnant population, the concept of ‘metabolically healthy obesity’ 
or ‘benign obesity’ is a current area of interest, and it has been suggested that 
this group may account for up to thirty percent of obese adults (Primeau et al., 
2011). There is no current consensus on the definition of ‘metabolically healthy 
obesity’, but some authors have indicated that this group includes those obese 
individuals who are insulin sensitive and do not display abnormal lipid profiles, 
clinical hypertension or type 2 diabetes (Boonchaya-anant and Apovian, 2014). 
Other authors have included obesity with a favourable metabolic profile which 
includes low ectopic liver fat, low triglycerides, low inflammation, high HDL, low 
intima-media thickness, high adiponectin and low apolipoprotein B (ApoB) 
(Primeau et al., 2011, Stefan et al., 2008). In addition, data in non-pregnant 
adults show that obesity associated with visceral fat was associated with 
dyslipidaemia, atherosclerosis and insulin resistance but abdominal subcutaneous 
fat was not (Neeland et al., 2013).  
In a population of obese postmenopausal women the definition of ‘metabolically 
healthy obese’ was based on insulin sensitivity. Brochu et al, showed that those 
women described as ‘metabolically healthy’ obese also displayed smaller 
adipocyte cell size and less visceral fat (Brochu et al., 2001). In addition, obese 
individuals found to be metabolically healthy, again based on insulin resistance, 
had higher levels of the nuclear receptor subtype peroxisome proliferator-
activated receptor γ (PPAR-γ), which is important in stimulating adipogenesis 
(McLaughlin et al., 2007) and could lead to a hyperplasic rather than 
hypertrophic expansion of adipose tissue. In the current study, the OW/OB 
women recruited may be individuals who, although they exhibit increased insulin 
resistance compared to the lean group, are more insulin sensitive than other 
studied obese pregnant populations (Stewart et al., 2007a) and thus may still fit 
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into the ‘metabolically healthy obese’ category. If so they might be expected to 
exhibit similar gestational vascular improvement in pregnancy as lean women. 
On this basis, this study has not recruited women who are ‘at risk’ of obesity 
related obstetric complications.  
In this thesis, much useful data which has bearing on current ongoing research in 
maternal obesity and clinical practice was collected. The study adds evidence to 
the existing non-pregnant data showing that obesity is a heterogeneous 
condition, and that many obese women remain healthy during their pregnancies. 
This study has produced a variety of data showing that many healthy OW/OB 
women respond to pregnancy in much the same way as healthy lean women in 
terms of metabolic and vascular response. Although the OW/OB women exhibit a 
subtle degree of metabolic disturbance, this had no impact on either vascular 
function or biomarkers of lipotoxicity during pregnancy. In conclusion whilst 
there is a significant proportion of obese women who may display a lipotoxic 
phenotype resulting in poor vascular adaptation during pregnancy, there are also 
many OW/OB women for whom pregnancy remains a period of health and should 
not be considered, at least in terms of vascular and metabolic function as high 
risk in the clinical setting.  
 
7.2 Strengths and Limitations  
There are significant strengths to this study. This study has provided extensive 
phenotyping that has been performed at both a physiological and biochemical 
level. The strengths and expertise of the methodologies employed has been 
discussed at length in the relevant chapters. In the current literature, there are 
limited data available on metabolically healthy obese pregnancies. Although this 
data set does not contain at risk OW/OB women, it offers detailed observations 
of the healthy OW/OB pregnant response during pregnancy. The design of the 
study, (all women were observed longitudinally by the same researcher) adds 
statistical power to the findings in the current data set. By performing multiple 
measures of subcutaneous fat stores during pregnancy the current study has 
shown how these fat depots change over pregnancy in lean and potentially 
‘metabolically healthy’ OW/OB pregnant women; at the time of submission of 
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this thesis there were few published data available on this topic. In addition, not 
only has the current study extensively phenotyped a healthy cohort of women 
during pregnancy but the same measurements have been collected three months 
postnatally as well. In addition, there are stored samples for placentae, 
umbilical cord and cord blood which will be used in future studies. 
 
The limitations of the current study should be considered. The main limitation is 
that the obese women most at risk of vascular complications were not recruited 
to the study. This was despite continued publicity and recruitment drives by the 
researcher. This may have been because obese women with extreme BMI do not 
considered themselves at risk, have no interest in being involved with a study 
about body shape or because they are self conscious about their weight and 
therefore also do not wish to participate in such a study. One potential OW/OB 
recruit reported to the researcher that she felt victimised for being asked to 
participate because she was being recruited to the OW/OB group. The converse 
was true about the lean group, it did not take long to recruit these women and 
again this may be self selection – those interested in how their body works and 
responds during pregnancy also are probably motivated to exercise outwith 
pregnancy and maintain a healthy weight. The reasons why obese women may or 
may not take part in this type of study are multifactorial and probably not only 
based on self image but also perceived ‘ill-health’ by being approached to 
participate in a study based on BMI. On reflection, prior to commencement of 
recruitment to this study it may have been advantageous to consult with patient 
groups or member of the general public to review the study protocol. Such a 
review may have helped gauge opinion on whether the intensity of the study 
visits was deemed appropriate and help to streamline the visit protocol. This 
may have helped improve either recruitment or retention to the study. In 
addition, because we did not achieve the number of study participants (n=30), 
which have been detailed in section 2.6, the sample size and number of 
gestation time points is a limiting factor in the results we have obtained.  
 
Another limitation is that the visceral fat compartment was not assessed. 
Although in this study there is certainly a suggestion of site-specific 
accumulation of subcutaneous fat in lean pregnancies, unless there is 
information on the visceral fat compartment accumulation it is impossible to link 
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the impact of gestational fat gain to metabolic adaptations and lipotoxicity in 
pregnancy.  
 
The analysis performed in this study looked at simple summary measures of the 
data such as change over time. Prior to analysis, biomedical statisticians 
provided advice on building a statistical model that would address the 
hypothesis and the aims of this study. The statistical analysis presented in this 
thesis using this model does address the key research questions from the outset 
therefore for the aims of this thesis the analysis was fit for purpose. However 
there are other approaches to analyse the collected data (such as area under the 
curve) any further analysis should take these approaches into consideration. 
 
Dietary data are notoriously difficult to record and, the gold standard technique 
of four day weighed dietary intake (Holmes et al., 2008) was not feasible in this 
study. Therefore, recall bias may have resulted in the lack of differences 
between the lean and OW/OB dietary data. One of the most consistent problems 
in dietary analysis is participant’s unintentional under-reporting of dietary 
intake. The dietary data was extensively studied for the occurrence of under 
reporting using the Goldberg cut-off value (Black, 2000)(not reported in this 
thesis). No differences were found in the rates of underreporting between the 
lean and OW/OB groups.  
 
Although there was comprehensive collection of data throughout pregnancy and 
three months’ postnatal (the latter not presented in the thesis) to compare lean 
and OW/OB women, the study did not have any data from either early pregnancy 
(less than 12 weeks) or non-pregnant women. Having a prospective data set from 
lean and OW/OB women preconception that were subsequently followed up 
through pregnancy and postnatally would be ideal, but recruitment and 
retention in this type of study would be extremely difficult. In the current study 
there was also no adipose tissue sampling. If, as in the non pregnant population, 
there are functional differences in depots (abdominal and lower body) then 
exploring this in ex vivo sample from pregnant women would be very 
informative. However it is difficult to anticipate when pregnant recruits will 
deliver their babies and collection of adipose tissue would only be appropriate at 
an elective caesarean section delivery. One could collect samples from a cross 
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section of healthy lean and OW/OB women undergoing uncomplicated caesarean 
delivery but you would lack the antenatal data in this case. Another option could 
be collection of needle biopsies of subcutaneous fat at different gestation but 
this is unlikely to be acceptable to all participants. 
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7.3 Clinical implications  
This thesis provided support for the theory that not all obese women should be 
considered ‘high risk’ for an adverse pregnancy outcome based solely on their 
BMI. Thus current clinical practice needs to be reviewed. BMI is currently used to 
risk assess for GDM and PET at her initial antenatal appointment. It is also used 
to assess the need for thromboprophylaxis during pregnancy and referral for 
anaesthetic review. Although the latter risk assessment is still very valid, if an 
obese woman is metabolically healthy her risk of the former conditions may not 
be as high as previously thought. However, although many more obese than lean 
women develop antenatal complications, BMI may still be too unsophisticated a 
measure to accurately identify the 30% of obese women who do develop 
obstetric complications (see Table 1.2). By categorising every woman with a BMI 
of >30kg/m2 as high risk, many of these women are being unnecessarily 
medicalised during pregnancy. Resources within the NHS are limited, and the 
escalation of healthy obese women’s antenatal care to involve additional 
hospital appointments with consultant Obstetricians and specialist testing (such 
as glucose tolerance testing [GTT]), is not a good use of resources. In addition, 
with reference to figure 1.3, using BMI as a measure of risk means that the 
approximately 15% of lean women who are at increased risk of similar obstetric 
complications are not identified.  
 
Subsequently any new screening method of ascertaining metabolic risk requires 
to be simple and quick and to be able to perform in the busy antenatal clinic 
environment. If visceral fat proves to be a discriminating marker that can 
separate benign and metabolic obesity then it could be amenable to simple 
assessment at least for screening purposes. Abdominal waist circumference has 
been used as a measure of central and therefore visceral fat in the past. In 
pregnancy abdominal waist circumference has been assessed at 16 weeks’ 
gestation and larger waist circumferences (>80cm) have been associated with an 
increased risk of hypertensive disorders in pregnancy (Sattar et al., 2001). 
Newer techniques to measure visceral fat are currently being assessed in the 
non-pregnant adult population. One technique which looks promising and is 
conveniently quick to perform is the use of bioimpedance assessment (Khalil et 
al., 2014), which can now be used to identify the visceral fat compartment, and 
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highly correlates with measurements obtained by computed tomography 
(Yamakage et al., 2014). Most of these scales also measure total body mass 
which is part of the routine assessment of a woman at her initial antenatal 
appointment so this would not require additional time in the clinic.  
 
In 2012, the Scottish Government introduced the HEAT targets (Health 
Improvement, Efficiency, Access to Services and Treatment) antenatal access 
target which aims to have at least 80% of pregnant women from each SMID 
deprivation quintile booked for antenatal care by the 12th week of pregnancy to 
improve breastfeeding rates and other poor pregnancy outcomes (NHS, 2012a). 
The aim is to have this target met by March 2015. If this target is met and a 
screening tool to measure visceral fat then this fat depot could be measured at 
this earlier gestation. Its’ impact on metabolic profiles in early pregnancy could 
be could be assessed before gestational fat increases. In addition the 
measurement of visceral fat at 12 weeks’ gestation was predictive of adverse 
metabolically-related pregnancy outcome, then it could also work as a triage 
tool for further assessment of women. For instance if visceral fat was found to 
be in the upper tertile then an early measurement of fasting insulin or a GTT 
could be used to further select those women, possibly both lean and obese, with 
a higher risk of metabolic complications in pregnancy. Present policy is to have 
all women with BMI>30 to be screened for gestational diabetes (NICE, 2010), if 
another screening tool could be implemented it may reduced unnecessary tests 
and improve costings within the NHS. 
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7.4 Future Research 
7.4.1 Further potential analysis of existing data 
As there were no differences in vascular adaptation between the lean and 
OW/OB groups, the current cohort could be regrouped based on a functional 
assessment of central obesity such as insulin resistance or on vascular 
improvement in pregnancy. The hypothesis of this thesis was that lipotoxicity is 
the mechanism which results poorer vascular adaptation to pregnancy, then 
grouping women with ‘good’ versus ‘poor’ function who allow phenotyping of 
these women. This could also apply to classifying women based on insulin 
resistance, as this metabolic biomarker has been used to categorise 
‘metabolically healthy obese’ women.  
 
Alternatively the cohort could be assessed as one whole group and the changes 
assessed across the tertiles. In this analysis, absolute values of the variables 
described could be analysed rather than looking at simple changes between 
gestational time points. This would be helpful in confirming or refuting the lack 
of differences noted between the lean and OW/OB groups. This could be done 
for all values or perhaps using visit 3 to gain a cross sectional analysis of the 
data.  
 
There are alternative ways of analysing the data which could be employed using 
the entire cohort. These would include using incremental area under the curve 
in the total population with the addition of BMI as a covariate in the model. In 
addition, the possibility of multiple regression analysis could be explored to 
ascertain any differences in the absolute values as discussed above. 
 
7.4.2 Future analysis of stored samples and data 
In this study the dietary data was only assessed in terms of macronutrients (total 
fat, carbohydrate and protein intake). As mentioned above there has been more 
work performed on this data examining micronutrient intake (not included in 
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this thesis). There is also the potential to look at the essential fatty acid intake 
to include LC-PUFA, as well as comparing simple sugars and more complex 
carbohydrates (primarily starch) which could be correlated with maternal insulin 
resistance and anatomical adiposity. 
 
As yet, the postnatal data has to be analysed, which covers all of the same 
parameters described in each of the results chapters. Information on breast 
feeding rates and duration were collected and the impact of this on any loss of 
subcutaneous fat distribution and vascular function in the postnatal period 
warrants further investigation. 
 
Some tissue samples were obtained from our participants at delivery and 
included placental, umbilical cord and umbilical blood samples. Again assessing 
lipotoxicity markers in the umbilical cord blood and relating this to maternal 
markers of lipotoxicity and fatty acid metabolism would be informative.  
 
In addition it would have been interesting to measure LDL size to see if this 
explained the lack of differences between the groups in terms of oxidised LDL. 
Further assays on other markers of lipotoxicity such as plasma isoprostanes and 
oxysterols concentrations are currently being performed to look for evidence of 
lipotoxicity which will add more information to the comprehensive panel of 
markers we have already assessed. 
 
In order to try and establish whether obese women can also be considered 
healthy in terms of endothelial adaptation and lipotoxicity during pregnancy 
further assessment of CD36 expression and oxysterols would be important.  
Plasma sCD36, can be used as a marker of insulin resistance and ectopic liver fat 
accumulation (Handberg et al., 2012). If the recruited OW/OB group in this study 
are ‘metabolically healthy obese’, then lower concentration of sCD36 would 
support this theory. At the time of writing this thesis funding was not available 
to assess these markers although aliquots had been obtained for any further 
analysis.  
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7.4.3 Future research directions 
This thesis has shown that there is further research which needs to be performed 
into how to clinically categorise metabolic ‘at risk’ pregnancies. One of the most 
important avenues of future research that this thesis has indicated is the need to 
recruit women who exhibit a metabolically abnormal phenotype. A similar 
longitudinal study should be performed to include obese women who are with in 
this group. In turn they could be compared to the existing data collected in this 
study. This would allow the idea of obesity heterogeneity which exists in non-
pregnant adults, to be evaluated in the pregnant population. A future study 
should also be performed to include lean women who are considered 
‘metabolically unhealthy’ (i.e. insulin resistant lean individuals) and this would 
allow an even more extensive phenotyping of both lean and obese women who 
may be at risk of metabolic related obstetric complications. To classify those 
women in either ‘metabolically healthy’ or ‘metabolically unhealthy’ HOMA or 
visceral fat thickness could potentially be used as classification criteria. 
 
It would be vital that this future study assessed the visceral adipose tissue 
compartment measured throughout gestation as that was one of the limitations 
discussed in this thesis. Measuring this depot would yield information as to 
whether the size of this depot is important in early pregnancy and if it is an 
important site of gestational fat deposition. Further comparison of how these 
depots change in pregnancies complicated by gestational diabetes or pre-
eclampsia would be important in completing the lipotoxic phenotype. 
 
 
.
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Appendices 
8.1 Appendix I 
PATIENT INFORMATION LEAFLET 
 
BODY SHAPE IN PREGNANCY STUDY 
 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for 
you. Please take time to read the following information carefully. Talk to others 
about the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part.  
Part 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear, or, if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
PART 1 
1. What is the purpose of the study? 
Congratulations on your pregnancy!  
During pregnancy, a woman’s body goes through many normal changes both 
inside and out. We wish to study how a woman’s body shape changes during 
pregnancy, for instance where she gains weight. We think that where a woman 
gains her pregnancy weight may have an effect on her metabolic health. 
 
2. Why have I been chosen? 
We wish to study healthy pregnant women, like you, who have no current medical 
conditions and have fallen pregnant naturally. We are recruiting first time mums of 
different ages and weights.  
 
3. Do I have to take part? 
No.   
It is up to you to decide whether or not to take part.  If you do, you will be given 
this information sheet to keep and be asked to sign a consent form.  You are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
4. What will happen to me if I take part? 
If you decide to take part in this study you will have three additional appointments 
during your pregnancy and one after you have delivered your baby. These will be 
with the research doctor, Dr Eleanor Jarvie. She is an obstetric doctor and once 
enrolled in the study you will be able to contact her directly regarding your 
appointments and your pregnancy. These appointments will be at approximately 
15 weeks, 25 weeks and 35 weeks of your pregnancy and when your baby is 
approximately 3 months old. 
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The tests require you to be fasted. We would ask that you not have anything to eat 
after 10pm the previous night.  You can drink water. If possible you should not 
drink caffeinated drinks (tea and coffee) or fizzy drinks. Please avoid any over the 
counter medications and try not to smoke.  The appointments will be at 8:00 or 
9:30 in the morning. We will provide breakfast for you. We anticipate that the 
appointments will take 90 minutes.    
 
In addition we would like to obtain tissue samples at the time of your delivery and 
gain information about your baby just after birth.  
 
5. What measurements are being recorded during and after my pregnancy? 
 
All tests are completely harmless to you and your baby. 
 
(A) We will measure your height, weight and blood pressure. 
 
(B) We will take a sample of blood (40ml which is about 3 tablespoons) and urine 
at each visit. 
 
(C) Body composition tests 
These tests are carried out to assess where in your body weight is put on during 
pregnancy.  The first test is skin fold thickness measurements. The second test is 
a measure of percentage fat mass and percentage lean mass measured by the 
way your body displaces air around it. This measurement is carried out seated in a 
person-sized chamber (or capsule) with a window while you are wearing a 
swimsuit or similar which you will need to bring with you. Private changing facilities 
are available. Dr Jarvie and a research nurse will be present. 
 
(D) Resting metabolic rate 
This is measured by assessing the air that you breathe in and out through a 
special clear plastic hood. 
 
(E) Endothelial function tests  
This test looks at blood vessel function. We assess how well the cells which line 
the blood vessels (endothelial cells) are working.  The assessment of skin blood 
flow is not painful. We have used this technique with pregnant ladies before and it 
is safe in pregnancy. 
 
(F) Dietary analysis 
We will be asking you about your diet and what you usually eat and drink. 
 
(G) Activity assessment 
At each visit we will give you an accelerometer (activity monitor) to take away with 
you. This is a small device (about the size of a mobile phone) that can clip onto a 
waistband and record the daily amount of activity of the wearer. We will ask you to 
wear this every day for 7 days. The accelerometer can then be posted back to 
Eleanor Jarvie in the pre-paid envelope provided.  
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6. Samples at the time of your delivery 
(A) Fat cell samples 
We are interested in how fat cells work in different sites of the body.  We would 
like to obtain samples (a biopsy) of fat cells at your delivery but only if you happen 
to have a caesarean section delivery where there is a cut in the tummy already. 
We would not take samples of fat cells at natural or vaginal deliveries. The 
decision to have a Caesarean delivery is made by your own obstetrician in 
charge of your clinical care and not by the research team. 
 
We would take two samples. The first is from just under the skin after the cut has 
been made. The second is from fat cells within the abdominal cavity after the 
womb had been stitched closed, but before the skin is stitched closed. This is an 
additional procedure that takes approximately 1-2 minutes. It will not significantly 
lengthen the time of your operation.  
 
If you require a caesarean section because of concern about you or your baby’s 
wellbeing or your surgeon does not consider it appropriate, we may not collect 
these samples. 
 
(B)Samples from the placenta (afterbirth) 
We would like to gain information about how the placenta (afterbirth) functions 
during pregnancy.  Normally the placenta and its attached umbilical cord are 
delivered after the baby and it is discarded because it has completed its function.  
In our study, instead of the afterbirth being discarded it will be passed onto the 
laboratory where it will be studied.   
 
7. What do I have to do? 
You will be asked to attend four additional appointments (three during your 
pregnancy and one after when your baby is about three months old).  These 
appointments will be held in the Metabolic Suite at the University of Glasgow, 
which is next to the Western Infirmary of Glasgow.  Dr Jarvie can meet you at the 
entrance of the University (on University Avenue) and accompany you to the 
Metabolic Suite.  
 
So that we can collect tissue when you deliver, we would ask that you inform Dr 
Jarvie when you go into labour, or ask the midwife looking after you to inform her. 
There is a contact number at the end of this sheet. 
 
8. Expenses and payment 
You would not receive explicit payment for this study but we will reimburse you a 
nominal amount for your travel expenses or if you prefer we will organise a taxi to 
take you to and from your study appointment. 
9. What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you or your baby by taking part in this 
study.  These appointments do not replace your antenatal care and you will need 
to see your midwife as planned. 
 
10. What are the possible benefits of taking part? 
There is no direct benefit for you in taking part in this study. We hope that the 
information we get from this study will help improve the care of women who 
develop problems in pregnancy. 
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11. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions.  The contact 
number is provided in this form.  If you remain unhappy and wish to complain 
formally, you can do so through the NHS complaints procedure.  Details can be 
obtained from the hospital.   
 
12. Will my taking part in the study be kept confidential? 
Yes 
All the information which we collect will remain completely confidential.  
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
 
PART 2 
13. What if relevant new information becomes available?  
Sometimes we get new information about the conditions being studied. If this 
happens, your research doctor will tell you and discuss whether you should 
continue in the study. If you or your research doctor decides not to carry on, we 
will inform your midwife or obstetrician. If you decide to continue in the study he 
may ask you to sign an updated consent form.  
 
If the study is stopped for any other reason, we will tell you and inform your 
midwife or obstetrician. 
  
14. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will retain the data that has been collected up to 
your withdrawal. However, should you wish for samples and data to be destroyed 
we will comply with this request. 
  
15. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions.  The contact 
number is provided in this form.  If you remain unhappy and wish to complain 
formally, you can do so through the NHS complaints procedure.  Details can be 
obtained from the hospital.   
In the event that something does go wrong and you are harmed during the 
research study, there are no special compensation arrangements.  If you are 
harmed and this is due to someone’s negligence, then you may have grounds for 
a legal action for compensation against NHS Greater Glasgow and Clyde, but you 
may have to pay your legal costs.  The normal National Health Service complaints 
mechanisms will still be available to you. 
 
16. Will my taking part in this study be kept confidential? 
Yes 
All the information which we collect will remain completely confidential. Any 
information about you which leaves the hospital will have your name and address 
removed so you cannot be identified from it. 
 
If you join the study, some of the data collected for the study may be looked at by 
authorised persons from the University of Glasgow. They may also be looked at by 
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people or representatives of regulatory authorities and by authorised people to 
check that the study is being carried out correctly. 
 
17. What will happen to any tissue samples or data that I give? 
Data and tissue samples collected from the study are retained by the University of 
Glasgow. Sometimes new research indicates further tests that would expand the 
knowledge coming from the study and we can use the archived material to carry 
out additional tests.  This allows us to maximise the amount of information on 
pregnancy complications that we can get from the study. Anonymised data and 
samples may be shared with collaborators in other institutions who may be able to 
offer specialised techniques that we do not have in Glasgow.   
 
18. What will happen to the results of the research study? 
New information that we gain from the study will be published in scientific journals.  
No specific individual from whom we have collected tissue will be identified in 
these publications.  These publications are available for all to read. 
 
19. Who is organising and funding the research? 
This research will be funded by the Wellbeing of Women (RCOG) with support 
from the Chief Scientist’s Office. 
 
20. Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by National Research 
Ethics Committee. 
 
21. Further Information 
Further information about this study may be obtained from Dr Eleanor Jarvie 
(e.jarvie@clinmed.gla.ac.uk) 
Dr. Eleanor Jarvie MBChB MRCOG 
Clinical Research Fellow  
Department of Reproductive & Maternal Medicine  
University of Glasgow 
Level 3, McGregor Building Western Infirmary of Glasgow 
Tel: 0141 211 2327 (office), study mobile 07790217442 
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8.2 Appendix II 
LIPOTOXICITY IN PREGNANCY STUDY 
VISIT PROTOCOLS 
BOOKING/RECRUITMENT VISIT – antenatal clinic (12-14 weeks’ gestation) 
Trained midwives or other clinical members of the study team will ask if pregnant 
women agree to take part in the study at the booking visit identified by the criteria 
listed below (tables 1 and 2).  Women who are interested in the study will have a 
consultation with the research doctor (Eleanor Jarvie EMKJ), to ensure their 
wellbeing, and to give them the opportunity to ask any questions. The research 
doctor will explain the additional appointments of the study, supply the participant 
with patient information leaflets, contact telephone numbers and first appointment 
time and location.  
Table 1 Inclusion criteria 
Criteria Rationale 
Primigravid 
 
 
 
Age 16-40 
 
 
Three groups lean BMI<25, 
 obese BMI≥30 kg/m2 
 
 
Caucasian 
No  influence of previous pregnancy on 
index pregnancy outcome 
Adverse outcomes will be excluded 
from analysis 
Women are of age to give consent and 
are within the range of normal healthy 
pregnancy 
Established poorer outcome in obese 
pregnant population (CEMACH, 2007) 
WHO criteria for obesity (WHO, 2004) 
Predominant ethnic group in Glasgow 
Table 2 Exclusion criteria 
 
VISIT 1 – 15 weeks’ gestation  
 Starting time 08:00  
 Subjects fasted for at least 10 hours overnight 
 Subjects to be met at the Faculty of Biomedical and Life Sciences (West 
medical building, University of Glasgow) entrance by research doctor (Dr 
Jarvie) 
 Informed written consent will be obtained (copy to remain with patient, with 
investigators and in medical notes) 
 Following consent, the demographic questionnaire will be completed which 
will highlight the maternal age and date of birth to check that the participant 
is suitable for the study before any investigations are commenced. 
 Actual dietary intake (24 hour recall) will be performed at this point in the 
appointment or at the time of the Food Frequency Questionnaire. 
Known metabolic disease (diabetes, thyroid disease, PCOS) 
Cardiovascular disease 
Parous women 
Assisted conception pregnancies 
Multiple pregnancies 
Previous loss >12 weeks’ gestation 
Co-existing conditions that require treatment 
Women with a complicated pregnancy outcome (excluded from analysis) 
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Table 3 - Demographic data 
Data Details 
Date of visit 
Age 
PMHx 
OBHx 
FHx including OBHx 
 
DOB, and age noted 
CVD/DM 
Infertility/PCOS/misc/TOP/AC 
CVD/DM/PET/GDM 
Social Hx 
 
 
 
Alcohol, drugs, smoking  
Medication esp contraception at PN visit 
employment 
postcode 
 
 
 
1) ENERGY METABOLISM/EXPENDITURE 
 Participant will then have indirect calorimetry performed.  (in total 20- 
25mins) 
Table 4 – procedure for indirect calorimetry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Ventilation hood and circuit must first be calibrated – 5 mins 
 The subject lies supine at  45 degree angle 
 Once the hood is in position they are asked to relax but not to 
fall asleep 
 Once their ventilation rate has reached equilibrium then the 
recording starts 
 Normally the first 5-10 mins will not be counted as subject will 
not be at a steady ventilation rate 
 Measurements – VO2 (ml/min) and VCO2 (ml/min) are 
recorded onto hard drive of computer, ratio of VO2/VCO2 and 
energy expenditure are also collected.  Measurements need to 
be converted into l/min for calculations. 
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2) ENDOTHELIAL FUNCTION 
Non-invasive peripheral endothelial function Laser Doppler Iontophoresis (LDI) will 
be performed immediately after the indirect calorimetry as the subject will be 
rested. Skin blood flow will be assessed using LDI combined with constant current 
iontophoresis of vasoactive agents to assess vascular reactivity and the role of the 
endothelium.  
Table 5  procedure for laser Doppler iontophoresis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in response to these drugs are quantifiable as the area under the curve 
(AUC) with repeated scans. This method is highly reproducible (Jadhav et al., 
2007) and has been previously used in a pregnant cohort(Stewart et al., 2007a).  
(in total 20mins) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Measurements conducted in quiet, temperature 
controlled room 
 Subject lies semirecumbent position 
 Laser scanned over the areas to be assessed 
 Iontophoresis chambers attached to the flexor 
aspect of the forearms (avoiding broken skin, hair 
and superficial veins) 
 1% solution of Acetylcholine (dissolved in 0.5% 
saline) placed in the anode chamber 
 1% sodium nitroprusside (dissolved in 0.5% 
saline), placed in the cathode chamber 
 Skin perfusion is measured before, during and 
after an incremental current (baseline scan, four 
scans at 5A, four at 10A, four at 15A, and two 
at 20A, and five recovery scans) 
 Laser doppler imaging (red laser) is used to 
record the changes in endothelial reactivity 
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3) BLOOD & URINE SAMPLE COLLECTION 
Fasting blood (20ml in EDTA) and urine (25mL) will be collected. Blood and urine 
will be handed to technician for immediate processing. (5 mins) 
Table 8 –Sample processing 
 
 
4) ANTHROPOMETRIC TESTS/BODY COMPOSITION 
 Patient to change into swimming costume/underwear and observed in 
BODPOD)  
 Height (cm) and weight (kg) to be measured to 0.5 cm, and recorded 
 
Table 6 – procedure for BODPOD assessment 
 
Following BODPOD measurements participant will have anthropometric data 
measurements performed. Waist, Hip and thigh circumferences will also be 
measured in metric units. Skinfold thickness will be performed with the participant 
in their underwear and covered by a hospital gown.  Based on previous studies by 
Catalano(Okereke et al., 2004, Presley et al., 2000)  the skinfold thickness 
measurements shown in Table 5 will be used.  Our group has previously used the 
following criteria for waist and hip measurements(Stewart et al., 2007b). Thigh 
circumference has been publish with respect to being a risk factor for 
cardiovascular disease (Heitmann and Frederiksen, 2009). 
 
 
 
  
 They are also required to wear a swimming cap – provided – 
to prevent air being trapped in hair. 
 The machine is calibrated with the door open and an empty 
canister inside it to predict lung volume 
 The subject is then asked to sit in the BODPOD and rests her 
hands on her lap, and asked to remain still 
 The door is closed and recording starts – there is normally 
three separate recording and these take approximately 2mins 
each.  The door is opened in between measurements. 
 The data collected is stored on the hard drive of the 
computer, serial measurements for each subject will be kept 
i.e. longitudinal data can be compared. 
 
Blood: 
 Whole blood Electron Spin Resonance 
 Freeze aliquots of whole blood 
 Separation of rest of whole blood by Histopaque into plasma, 
white cells and erythrocytes 
 FACS analysis of white cells (Scott Claire) 
 Fresh plasma for lipoprotein fractionation (see Dorothy) 
 Freeze aliquots of plasma, white cells and erthyrocytes 
Urine: 
 Freeze aliquots of urine 
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Table 7 Sites for skin fold measurements 
 
 
5) DIETARY ASSESSMENT 
 Participant will be served breakfast  
 The participant will have usual (food frequency questionnaire) dietary intake 
assessed.  This will be performed using questionnaires which the 
participant will go through with the research doctor (EMKJ) (15mins) 
Table 9 Confounding variables in dietary assessment 
Information Details 
Hyperemesis 
Food frequency questionnaire 
 
 
 
Vitamin supplementation 
Smoking status 
Socioeconomic status 
Breast feeding status 
Yes/no/hospitalisation 
Socioeconomic status may affect this.   
If asking subject to fill in a questionnaire 
prior to appointment levels of literacy 
will affect reporting 
Pregaday/pregacare/ferrous sulphate 
Y/N current – how many 
Ex – how long/years smoked 
 
6) ACCELEROMETERS 
 Study participants will be supplied with an accelerometer, at each visit, 
which they will be asked to wear for one week (7 days).  This is to assess 
actual activity. (5 mins) 
 The accelerometers will be collected by the research doctor. 
(TOTAL VISIT TIME 90 MINUTES) 
VISIT 2 25 weeks’ gestation 
VISIT 3 35 weeks’ gestation 
Visit 2 and visit 3 will have same protocol as visit 1.   
 
 Triceps (midway between lateral projection of acromion and 
olecranon) 
 Biceps (anterior aspect of arm, midway between acromion 
and antecubital fossa) 
 Subscapular (at a 45 degree angle just below inferior angle 
of scapula) 
 Subcostal (midaxiliary line at the level of lowest rib) 
 Suprailiac (skinfold at the mid point between superior anterior 
iliac crest and lowest rib) 
 Mid thigh (at the midpoint between inguinal crease and 
proximal patella – anterior aspect of leg) 
 Suprapatellar (anterior aspect of the thigh just above the 
patella)  
 
Waist circumference level of umbilicus 
Hip circumference widest point over buttocks 
Thigh circumference (directly below the gluteal fold of the right 
thigh)  
Measure twice, to the nearest 0.5cm and mean 
If difference >2cm take a third measurement and mean 
Waist Hip Ratio (WHR) waist circumference divided by the hip 
circumference 
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DELIVERY DATA 
Delivery data will be easier to obtain when women have elective delivery dates.  
Study participants have contact details for the research doctor and asked to inform 
if admitted in labour.  In addition, stickers which indicate that the labouring woman 
is involved in our study will be on the hand held pregnancy notes, and the 
attending midwife or doctor can then contact the research doctor on the dedicated 
study mobile phone.   A lot of the following data is normally recorded in delivery 
summary so could be collected retrospectively from maternity notes. 
 
Table 10 Delivery data to be collected 
Record: 
 Birth weight 
 APGAR scores 
 placental weight 
 mode of delivery 
 labour yes/no 
 gestation at delivery 
 sex of baby 
 
Collect (where feasible): 
 placental tissue (Full thickness biopsy sections of third trimester placentae 
will be obtained [approximately five grams] at time of delivery from four 
separate pre-determined areas on each placenta, distinct from the umbilical 
cord insertion, and then samples will be randomised. Three biopsies will be 
immediately snap frozen in liquid nitrogen and stored at -70°C, one biopsy 
will be washed in PBS and fixed in 10% neutral buffered formalin and 
paraffin-embedded for immunocytochemistry. 
 cord blood from the umbilical vein 
 endothelial cells from cord – collagenase digestion 
 maternal adipose tissue (subcutaneous and visceral) approximately 1cm3 
will be collected from the incision site at time of Caesarean section, and 
washed in phosphate buffered saline. One half sample will be fixed in zinc 
formalin. The other half biopsy will be immediately snap frozen in liquid 
nitrogen and stored at -70°C.  
 
 
Visit 4 – postnatal data (12 weeks following delivery) 
The postnatal visit for the mother would be similar to visit 1-3.  Additional 
information regarding breastfeeding status and contraception use is required (see 
Tables 8 and 9). 
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 STUDY IDENTIFICATION 
NUMBER______________ 
LIPOTOXICITY IN PREGNANCY STUDY (LIPS) 
Your Consent Please initial 
box 
I confirm that I have read and understand the patient 
information sheet dated May 2011 (version 5) for the above 
study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.  
 
I understand that my participation is voluntary and that I am 
free to withdraw without giving any reason, without my medical 
care or legal rights being affected. 
 
I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by individuals 
from the University of Glasgow, from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have 
access to my records. 
 
I understand that data and samples used in this study may be 
used in relevant future research. I give my consent for this. 
 
I consent to the collection of blood samples at each visit and 
tissue samples at delivery. These samples will be retained by 
the section of Reproductive and Maternal Medicine at the 
University of Glasgow. 
 
I consent to the collection, processing, reporting and transfer 
within and outside Europe of my anonymised data for 
healthcare and/or medical research purposes. 
 
I agree to take part in the above study  
 
 
_______________   ________________  _________________ Name 
of Patient   Date     Signature  
 
 
_______________   ________________  __________________ 
Name of Person   Date     Signature  
obtaining consent  
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
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DEMOGRAPHIC QUESTIONNAIRE – LIPOTOXICITY IN PREGNANCY STUDY 
(this questionnaire should be completed on the first visit – please see ‘update’ page 
for visits 2 and 3 and postnatal section for visit 4) 
 
Date of visit 
Study identification number  
Maternal date of birth  
Maternal age  
Current gestation  (weeks)  
Estimated date of delivery  
Postcode for social deprivation 
score 
(use postcode minus last 2 letters 
to avoid identification of street 
where they live) 
 
Highest level of education  
Current employment   
 
Personal Past medical history 
condition yes no 
Cardiovascular disease , angina, 
essential hypertension  
  
Diabetes Type 1 
 
  
Diabetes Type 2    
Thyroid disease   
Asthma or breathing problems   
bowel conditions (irritable bowel)   
kidney disease   
Musculoskeletal e.g. arthritis    
Previous operations 
 
 
  
 
Obstetric History 
 yes no 
Hospital admissions in this 
pregnancy 
 
 
If yes please detail  
Hyperemesis/severe morning 
sickness, if so what treatment 
 
 
 
 
 
 
Miscarriage/Termination of 
pregnancy 
 
  
Assisted conception  
 
  
Polycystic ovarian syndrome 
 
  
Problems conceiving   
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Family medical history 
Condition yes no 
Cardiovascular disease in any 
relatives 
 
1st degree  
Relative  
2
nd
 degree  
Relative  
Relationship to 
subject 
_________________ 
 
Diabetes any relatives  
Type 1  
Type 2  
Gestational diabetes mellitus    
 
1st degree  
Relative  
2
nd
 degree  
Relative  
Relationship to 
subject 
_________________ 
 
Pre-eclampsia in female relatives 
 
  
Intrauterine growth restriction 
Stillbirth or recurrent miscarriage 
in your family members 
 
  
Drug & Medicines History 
 yes no 
Are you currently taking any 
regular prescribed medications 
If yes details of meds  
Are you taking vitamins 
supplements? If so what brand 
  
Are you taking any fish oil 
capsules 
  
Have you recently used or are you 
using over the counter 
medications? 
i.e. gaviscon 
  
Social history  
 yes no 
Alcohol ( a unit of alcohol is one 
25ml single measure of whisky 
(ABV 40%), or a third of a pint of 
beer (ABV 5-6%) or half a 
standard (175ml) glass of red 
wine (ABV 12%). 
 
Current      Y 
                  N 
No of unit/wk___ 
 
Prior to preg  Y 
                      N 
No of unit.wk___ 
 
smoking Current      Y 
                  N 
No of cig.day___ 
 
Prior to preg  Y 
                      N 
No of cig/day___ 
If ex smoker, when did they 
stop, how long did they 
smoke for and how many a 
day 
Recreational drug use 
Please specify type and pattern of use 
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Update section: (for visits 2 and 3) 
Since your last visit have there been any changes in your health including 
stopping/starting smoking 
 
 
 
 
 
 
Since your last visit have you started to take any prescribed medications/vitamins 
or fish oils (please specifiy) 
 
 
 
 
 
 
Since your last visit, has anything changed in your pregnancy that you think is 
important (additional trips to hospital/admissions to hospital/moved house) 
 
 
 
 
 
 
Postnatal details only 
Date of delivery 
 
 
 
 
Place of delivery 
 
 
 
 
Method of contraception currently 
used 
 
 
Initial infant feeding method 
Tick as appropriate and detail 
Bottle fed Breast fed 
If yes for how long 
 
Top up feeding? 
Current Infant feeding status 
 
 
 
Bottle fed Breast fed 
Top up feeding? 
Fish oil capsules  
Vitamins  
Prescribed medications  
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LIPOTOXICITY IN PREGNANCY STUDY - RESTING METABOLIC RATE ASSESSMENT 
 
SUBJECT ID _______________________ DATE ______________________ 
 
TIME  _______________________ GESTATION __________________ 
FASTING    YES/NO 
IF POSTNATAL BREAST FEEDING YES/NO 
FIRST TEN MINUTES ACCLIMITISATION PERIOD 
TIME 
(x) 
DRIFT  
VO2 
VO2 
(ml/min) 
DRIFT  
VCO2 
VCO2 
(ml/min) 
RER EE CHO FAT PRO 
1.00          
2.00          
3.00          
4.00          
5.00          
6.00          
7.00          
8.00          
9.00          
10.00          
11.00 HOOD JUST ON 
12.00          
13.00          
14.00          
15.00          
16.00          
17.00          
18.00          
19.00          
20.00          
21.00          
22.00          
23.00          
24.00          
25.00          
26.00          
27.00          
28.00          
29.00          
30.00          
31.00          
32.00          
33.00          
34.00          
35.00          
36.00          
37.00 HOOD JUST OFF 
38.00          
39.00          
40.00          
41.00          
42.00          
43.00          
44.00          
45.00          
46.00          
47.00          
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LIPOTOXICITY IN PREGNANCY STUDY – BODPOD BODY COMPOSITION ASSESSMENT 
 
SUBJECT ID _______________________ height____________________________ 
 
TIME  _______________________ weight____________________________ 
 
 
Measurement 1: GESTATION _________________ DATE _________________________ 
FASTING    YES/NO 
Total body mass (kg)  
Total fat mass (kg)  
Total fat free mass (kg)  
Percentage body fat (%)  
 
 
 
Measurement 2: GESTATION _________________ DATE _________________________ 
FASTING    YES/NO 
Total body mass (kg)  
Total fat mass (kg)  
Total fat free mass (kg)  
Percentage body fat (%)  
 
 
 
Measurement 3: GESTATION _________________ DATE _________________________ 
FASTING    YES/NO 
Total body mass (kg)  
Total fat mass (kg)  
Total fat free mass (kg)  
Percentage body fat (%)  
 
 
 
Measurement 4: GESTATION _________________ DATE _________________________ 
IF POSTNATAL BREAST FEEDING YES/NO 
FASTING    YES/NO 
Total body mass (kg)  
Total fat mass (kg)  
Total fat free mass (kg)  
Percentage body fat (%)  
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24 HOUR DIETARY RECALL QUESTIONNAIRE 
 LIPOTOXICITY IN PREGNANCY STUDY 
 
I would like you to tell me everything that you had to eat and drink 
yesterday. 
By yesterday I mean, from midnight to midnight, (or from the moment you 
got up until you went to bed yesterday). 
 
Include everything that you had to eat and drink at home and away from home, 
including snacks, tea, coffee, sweets and soft drinks.  
 
First we’ll make a list of the foods you ate and drank all day yesterday (DAY). 
 
Next I’ll ask you about the foods including amounts and then I’ll ask you a few 
questions.  
 
It may help you to remember what you ate by thinking about where you were, 
whom you were with, or what you were doing yesterday; like going to work, eating 
out or watching television.  
 
Feel free to keep these activities in mind and say them aloud if it helps you. 
 
If you would like to start at midnight at the beginning of (DAY). 
 
There are some foods that people often forget. In addition to what you have 
already told me about, did you have any: 
 Coffee, tea, soft drinks or milk 
 Alcoholic drinks 
 Biscuits, cakes, sweets, chocolate bars or other confectionery 
 Crisps, peanuts or other snacks 
 Sauces, dressings, 
 Anything you have not already told me about? 
 
 Type of food or drink 
• How was it bought – fresh, canned, frozen, dehydrated etc? 
  239 
• Was it home-made – if so – what was in it? Don’t forget to record any recipes on 
the Recipe Pages. 
• How was it cooked – boiled, grilled, fried etc? 
• If it was cooked in fat, or fat was used in pastry or cakes or any other dish, what 
sort of fat or oil was used? 
• If it was a dried / dehydrated product, was it reconstituted using water, milk or 
both? 
• Was the item coated before cooking – if so – was it flour, batter, egg, 
breadcrumbs etc? 
• Was it unsweetened, sweetened with sugar/honey, or artificially sweetened? 
• Was it low fat / low calorie? 
 
 
Measurement Imperial Metric 
Volumes 1 cup 0.568 pint 250 ml 
 I mug ~300ml 
Weight Tsp 5ml (3.5ml) 
 Tbsp 15ml or 30g (14.2ml) 
 ounce 28.3g 
 1.76 oz 50g 
 3.52 oz 100g 
 
Routine foods Yoghurt pot standard 125g 
 Med bowl cereal 45g 
 Slice bread med 30g 
 Slice bread thick 45g 
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Time         Description of food 
or drink  
Amount  Brand  Leftovers 
y/n 
amount  
 
 
 
 
 
 
 
Slices_______ 
 
Tsp_________ 
 
Tbsp________ 
 
Cup_________ 
 
Mug_________ 
 
Wgt if known 
___________ 
Bowl size 
___________ 
Plate size 
___________ 
Added fat? 
___________ 
  
  
 
Slices_______ 
 
Tsp_________ 
 
Tbsp________ 
 
Cup_________ 
 
Mug_________ 
 
Wgt if known 
___________ 
Bowl size 
___________ 
Plate size 
___________ 
Added fat? 
___________ 
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FOOD FREQUENCY QUESTIONNAIRE LIPOTOXICITY IN PREGNANCY 
STUDY 
 
DATE  
STUDY IDENTIFICATION NUMBER  
VISIT NUMBER/GESTATION  
 
 
1. What kind of bread do you usually eat    
 - white  
 - brown, granary, wheatmeal  
 - wholemeal  
 - other kind (please specify)  
 - no usual type  
 - do not know  
 - do not eat bread  
 
 
2. What do you usually spread on bread? 
 - butter  
 - hard/block margarine  
 - soft margarine  
 - reduced fat spread  
 - low fat spread  
 - no usual type  
 - do not know  
 - do not spread fat on bread  
 
 
3. How much do you usually eat in a day? 
 less 
than 
1 
1 2-3 4-5 6+ 
 - slices of bread/rolls      
 - biscuits (including chocolate biscuits)      
 - cakes, scones, sweet pies and pastries      
 
4. What kind of milk do you usually use for drinks in tea or coffee and on 
cereals etc? 
 - whole milk  
 - semi-skimmed  
 - skimmed  
 - other kind (please specify)  
 - no usual type  
 - do not know  
 - do not drink milk  
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5. Do you usually take sugar in: 
 YES NO 
 (a) tea   
 (b) coffee   
 DO NOT DRINK TEA/COFFEE   
 
6. At table do you: 
 YES NO 
 - generally add salt to food without tasting first   
 - taste food and then generally add salt   
 - taste food but only occasionally add salt   
 - rarely or never add salt at table   
 
7. Which type of breakfast cereal do you normally eat? 
 - high fibre (eg All Bran, Branflakes, Shredded 
   Wheat, Muesli, Porridge, Weetabix 
 
 - other (eg Cornflakes, Rice Krispies, Special K
   Sugar Puffs, Honey Snacks 
 
 - no usual type  
 - do not eat breakfast cereal  
 
8. How often do you eat these foods only fill in one box for each food 
 Per day (times)  Per week  Per month 
 6+ 4-5 2-3 onc
e 
 5-
6 
2-
4 
onc
e 
 1-3 Les
s 
than 
onc
e 
Breakfast cereal            
Fresh fruit            
Cooked green vegetables 
(fresh or frozen) 
           
Cooked root vegetables 
(fresh or frozen) 
           
Raw vegetables or salad 
(including tomatoes) 
           
Chips            
Potatoes, pasta, rice            
Meat            
Meat products            
Poultry            
White fish            
Oil rich fish            
Cheese            
Beans or pulses            
Sweets, chocolates            
Ice cream            
Crisps, savoury snacks            
Fruit juice (NOT squash)            
Soft/fizzy drinks            
Cakes, scones, sweet pies 
or pastries 
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biscuits            
 
 
9. In summary: 
(a)  how many times do you eat fruit and vegetables or pure fruit juice 
   
       per day  OR     per week  OR        per month 
 
(b) how many times do you eat oil rich fish 
 
                  per day  OR     per week  OR        per month 
 
 
(c) how many times do you eat sweets, chocolates, cakes, scones, sweet 
pies, pastries or biscuits 
 
           per day  OR     per week  OR        per month 
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Recipe pages: 
 
 
Recipe pages: 
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Physical activity monitor diary 
 
This activity monitor is only to be worn when you are up and about. 
You don’t need to wear it in bed or when having a shower or 
swimming. Please note down the times that you got up and went to 
bed so that we can discount this data from analysis. 
 
 
ACTIVITY MONITOR  
BEGINS _________________ 
FINISHES ________________ 
 
 
 
 
After the final day could you please send the activity monitor back to 
me in the pre-paid envelope as soon as is convenient. 
 
Many thanks 
Ellie  
 
 
 
 
 
 
 
  
 Get up  Bedtime 
Saturday 7/7/12   
Sunday 8/7/12   
Monday 9/7/12   
Tuesday 10/7/12   
Wednesday 11/7/12   
Thursday 12/7/12   
Friday 13/7/12   
Saturday 14/7/12   
  246 
8.3 Appendix III 
physical activity 
parameter 
 
visit  
(gestation 
wk) 
lean  
mean (SD) 
[n] 
OW/OB  
mean (SD) 
[n] 
2 sample t-
test  
p value 
 
total wear time 
(mins/day) 
 
V1 (15) 
 
V2 (25) 
 
V3 (35) 
 
 
803.5 (67.8) 
[22] 
810.7 (54.4) 
[23] 
785.2 (68.9) 
[22] 
 
 
810.0 (60.6) 
[14] 
813.6 (83.2) 
[14] 
796.8 (85.2) 
[12] 
 
0.77 
 
0.91 
 
0.69 
 
 
sedentary 
activity wear 
time (mins/day) 
 
V1 
V2 
V3 
550.8 (77.0) 
541.7 (64.8) 
526.6 (68.7) 
 
571.3 (47.0) 
565.4 (82.3) 
553.8 (86.7) 
0.29 
0.38 
0.37 
 
light activity 
wear time 
(mins/day) 
V1 
V2 
V3 
 
216.9 (72.3) 
238.2 (66.4) 
235.7 (33.4) 
214.2 (69.4) 
228.6 (73.1) 
226.3 (66.5) 
0.91 
0.66 
0.55 
MVPA wear time 
(mins/day) 
 
V1 
V2 
V3 
 
34.3 (20.0) 
30.1 (23.8) 
20.5 (17.4) 
21.6 (11.5) 
19.4 (10.4) 
14.0 (10.7) 
0.03 
0.16 
0.25 
ratio 
sedentary:total 
wear time  
V1 
V2 
V3 
 
0.69 (0.08) 
0.71 (0.07) 
0.67 (0.05) 
0.71 (0.07) 
0.70 (0.08) 
0.70 (0.08) 
0.39 
0.30 
0.31 
 
ratio light:total 
wear time 
V1 
V2 
V3 
 
0.27 (0.08) 
0.29 (0.08) 
0.30 (0.05) 
0.27 (0.07) 
0.28 (0.07) 
0.28 (0.07) 
0.77 
0.61 
0.45 
ratio MVPA:total 
wear time 
V1 
V2 
V3 
 
0.04 (0.02) 
0.04 (0.03) 
0.03 (0.02) 
0.03 (0.01) 
0.02 (0.01) 
0.02 (0.01) 
0.02 
0.08 
0.14 
  247 
Bibliography 
 
ABATE, N., GARG, A., COLEMAN, R., GRUNDY, S. M. & PESHOCK, R. M. 1997. 
Prediction of total subcutaneous abdominal, intraperitoneal, and 
retroperitoneal adipose tissue masses in men by a single axial magnetic 
resonance imaging slice. The American Journal of Clinical Nutrition, 65, 
403-8. 
ABDUL-GHANI, M., MULLER, F., LIU, Y., CHAVEZ, A., BALAS, B., ZUO, P., CHANG, 
Z., TRIPATHY, D., JANI, R., MOLINA-CARRION, M., MONROY, A., FOLLI, F., 
VAN REMMEN, H. & DEFRONZO, R. A. 2008. Deleterious action of FA 
metabolites on ATP synthesis: possible link between lipotoxicity, 
mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol 
Metab, 295, E678-685. 
AGHAJAFARI, F., NAGULESAPILLAI, T., RONKSLEY, P., TOUGH, S., O'BEIRNE, M. & 
RABI, D. 2013. Association between maternal serum 25-hydroxyvitamin D 
level and pregnancy and neonatal outcomes: systematic review and meta-
analysis of observational studies. BMJ, 346. 
ALKAZEMI, D., EGELAND, G., VAYA, J., MELTZER, S. & KUBOW, S. 2008. Oxysterol 
as a Marker of Atherogenic Dyslipidemia in Adolescence. J Clin Endocrinol 
Metab, 93, 4282-4289. 
AMBROSE, J. A. & BARUA, R. S. 2004. The pathophysiology of cigarette smoking 
and cardiovascular disease: An update. Journal of the American College 
of Cardiology, 43, 1731-1737. 
AMUNDSEN, Å. L., KHOURY, J., SANDSET, P. M., SELJEFLOT, I., OSE, L., 
TONSTAD, S., HENRIKSEN, T., RETTERSTØL, K. & IVERSEN, P. O. 2007. 
Altered hemostatic balance and endothelial activation in pregnant women 
with familial hypercholesterolemia. Thrombosis Research, 120, 21-27. 
ANBER, V., GRIFFIN, B. A., MCCONNELL, M., PACKARD, C. J. & SHEPHERD, J. 
1996. Influence of plasma lipid and LDL-subfraction profile on the 
interaction between low density lipoprotein with human arterial wall 
proteoglycans. Atherosclerosis, 124, 261-271. 
ANDERSON, T. J., UEHATA, A., GERHARD, M. D., MEREDITH, I. T., KNAB, S., 
DELAGRANGE, D., LIEBERMAN, E. H., GANZ, P., CREAGER, M. A., YEUNG, 
A. C. & SELWYN, A. P. 1995. Close relation of endothelial function in the 
human coronary and peripheral circulations. Journal of the American 
College of Cardiology, 26, 1235-1241. 
ANUMBA, D. O. C., ROBSON, S. C., BOYS, R. J. & FORD, G. A. 1999. Nitric oxide 
activity in the peripheral vasculature during normotensive and 
preeclamptic pregnancy. American Journal of Physiology - Heart and 
Circulatory Physiology, 277, H848-H854. 
ANURADHA, R., HEMACHANDRAN, S. & DUTTA, R. 2012. The waist circumference 
measurement: a simple method for assessing the abdominal obesity. Clin 
Diagn Res. , 6, 1510-3. 
ARTAL, R. & O'TOOLE, M. 2003. Guidelines of the American College of 
Obstetricians & Gynaecologists for exercise during pregnnacy and the 
postpartum period. Br J Sports Med, 37, 6-12. 
AUSTIN, M. A., HUTTER, C. M., ZIMMERN, R. L. & HUMPHRIES, S. E. 2004. 
Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE 
Association Review. American Journal of Epidemiology, 160, 421-429. 
BAKER, P. N., WHEELER, S. J., SANDERS, T. A., THOMAS, J. E., HUTCHINSON, C. 
J., CLARKE, K., BERRY, J. L., JONES, R. L., SEED, P. T. & POSTON, L. 
  248 
2009. A prospective study of micronutrient status in adolescent 
pregnancy. The American Journal of Clinical Nutrition, 89, 1114-1124. 
BARAKAT, R., PELAEZ, M., LOPEZ, C., LUCIA, A. & RUIZ, J. R. 2013. Exercise 
during pregnancy and gestational diabetes-related adverse effects: a 
randomised controlled trial. British Journal of Sports Medicine, 47, 630-
636. 
BARRETT-CONNOR, E. 2013. Menopause, atherosclerosis, and coronary artery 
disease. Current Opinion in Pharmacology, 13, 186-191. 
BARTHA, J. L., MARIN-SEGURA, P., GONZALEZ-GONZALEZ, N. L., WAGNER, F., 
AGUILAR-DIOSDADO, M. & HERVIAS-VIVANCOS, B. 2007. Ultrasound 
Evaluation of Visceral Fat and Metabolic Risk Factors During Early 
Pregnancy. Obesity, 15, 2233-2239. 
BECKMANN, I., VISSER, W., STRUIJK, P. C., VAN DOOREN, M., GLAVIMANS, J. & 
WALLENBURG, H. C. S. 1997. Circulating bioactive tumor necrosis factor-
α, tumor necrosis factor-α receptors, fibronectin, and tumor necrosis 
factor-α inducible cell adhesion molecule VCAM-1 in uncomplicated 
pregnancy. American Journal of Obstetrics and Gynecology, 177, 1247-
1252. 
BELAVY, D. L., MOHLIG, M., PFEIFFER, A. F. H., FELSENBERG, D. & ARMBRECHT, 
G. 2014. Preferential deposition of visceral adipose tissue occurs due to 
physical inactivity. Int J Obes. 
BELO, L., CASLAKE, M., SANTOS-SILVA, A., CASTRO, E. M. B., PEREIRA-LEITE, L., 
QUINTANILHA, A. & REBELO, I. 2004. LDL size, total antioxidant status and 
oxidised LDL in normal human pregnancy: a longitudinal study. 
Atherosclerosis, 177, 391-399. 
BESLER, C., HEINRICH, K., ROHRER, L., DOERRIES, C., RIWANTO, M., SHIH, D. M., 
CHRONI, A., YONEKAWA, K., STEIN, S., SCHAEFER, N., MUELLER, M., 
AKHMEDOV, A., DANIIL, G., MANES, C., TEMPLIN, C., WYSS, C., MAIER, W., 
TANNER, F. C., MATTER, C. M., CORTI, R., FURLONG, C., LUSIS, A. J., VON 
ECKARDSTEIN, A., FOGELMAN, A. M., XFC, SCHER, T. F. & LANDMESSER, U. 
2011. Mechanisms underlying adverse effects of HDL on eNOS-activating 
pathways in patients with coronary artery disease. The Journal of Clinical 
Investigation, 121, 2693-2708. 
BESLER, C., LÜSCHER, T. F. & LANDMESSER, U. 2012. Molecular mechanisms of 
vascular effects of High‐density lipoprotein: alterations in cardiovascular 
disease. 4, 251-268. 
BEVILACQUA, S., BONADONNA, R., BUZZIGOLI, G., BONI, C., CIOCIARO, D., 
MACCARI, F., GIORICO, M. A. & FERRANNINI, E. 1987. Acute elevation of 
free fatty acid levels leads to hepatic insulin resistance in obese subjects. 
Metabolism, 36, 502-506. 
BJORKHEM, I. & DICZFALUSY, U. 2002. Oxysterols: Friends, Foes, or Just Fellow 
Passengers? Arterioscler Thromb Vasc Biol, 22, 734-742. 
BLACK, A. 2000. The sensitivity and specificity of the Goldberg cut-off for EI:BMR 
for identifying diet reports of poor validity. Eur J Clin Nutr., 54, 395-404. 
BODZEK, P., OLEJEK, A. & ZAMŁYŃSKI, J. 2002. Concentration of the oxygenated 
derivates of cholesterol in pregnant women suffering from diabetes type 
I. Wiad Lek., 55, 50-3. 
BOONCHAYA-ANANT, P. & APOVIAN, C. 2014. Metabolically Healthy Obesity—
Does it Exist? Current Atherosclerosis Reports, 16, 1-9. 
BOS, G., SNIJDER, M., NIJPELS, G., DEKKER, J., STEHOUWER, C., BOUTER, L., 
HEINE, R. & JANSEN, H. 2005. Opposite contributions of trunk and leg fat 
mass with plasma lipase activities: the Hoorn study. Obes Res. , 13, 1817-
23. 
  249 
BRADLEY, R. D., FITZPATRICK, A. L., JACOBS JR, D. R., LEE, D.-H., SWORDS 
JENNY, N. & HERRINGTON, D. 2014. Associations between γ-
glutamyltransferase (GGT) and biomarkers of atherosclerosis: The multi-
ethnic study of atherosclerosis (MESA). Atherosclerosis, 233, 387-393. 
BRANCH, D. 1992. Physiological adaptations of pregnancy. Am J Reprod 
Immunol. , 28, 120-2. 
BRILEY, A., BARR, S., BADGER, S., BELL, R., CROKER, H., GODFREY, K., HOLMES, 
B., KINNUNEN, T., NELSON, S., OTENG-NTIM, E., PATEL, N., ROBSON, S., 
SANDALL, J., SANDERS, T., SATTAR, N., SEED, P., WARDLE, J. & POSTON, 
L. 2014. A complex intervention to improve pregnancy outcome in obese 
women; the UPBEAT randomised controlled trial. BMC Pregnancy and 
Childbirth, 14, 74. 
BROCHU, M., TCHERNOF, A., DIONNE, I. J., SITES, C. K., ELTABBAKH, G. H., 
SIMS, E. A. H. & POEHLMAN, E. T. 2001. What Are the Physical 
Characteristics Associated with a Normal Metabolic Profile Despite a High 
Level of Obesity in Postmenopausal Women? The Journal of Clinical 
Endocrinology & Metabolism, 86, 1020-1025. 
BRONSTEIN, M., MAK, R. & KING, J. 1996. Unexpected relationship between fat 
mass and basal metabolic rate in pregnant women. Br J Nutr., 75, 659-68. 
BROWN, A. J. & JESSUP, W. 2009. Oxysterols: Sources, cellular storage and 
metabolism, and new insights into their roles in cholesterol homeostasis. 
Molecular Aspects of Medicine, 30, 111-122. 
BUSH, M. 2008. The Low Income Diet and Nutrition Survey: overview of methods. 
Proceedings of the Nutrition Society, 67. 
BUTTE, N. F., ELLIS, K. J., WONG, W. W., HOPKINSON, J. M. & SMITH, E. O. B. 
2003. Composition of gestational weight gain impacts maternal fat 
retention and infant birth weight. American Journal of Obstetrics and 
Gynecology, 189, 1423-1432. 
BUTTE, N. F., WONG, W. W., TREUTH, M. S., ELLIS, K. J. & O’BRIAN SMITH, E. 
2004. Energy requirements during pregnancy based on total energy 
expenditure and energy deposition. The American Journal of Clinical 
Nutrition, 79, 1078-1087. 
CANOY, D. 2008. Distribution of body fat and risk of coronary heart disease in 
men and women. [Miscellaneous Article]. Current Opinion in Cardiology 
November, 23, 591-598. 
CANOY, D., BOEKHOLDT, S. M., WAREHAM, N., LUBEN, R., WELCH, A., BINGHAM, 
S., BUCHAN, I., DAY, N. & KHAW, K. 2007. Body Fat Distribution and Risk 
of Coronary Heart Disease in Men and Women in the European Prospective 
Investigation Into Cancer and Nutrition in Norfolk Cohort: A Population-
Based Prospective Study. Circulation, 116, 2933-2943. 
CARTY, D. M., ANDERSON, L. A., DUNCAN, C. N., BAIRD, D. P., ROONEY, L. K., 
DOMINICZAK, A. F. & DELLES, C. 2012. Peripheral arterial tone: 
assessment of microcirculatory function in pregnancy. Journal of 
Hypertension, 30, 117-123 10.1097/HJH.0b013e32834d76fb. 
CATALANO, P., HUSTON, L., AMINI, S. & KALHAN, S. 1999. Longitudinal changes 
in glucose metabolism during pregnancy in obese women with normal 
glucose tolerance and gestational diabetes mellitus. Am J Obstet 
Gynecol., 180, 903-16. 
CATALANO, P., MELE, L., LANDON, M., RAMIN, S., REDDY, U., CASEY, B., 
WAPNER, R., VARNER, M., ROUSE, D., THORP, J. J., SAADE, G., SOROKIN, 
Y., PEACEMAN, A. & TOLOSA, J. 2014. Inadequate weight gain in 
overweight and obese pregnant women: what is the effect on fetal 
growth? Am J Obstet Gynecol., 211, 137.e1-7. 
  250 
CATALANO, P., TYZBIR, E., ROMAN, N., AMINI, S. & EA., S. 1991. Longitudinal 
changes in insulin release and insulin resistance in nonobese pregnant 
women. Am J Obstet Gynecol. , 165 1667-72. 
CATALANO, P. M. 2003. Obesity and Pregnancy—The Propagation of a Viscous 
Cycle? Journal of Clinical Endocrinology & Metabolism, 88, 3505-3506. 
CATALANO, P. M. & EHRENBERG, H. M. 2006. Review article: The short- and 
long-term implications of maternal obesity on the mother and her 
offspring. BJOG: An International Journal of Obstetrics & Gynaecology, 
113, 1126-1133. 
CATALANO, P. M., PRESLEY, L., MINIUM, J. & HAUGUEL-DE MOUZON, S. 2009. 
Fetuses of Obese Mothers Develop Insulin Resistance in Utero. Diabetes 
Care, 32, 1076-1080. 
CATALANO, P. M., ROMAN-DRAGO, N. M., AMINI, S. B. & SIMS, E. A. 1998. 
Longitudinal changes in body composition and energy balance in lean 
women with normal and abnormal glucose tolerance during pregnancy. 
Am J Obstet Gynecol. 1998, 179, 156-65. 
CEMACH 2007. Saving Mothers’ Lives: reviewing maternal deaths to make 
motherhood safer 2003-2005. The Seventh Report on Confidential 
Enquiries into Maternal Deaths in the United Kingdom. . 
CEMACH 2011. Saving Mothers’ Lives: Reviewing maternal deaths to make 
motherhood safer: 2006–2008. BJOG, 118, s1-203. 
CHAIWORAPONGSA, T., ROMERO, R., YOSHIMATSU, J., ESPINOZA, J., KIM, Y. M., 
PARK, K., KALACHE, K., EDWIN, S., BUJOLD, E. & GOMEZ, R. 2002. Soluble 
adhesion molecule profile in normal pregnancy and pre-eclampsia. 
Journal of Maternal-Fetal and Neonatal Medicine, 12, 19-27. 
CHALLIER, J. C., BASU, S., BINTEIN, T., MINIUM, J., HOTMIRE, K., CATALANO, P. 
M. & HAUGUEL-DE MOUZON, S. 2008. Obesity in pregnancy stimulates 
macrophage accumulation and inflammation in the placenta. Placenta, 
29, 274-81. 
CHEN, X. & SCHOLL, T. 2005. Oxidative stress: changes in pregnancy and with 
gestational diabetes mellitus. Curr Diab Rep., 5, 282-8. 
CHENG, Y., DIBLEY, M., ZHANG, X., ZENG, L. & YAN, H. 2009. Assessment of 
dietary intake among pregnant women in a rural area of western China. 
BMC Public Health, 9, 222. 
CHIHARA, H., OTSUBO, Y. & ARAKI, T. 2002. Resting Energy Expenditure in 
Pregnant Japanese Women. Journal of Nippon Medical School, 69, 373-
375. 
CHU, S. Y., BACHMAN, D. J., CALLAGHAN, W. M., WHITLOCK, E. P., DIETZ, P. M., 
BERG, C. J., O'KEEFFE-ROSETTI, M., BRUCE, F. C. & HORNBROOK, M. C. 
2008. Association between Obesity during Pregnancy and Increased Use of 
Health Care. New England Journal of Medicine, 358, 1444-1453. 
COCKELL, A. P. & POSTON, L. 1997. Flow-Mediated Vasodilatation Is Enhanced in 
Normal Pregnancy but Reduced in Preeclampsia. Hypertension, 30, 247-
251. 
CONWAY, J. M., INGWERSEN, L. A. & MOSHFEGH, A. J. 2004. Accuracy of dietary 
recall using the USDA five-step multiple-pass method in men: An 
observational validation study. Journal of the American Dietetic 
Association, 104, 595-603. 
CRACOWSKI, J.-L., DURAND, T. & BESSARD, G. 2002. Isoprostanes as a biomarker 
of lipid peroxidation in humans: physiology, pharmacology and clinical 
implications. Trends in Pharmacological Sciences, 23, 360-366. 
  251 
CRAVEN, C., MORGAN, T. & WARD, K. 1998. Decidual spiral artery remodelling 
begins before cellular interaction with cytotrophoblasts. Placenta, 19, 
241-52. 
CRIST, B., ALEKEL, D., RITLAND, L., HANSON, L., GENSCHEL, U. & REDDY, M. 
2009. Association of oxidative stress, iron, and centralized fat mass in 
healthy postmenopausal women. J Womens Health (Larchmt), 18, 795-
801. 
CROZIER, S. R., ROBINSON, S., GODFREY, K. M., COOPER, C. & INSKIP, H. M. 
2009. Women's Dietary Patterns Change Little from Before to During 
Pregnancy. The Journal of Nutrition, 139, 1956-1963. 
DAVIES, S. S. & GUO, L. 2014. Lipid peroxidation generates biologically active 
phospholipids including oxidatively N-modified phospholipids. Chemistry 
and Physics of Lipids, 181, 1-33. 
DEIERLEIN, A. L., SIEGA-RIZ, A. M. & HERRING, A. 2008. Dietary energy density 
but not glycemic load is associated with gestational weight gain. The 
American Journal of Clinical Nutrition, 88, 693-699. 
DEMPSTER, P. & AITKENS, S. 1995. A new air displacement method for the 
determination of human body composition. Med Sci Sports Exerc. , 27, 
1692-7. 
DESPRES, J. & LEMIEUX, I. 2006. Abdominal obesity and metabolic syndrome. 
Nature, 444, 881-887. 
DESPRES, J., LEMIEUX, I., BERGERON, J., PIBAROT, P., MATHIEU, P., LAROSE, E., 
RODES-CABAU, J., BERTRAND, O. F. & POIRIER, P. 2008. Abdominal 
Obesity and the Metabolic Syndrome: Contribution to Global 
Cardiometabolic Risk. Arterioscler Thromb Vasc Biol, 28, 1039-1049. 
DIETZ, P. M., CALLAGHAN, W. M. & SHARMA, A. J. 2009. High pregnancy weight 
gain and risk of excessive fetal growth. American Journal of Obstetrics 
and Gynecology, 201, 51.e1-51.e6. 
DILL, D. B. & COSTILL, D. L. 1974. Calculation of percentage changes in volumes 
of blood, plasma, and red cells in dehydration. 
DING, Z., LIU, S., WANG, X., KHAIDAKOV, M., DAI, Y. & MEHTA, J. L. 2013. 
Oxidant stress in mitochondrial DNA damage, autophagy and inflammation 
in atherosclerosis. Sci. Rep., 3. 
DIVOUX, A., KARASTERGIOU, K., XIE, H., GUO, W., PERERA, R., FRIED, S. & 
SMITH, S. 2014. Identification of a novel lncRNA in gluteal adipose tissue 
and evidence for its positive effect on preadipocyte differentiation. 
Obesity, Epub May 23. 
DODD, J., CRAMP, C., SUI, Z., YELLAND, L., DEUSSEN, A., GRIVELL, R., MORAN, 
L., CROWTHER, C., TURNBULL, D., MCPHEE, A., WITTERT, G., OWENS, J. 
& ROBINSON, J. 2014a. The effects of antenatal dietary and lifestyle 
advice for women who are overweight or obese on maternal diet and 
physical activity: the LIMIT randomised trial. BMC Med. , 12, 161 [Epub 
ahead of print]. 
DODD, J. M., TURNBULL, D., MCPHEE, A. J., DEUSSEN, A. R., GRIVELL, R. M., 
YELLAND, L. N., CROWTHER, C. A., WITTERT, G., OWENS, J. A. & 
ROBINSON, J. S. 2014b. Antenatal lifestyle advice for women who are 
overweight or obese: LIMIT randomised trial. BMJ, 348. 
DOH 1991. Department of Health Dietary Reference Values for Food Energy and 
Nutrients Report of the Panel on Dietary Reference Values of the 
Committee on Medical Aspects of Food Policy. Report on Health and Social 
Subjects 41. 
DOH 2010. Health Survey for England (2009)  
  252 
DØRUP, I., SKAJAA, K. & SØRENSEN, K. E. 1999. Normal pregnancy is associated 
with enhanced endothelium-dependent flow-mediated vasodilation. 276, 
H821-H825. 
DUCKITT, K. & HARRINGTON, D. 2005. Risk factors for pre-eclampsia at 
antenatal booking: systematic review of controlled studies. BMJ, 330. 
EHRENBERG, H. M., HUSTON-PRESLEY, L. & CATALANO, P. M. 2003. The 
influence of obesity and gestational diabetes mellitus on accretion and 
the distribution of adipose tissue in pregnancy. American Journal of 
Obstetrics and Gynecology, 189, 944-948. 
ELBELT, U., SCHUETZ, T., HOFFMANN, I., PIRLICH, M., STRASBURGER, C. J. & 
LOCHS, H. 2010. Differences of energy expenditure and physical activity 
patterns in subjects with various degrees of obesity. Clinical Nutrition, 
29, 766-772. 
ELCHALAL, U., SCHAIFF, W. T., SMITH, S. D., RIMON, E., BILDIRICI, I., NELSON, 
D. M. & SADOVSKY, Y. 2005. Insulin and fatty acids regulate the 
expression of the fat droplet-associated protein adipophilin in primary 
human trophoblasts. American Journal of Obstetrics and Gynecology, 193, 
1716-1723. 
EMET, T., ÜSTÜNER, I., GÜVEN, S., BALıK, G., URAL, Ü., TEKIN, Y., ŞENTÜRK, Ş., 
ŞAHIN, F. & AVŞAR, A. 2013. Plasma lipids and lipoproteins during 
pregnancy and related pregnancy outcomes. Archives of Gynecology and 
Obstetrics, 288, 49-55. 
ENDO, K., OYAMA, T., SAIKI, A., BAN, N., OHIRA, M., KOIDE, N., MURANO, T., 
WATANABE, H., NISHII, M., MIURA, M., SEKINE, K., MIYASHITA, Y. & 
SHIRAI, K. 2008. Determination of serum 7-ketocholesterol concentrations 
and their relationships with coronary multiple risks in diabetes mellitus. 
Diabetes Research and Clinical Practice, 80, 63-68. 
FAIN, J. N., MADAN, A. K., HILER, M. L., CHEEMA, P. & BAHOUTH, S. W. 2004. 
Comparison of the Release of Adipokines by Adipose Tissue, Adipose 
Tissue Matrix, and Adipocytes from Visceral and Subcutaneous Abdominal 
Adipose Tissues of Obese Humans. Endocrinology, 145, 2273-2282. 
FANTUZZI, G. 2005. Adipose tissue, adipokines, and inflammation. Journal of 
Allergy and Clinical Immunology, 115, 911-919. 
FARZADNIA, M., AYATOLLAHI, H., HASAN-ZADE, M. & RAHIMI, H. 2013. A 
Comparative Study of Serum Level of Vascular Cell Adhesion Molecule-1 
(sVCAM-1), Intercellular Adhesion Molecule-1(ICAM-1) and High Sensitive C 
- reactive protein (hs-CRP) in Normal and Pre-eclamptic Pregnancies. Iran 
J Basic Med Sci. , 16, 689-93. 
FITZSIMONS, K. J. & MODDER, J. 2010. Setting maternity care standards for 
women with obesity in pregnancy. Seminars in Fetal and Neonatal 
Medicine, 15, 100-107. 
FORSUM, E. & LOF, M. 2007. Energy Metabolism During Human Pregnancy. 
Annual Review of Nutrition, 27, 277-292. 
FRAYN, K. 2000. Visceral fat and insulin resistance-causative or correlative? Br J 
Nutr., 83 Suppl 1, S71-7. 
FRAYN, K. N. 1983. Calculation of substrate oxidation rates in vivo from gaseous 
exchange. Journal of Applied Physiology, 55, 628-634. 
FREEDSON, P., MELANSON, E. & SIRARD, J. 1998. Calibration of the Computer 
Science and Applications, Inc. accelerometer. Med Sci Sports Exerc, 30, 
777-81. 
FREEMAN, D. J. 2010. Effects of maternal obesity on fetal growth and body 
composition: implications for programming and future health. Seminars in 
Fetal and Neonatal Medicine, 15, 113-118. 
  253 
FREEMAN, D. J., MCMANUS, F., BROWN, E. A., CHERRY, L., NORRIE, J., RAMSAY, 
J. E., CLARK, P., WALKER, I. D., SATTAR, N. & GREER, I. A. 2004. Short- 
and Long-Term Changes in Plasma Inflammatory Markers Associated With 
Preeclampsia. Hypertension, 44, 708-714. 
FRIED, S. K., BUNKIN, D. A. & GREENBERG, A. S. 1998. Omental and 
Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: 
Depot Difference and Regulation by Glucocorticoid. J Clin Endocrinol 
Metab, 83, 847-850. 
GARBARINO, J. & STURLEY, S. L. 2009. Saturated with fat: new perspectives on 
lipotoxicity. Current Opinion in Clinical Nutrition & Metabolic Care, 12, 
110-116. 
GARDNER, B., WARDLE, J., POSTON, L. & CROKER, H. 2011. Changing diet and 
physical activity to reduce gestational weight gain: a meta-analysis. 
Obesity Reviews, 12, e602-e620. 
GASTON, A. & PRAPAVESSIS, H. 2013. Tired, moody and pregnant? Exercise may 
be the answer. Psychology & Health, 28, 1353-1369. 
GATE, E. & RAMSAY, J. E. 2007. Antenatal complications of maternal obesity: 
miscarriage, fetal abnormalities, maternal gestational diabetes and pre-
eclampisa. In: PHILIP BAKER, A. B., LUCILLA POSTON & NAVEED SATTAR 
(ed.) Obesity and Reproductive Health. London: RCOG Press. 
GEALEKMAN, O., GUSEVA, N., HARTIGAN, C., APOTHEKER, S., GORGOGLIONE, 
M., GURAV, K., TRAN, K.-V., STRAUBHAAR, J., NICOLORO, S., CZECH, M. 
P., THOMPSON, M., PERUGINI, R. A. & CORVERA, S. 2011. Depot-Specific 
Differences and Insufficient Subcutaneous Adipose Tissue Angiogenesis in 
Human Obesity. Circulation, 123, 186-194. 
GOHEL, M. & CHACKO, A. 2013. Serum GGT activity and hsCRP level in patients 
with type 2 diabetes mellitus with good and poor glycemic control: An 
evidence linking oxidative stress, inflammation and glycemic control. 
Journal of Diabetes & Metabolic Disorders, 12, 56. 
GOODPASTER, B., THAETE, F., SIMONEAU, J. & KELLEY, D. 1997. Subcutaneous 
abdominal fat and thigh muscle composition predict insulin sensitivity 
independently of visceral fat. Diabetes, 46, 1579-85. 
GRIFFIN, B. A. 1999. Lipoprotein atherogenicity: an overview of current 
mechanisms. Proceedings of the Nutrition Society, 58, 163-169. 
GRINDHEIM, G., ESTENSEN, M., LANGESAETER, E., ROSSELAND, L. & TOSKA, K. 
2012. Changes in blood pressure during healthy pregnancy: a longitudinal 
cohort study. J Hypertens., 30, 342-50. 
GUO, Z., HENSRUD, D. D., JOHNSON, C. M. & JENSEN, M. D. 1999. Regional 
postprandial fatty acid metabolism in different obesity phenotypes. 
Diabetes, 48, 1586-1592. 
GUSTAFSON, B., GOGG, S., HEDJAZIFAR, S., JENNDAHL, L., HAMMARSTEDT, A. & 
SMITH, U. 2009. Inflammation and impaired adipogenesis in hypertrophic 
obesity in man. American Journal of Physiology - Endocrinology and 
Metabolism, 297, E999-E1003. 
HAGGARTY, P. 2002. Placental Regulation of Fatty Acid Delivery and its Effect on 
Fetal Growth—A Review. Placenta, 23, Supplement A, S28-S38. 
HANDBERG, A., HØJLUND, K., GASTALDELLI, A., FLYVBJERG, A., DEKKER, J. M., 
PETRIE, J., PIATTI, P., BECK-NIELSEN, H. & THE, R. I. 2012. Plasma sCD36 
is associated with markers of atherosclerosis, insulin resistance and fatty 
liver in a nondiabetic healthy population. Journal of Internal Medicine, 
271, 294-304. 
  254 
HEITMANN, B. L. & FREDERIKSEN, P. 2009. Thigh circumference and risk of heart 
disease and premature death: prospective cohort study. BMJ, 339, b3292-
. 
HESLEHURST, N., RANKIN, J., WILKINSON, J. R. & SUMMERBELL, C. D. 2010. A 
nationally representative study of maternal obesity in England, UK: trends 
in incidence and demographic inequalities in 619323 births, 1989-2007. Int 
J Obes, 34, 420-428. 
HOLMES, B., DICK, K. & NELSON, M. 2008. A comparison of four dietary 
assessment methods in materially deprived households in England. Public 
Health Nutrition, 11, 444-456. 
HOTAMISLIGIL, G., PERALDI, P., BUDAVARI, A., ELLIS, R., WHITE, M. & 
SPIEGELMAN, B. 1996. IRS-1-mediated inhibition of insulin receptor 
tyrosine kinase activity in TNF and obesity induced insulin resistance. 
Science, 271, 665-668. 
HOTAMISLIGIL, G. S., MURRAY, D. L., CHOY, L. N. & SPIEGELMAN, B. M. 1994. 
Tumor necrosis factor alpha inhibits signaling from the insulin receptor. 
Proceedings of the National Academy of Sciences, 91, 4854-4858. 
HUANG, P. L. 2009. A comprehensive definition for metabolic syndrome. Disease 
Models & Mechanisms, 2, 231-237. 
HUDA, S. S., FORREST, R., PATERSON, N., JORDAN, F., SATTAR, N. & FREEMAN, 
D. J. 2014. In Preeclampsia, Maternal Third Trimester Subcutaneous 
Adipocyte Lipolysis Is More Resistant to Suppression by Insulin Than in 
Healthy Pregnancy. Hypertension, 63, 1094-1101. 
HUDA, S. S., SATTAR, N. & FREEMAN, D. J. 2009. Lipoprotein metabolism and 
vascular complications in pregnancy. Clinical lipidology, 4, 91-102. 
HUGHES, H., MATHEWS, B., LENZ, M. L. & GUYTON, J. R. 1994. Cytotoxicity of 
oxidized LDL to porcine aortic smooth muscle cells is associated with the 
oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler 
Thromb. 1994 Jul, 14, 1177-85. 
HULL, H. R., DINGER, M. K., KNEHANS, A. W., THOMPSON, D. M. & FIELDS, D. A. 
2008. Impact of maternal body mass index on neonate birthweight and 
body composition. American Journal of Obstetrics and Gynecology, 198, 
416.e1-416.e6. 
HUTLEY, L. & PRINS, J. B. 2005. Fat as an Endocrine Organ: Relationship to the 
Metabolic Syndrome. Am J Med Sci, 330, 280-289. 
IL'YASOVA, D., WANG, F., SPASOJEVIC, I., BASE, K., D'AGOSTINO, R. & 
WAGENKNECHT, L. 2007. Longitudinal Assessment of Maternal Endothelial 
Function and Markers of Inflammation and Placental Function throughout 
Pregnancy in Lean and Obese Mothers. The Journal of Clinical 
Endocrinology & Metabolism, 92, 969-975. 
IOM 2002. Subcommittee for a Clinical Applications Guide, Institute of Medicine. 
Nutrition During Pregnancy and Lactation:An Implementation Guide. 
IOM 2009. Weight Gain During Pregnancy: Reexamining the Guidelines, The 
National Academies Press. 
ISHIHARA, O., HAYASHI, M., OSAWA, H., KOBAYASHI, K., TAKEDA, S., VESSBY, B. 
& BASU, S. 2004. Isoprostanes, Prostaglandins and Tocopherols in Pre-
eclampsia, Normal Pregnancy and Non-pregnancy. Free Radical Research, 
38, 913-918. 
IULIANO, L., MICHELETTA, F., NATOLI, S., GINANNI CORRADINI, S., IAPPELLI, M., 
ELISEI, W., GIOVANNELLI, L., VIOLI, F. & DICZFALUSY, U. 2003. 
Measurement of oxysterols and [alpha]-tocopherol in plasma and tissue 
samples as indices of oxidant stress status. Analytical Biochemistry, 312, 
217-223. 
  255 
JACKSON, C. A., JONES, N. R. V., WALKER, J. J., FISCHBACHER, C. M., 
COLHOUN, H. M., LEESE, G. P., LINDSAY, R. S., MCKNIGHT, J. A., MORRIS, 
A. D., PETRIE, J. R., SATTAR, N. & WILD, S. H. 2012. Area-based 
socioeconomic status, type 2 diabetes and cardiovascular mortality in 
Scotland. Diabetologia, 55, 2938-2945. 
JADHAV, S., SATTAR, N., PETRIE, J., COBBE, S. & FERRELL, W. R. 2007. 
Reproducibility and Repeatability of Peripheral Microvascular Assessment 
Using Iontophoresis in Conjunction With Laser Doppler Imaging. Journal of 
Cardiovascular Pharmacology, 50, 343-9. 
JAKOBSSON, T., TREUTER, E., GUSTAFSSON, J.-Å. & STEFFENSEN, K. R. 2012. 
Liver X receptor biology and pharmacology: new pathways, challenges and 
opportunities. Trends in Pharmacological Sciences, 33, 394-404. 
JARVIE, E., HAUGUEL‑DE‑MOUZON, S., NELSON, S. M., SATTAR, N., CATALANO, 
P. M. & FREEMAN, D. J. 2010. Lipotoxicity in obese pregnancy and its 
potential role in adverse pregnancy outcome and obesity in the offspring. 
Clinical Science, 119, 123-129. 
JARVIE, E. & RAMSAY, J. E. 2010. Obstetric management of obesity in pregnancy. 
Seminars in Fetal and Neonatal Medicine, 15, 83-88. 
JAVITT, N. 2007. Oxysterols: functional significance in fetal development and 
the maintenance of normal retinal function. Curr Opin Lipidol. , 18, 283-
8. 
JENSEN, M. D. 2008. Role of Body Fat Distribution and the Metabolic 
Complications of Obesity. The Journal of Clinical Endocrinology & 
Metabolism, 93, s57-s63. 
JENSEN, M. D., CARDIN, S., EDGERTON, D. & CHERRINGTON, A. 2003. Splanchnic 
free fatty acid kinetics. Am J Physiol Endocrinol Metab, 284, E1140-
E1148. 
JESSUP, W., KRITHARIDES, L. & STOCKER, R. 2004. Lipid oxidation in 
atherogenesis: an overview. Biochem Soc Trans., 32, 134-8. 
JOLES, J. A. & POSTON, L. 2010. Can exercise prevent preeclampsia? Journal of 
Hypertension, 28, 2384-2385 10.1097/HJH.0b013e3283400653. 
KANAGALINGAM, M. G., FOROUHI, N. G., GREER, I. A. & SATTAR, N. 2005. 
Changes in booking body mass index over a decade: retrospective analysis 
from a Glasgow Maternity Hospital. BJOG: An International Journal of 
Obstetrics & Gynaecology, 112, 1431-1433. 
KASPRZAK, J., KŁOSIŃSKA, M. & DROZDZ, J. 2006. Clinical aspects of assessment 
of endothelial function. Pharmacol Rep, 58. 
KEANEY, J. F., LARSON, M. G., VASAN, R. S., WILSON, P. W. F., LIPINSKA, I., 
COREY, D., MASSARO, J. M., SUTHERLAND, P., VITA, J. A. & BENJAMIN, E. 
J. 2003. Obesity and Systemic Oxidative Stress: Clinical Correlates of 
Oxidative Stress in The Framingham Study. Arteriosclerosis, Thrombosis, 
and Vascular Biology, 23, 434-439. 
KELLY, A., DENGEL, D., HODGES, J., ZHANG, L., MORAN, A., CHOW, L., SINAIKO, 
A. & STEINBERGER, J. 2014. The Relative Contributions of the Abdominal 
Visceral and Subcutaneous Fat Depots to Cardiometabolic Risk in Youth. 
Clin Obes., 4, 101-107. 
KHALIL, S., MOHKTAR, M. & IBRAHIM, F. 2014. The Theory and Fundamentals of 
Bioimpedance Analysis in Clinical Status Monitoring and Diagnosis of 
Diseases. Sensors, 14, 10895-10928. 
KHOURY, J., AMUNDSEN, Å. L., TONSTAD, S., HENRIKSEN, T., OSE, L., 
RETTERSTØL, K. & IVERSEN, P. O. 2009. Evidence for impaired 
physiological decrease in the uteroplacental vascular resistance in 
  256 
pregnant women with familial hypercholesterolemia. Acta Obstetricia et 
Gynecologica Scandinavica, 88, 222-226. 
KIEL, D., DODSON, E., ARTAL, R., BOEHMER, T. & LEET, T. 2007. Gestational 
weight gain and pregnancy outcomes in obese women: how much is 
enough? Obstet Gynecol. , 110, 752-8. 
KIM, B., LEE, H., KAWATA, K. & PARK, J.-Y. 2014. Exercise-Mediated Wall Shear 
Stress Increases Mitochondrial Biogenesis in Vascular Endothelium. . PLoS 
One, 9, e111409. 
KIM, S. Y., DIETZ, P. M., ENGLAND, L., MORROW, B. & CALLAGHAN, W. M. 2007. 
Trends in Pre-pregnancy Obesity in Nine States, 1993-2003. Obesity, 15, 
986-993. 
KINNUNEN, T., TENNANT, P., MCPARLIN, C., POSTON, L., ROBSON, S. & BELL, R. 
2011. Agreement between pedometer and accelerometer in measuring 
physical activity in overweight and obese pregnant women. BMC Public 
Health, 11, 501. 
KINOSHITA, T. & ITOH, M. 2006. Longitudinal variance of fat mass deposition 
during pregnancy evaluated by ultrasound: the ratio of visceral fat to 
subcutaneous fat in the abdomen. Gynaecol Obstet Invest, 61, 115-8. 
KIRWAN, J. P., HAUGUEL-DE MOUZON, S., LEPERCQ, J., CHALLIER, J.-C., 
HUSTON-PRESLEY, L., FRIEDMAN, J. E., KALHAN, S. C. & CATALANO, P. M. 
2002. TNF-α Is a Predictor of Insulin Resistance in Human Pregnancy. 
Diabetes, 51, 2207-2213. 
KRAMER, F. M., STUNKARD, A. J., MARSHALL, K. A., MCKINNEY, S. & 
LIEBSCHUTZ, J. 1993. Breast-feeding reduces maternal lower-body fat. J 
Am Diet Assoc. , 93, 429-33. 
LARAIA, B. A., BODNAR, L. M. & SIEGA-RIZ, A. M. 2007. Pregravid body mass 
index is negatively associated with diet quality during pregnancy. Public 
Health Nutrition, 10, 920-926. 
LAU, D., BIKRAMJIT, D., HONGYUN, Y., SZMITKO, P. & VERMA, S. 2005. 
Adipokines: molecular links between obesity and atheroslcerosis. 
American Journal of Physiology - Heart and Circulatory Physiology, 288, 
H2031-H2041. 
LAWRENCE, M., COWARD, W. A., LAWRENCE, F., COLE, T. & WHITEHEAD, R. 
1987. ENERGY REQUIREMENTS OF PREGNANCY IN THE GAMBIA. The Lancet, 
330, 1072-1076. 
LEAN, M. E. J., ANDERSON, A. S., MORRISON, C. & CURRALL, J. 2003. Evaluation 
of a Dietary Targets Monitor. Br J Pharmacol, 57, 667-673. 
LIGUORI, A., D'ARMIENTO, F., PALAGIANO, A., PALINSKI, W. & NAPOLI, C. 2008. 
Maternal C-reactive protein and developmental programming of 
atherosclerosis. Am J Obstet Gynecol. , 198, 281e1-5. 
LIM, E. L., HOLLINGSWORTH, K. G., ARIBISALA, B. S., CHEN, M. J., MATHERS, J. 
C. & TAYLOR, R. 2011. Reversal of type 2 diabetes: normalisation of beta 
cell function in association with decreased pancreas and liver 
triacylglycerol. Diabetologia, 54, 2506-2514. 
LIM, J.-S., YANG, J.-H., CHUN, B.-Y., KAM, S., JACOBS JR, D. R. & LEE, D.-H. 
2004. Is serum γ-glutamyltransferase inversely associated with serum 
antioxidants as a marker of oxidative stress? Free Radical Biology and 
Medicine, 37, 1018-1023. 
LISSNER, L., BJORKELUND, C., HEITMANN, B., SEIDELL, J. & BENGTSSON, C. 
2001. Larger Hip Circumference Independently Predicts Health and 
Longevity in a Swedish Female Cohort. Obesity, 9, 644-646. 
  257 
LITTLE, R. E. & GLADEN, B. C. 1999. Levels of lipid peroxides in uncomplicated 
pregnancy: a review of the literature. Reproductive Toxicology, 13, 347-
352. 
LOF, M. & FORSUM, E. 2006. Activity pattern and energy expenditure due to 
physical activity before and during pregnancy in healthy Swedish women. 
British Journal of Nutrition, 95, 296-302. 
LOF, M., OLAUSSON, H., BOSTROM, K., JANEROT-SJÖBERG, B., SOHLSTROM, A. & 
FORSUM, E. 2005. Changes in basal metabolic rate during pregnancy in 
relation to changes in body weight and composition, cardiac output, 
insulin-like growth factor I, and thyroid hormones and in relation to fetal 
growth. The American Journal of Clinical Nutrition, 81, 678-685. 
MACKAY, V. A., HUDA, S. S., STEWART, F. M., THAM, K., MCKENNA, L. A., 
MARTIN, I., JORDAN, F., BROWN, E. A., HODSON, L., GREER, I. A., MEYER, 
B. J. & FREEMAN, D. J. 2012. Preeclampsia Is Associated With 
Compromised Maternal Synthesis of Long-Chain Polyunsaturated Fatty 
Acids, Leading to Offspring Deficiency. Hypertension, 60, 1078-1085. 
MACKNESS, M. I., ARROL, S., ABBOTT, C. & DURRINGTON, P. N. 1993. Protection 
of low-density lipoprotein against oxidative modification by high-density 
lipoprotein associated paraoxonase. Atherosclerosis, 104, 129-135. 
MAKEDOU, K., KOURTIS, A., GKIOMISI, A., TOULIS, K. A., MOUZAKI, M., 
ANASTASILAKIS, A. D., GEROU, S., GAVANA, E. & AGORASTOS, T. 2011. 
Oxidized low-density lipoprotein and adiponectin levels in pregnancy. 
Gynecological Endocrinology, 27, 1070-1073. 
MALEK, A., BERSINGER, N. A., DI SANTO, S., MUELLER, M. D., SAGER, R., 
SCHNEIDER, H., GHEZZI, F., KAROUSOU, E., PASSI, A., DE LUCA, G. & 
RAIO, L. 2006. C-Reactive Protein Production in Term Human Placental 
Tissue. Placenta, 27, 619-625. 
MARCEAU, G., VOLLE, D. H., GALLOT, D., MANGELSDORF, D. J., SAPIN, V. & 
LOBACCARO, J. A. 2005. Placental expression of the nuclear receptors for 
oxysterols LXRalpha and LXRbeta during mouse and human development. 
The Anatomical Record Part A: Discoveries in Molecular, Cellular, and 
Evolutionary Biology, 283A, 175-181. 
MARTIN-HIDALGO, A., HOLM, C., BELFRAGE, P., SCHOTZ, M. & HERRERA, E. 
1994. Lipoprotein lipase and hormone-sensitive lipase activity and mRNA 
in rat adipose tissue during pregnancy. Am J Physiol. , 266, E930-5. 
MARTIN, A. M., BERGER, H., NISENBAUM, R., LAUSMAN, A. Y., MACGARVIE, S., 
CRERAR, C. & RAY, J. G. 2009. Abdominal Visceral Adiposity in the First 
Trimester Predicts Glucose Intolerance in Later Pregnancy. Diabetes Care, 
32, 1308-1310. 
MATSUURA, E., KOBAYASHI, K., TABUCHI, M. & LOPEZ, L. R. 2006. Oxidative 
modification of low-density lipoprotein and immune regulation of 
atherosclerosis. Progress in Lipid Research, 45, 466-486. 
MATTHEWS, D., HOSKER, J., RUDENSKI, A., NAYLOR, B., TREACHER, D. & 
TURNER, R. 1985. Homeostasis model assessment: insulin resistance and 
beta-cell function from fasting plasma glucose and insulin concentrations 
in man. Diabetologia, 28, 412-9. 
MCCARTY, M. F. 2003. A paradox resolved: the postprandial model of insulin 
resistance explains why gynoid adiposity appears to be protective. 
Medical Hypotheses, 61, 173-176. 
MCCURDY, C. E., BISHOP, J. M., WILLIAMS, S. M., GRAYSON, B. E., SMITH, M. S., 
FRIEDMAN, J. E. & GROVE, K. L. 2009. Maternal high-fat diet triggers 
lipotoxicity in the fetal livers of nonhuman primates. The Journal of 
Clinical Investigation, 119, 323-335. 
  258 
MCGARRY, J. D. 2002. Banting Lecture 2001: Dysregulation of Fatty Acid 
Metabolism in the Etiology of Type 2 Diabetes. Diabetes, 51, 7-18. 
MCLAUGHLIN, T., SHERMAN, A., TSAO, P., GONZALEZ, O., YEE, G., LAMENDOLA, 
C., REAVEN, G. M. & CUSHMAN, S. W. 2007. Enhanced proportion of small 
adipose cells in insulin-resistant vs insulin-sensitive obese individuals 
implicates impaired adipogenesis. Diabetologia, 50, 1707-1715. 
MELZER, K., SCHUTZ, Y., BOULVAIN, M. & KAYSER, B. 2009. Pregnancy-related 
changes in activity energy expenditure and resting metabolic rate in 
Switzerland. Eur J Clin Nutr, 63, 1185-1191. 
MEYER, B. J., STEWART, F. M., BROWN, E. A., COONEY, J., NILSSON, S., 
OLIVECRONA, G., RAMSAY, J. E., GRIFFIN, B. A., CASLAKE, M. J. & 
FREEMAN, D. J. 2013. Maternal Obesity Is Associated With the Formation 
of Small Dense LDL and Hypoadiponectinemia in the Third Trimester. The 
Journal of Clinical Endocrinology & Metabolism, 98, 643-652. 
MEYER, M. R., FREDETTE, N. C., HOWARD, T. A., HU, C., RAMESH, C., DANIEL, 
C., AMANN, K., ARTERBURN, J. B., BARTON, M. & PROSSNITZ, E. R. 2014. 
G Protein-coupled Estrogen Receptor Protects from Atherosclerosis. Sci. 
Rep., 4. 
MINEO, C., DEGUCHI, H., GRIFFIN, J. H. & SHAUL, P. W. 2006. Endothelial and 
Antithrombotic Actions of HDL. Circulation Research, 98, 1352-1364. 
MINUZ, P., FAVA, C. & LECHI, A. 2006. Lipid peroxidation, isoprostanes and 
vascular damage. Pharmacol Rep., 58 suppl, 57-68. 
MIYAGUE, A., MARTINS, W., MACHADO, J., PALEI, A., AMARAL, L., TEIXEIRA, D., 
SANDRIM, V., SERTORIO, J., TANUS-SANTOS, J., DUARTE, G. & CAVALLI, R. 
2013. Maternal Flow-Mediated Dilation and Nitrite Concentration During 
Third Trimester of Pregnancy and Postpartum Period. Hypertension in 
Pregnancy, 32, 225-234. 
MOJTAHEDI, M., DE GROOT, L. C., BOEKHOLT, H. A. & VAN RAAIJ, J. M. A. 2002. 
Nitrogen balance of healthy Dutch women before and during pregnancy. 
The American Journal of Clinical Nutrition, 75, 1078-1083. 
MORELLO, F., SAGLIO, E., NOGHERO, A., SCHIAVONE, D., WILLIAMS, T. A., 
VERHOVEZ, A., BUSSOLINO, F., VEGLIO, F. & MULATERO, P. 2009. LXR-
activating oxysterols induce the expression of inflammatory markers in 
endothelial cells through LXR-independent mechanisms. Atherosclerosis, 
207, 38-44. 
MOURATIDOU, T., FORD, F., PROUNTZOU, F. & FRASER, R. 2006. Dietary 
assessment of a population of pregnant women in Sheffield, UK. British 
Journal of Nutrition, 96, 929-935. 
MURAKAMI, H., TAMASAWA, N., MATSUI, J., YASUJIMA, M. & SUDA, T. 2000. 
Plasma oxysterols and tocopherol in patients with diabetes mellitus and 
hyperlipidemia. Lipids. 2000 Mar, 35, 333-8. 
NAPOLI, C., D'ARMIENTO, F. P., MANCINI, F. P., POSTIGLIONE, A., WITZTUM, J. 
L., PALUMBO, G. & PALINSKI, W. 1997. Fatty streak formation occurs in 
human fetal aortas and is greatly enhanced by maternal 
hypercholesterolemia. Intimal accumulation of low density lipoprotein 
and its oxidation precede monocyte recruitment into early atherosclerotic 
lesions. The Journal of Clinical Investigation, 100, 2680-2690. 
NEELAND, I. J., AYERS, C. R., ROHATGI, A. K., TURER, A. T., BERRY, J. D., DAS, 
S. R., VEGA, G. L., KHERA, A., MCGUIRE, D. K., GRUNDY, S. M. & DE 
LEMOS, J. A. 2013. Associations of visceral and abdominal subcutaneous 
adipose tissue with markers of cardiac and metabolic risk in obese adults. 
Obesity, 21, E439-E447. 
  259 
NELSON-PIERCY, C. 2006. Handbook of Obstetric Medicine, London, Informa UK 
Ltd. 
NELSON, S. M., MATTHEWS, P. & POSTON, L. 2010. Maternal metabolism and 
obesity: modifiable determinants of pregnancy outcome. Human 
Reproduction Update, 16, 255-275. 
NHMRC.GOV.AU. 2006. Austrialian Government Department of Health & Aging. 
Nutritional reference ranges for Australia and New Zeland [Online].  
2012]. 
NHS 2012a. HEAT antenatal access target e-toolkit. NHS Scotland. 
NHS 2012b. "Ready, steady baby". NHS Scotland. 
NICE 2010. clinical guidance 62 Antenatal care. 
NIKI, E. 2008. Lipid peroxidation products as oxidative stress biomarkers. 
Biofactors. , 34, 171-80. 
NORATA, G. D., PIRILLO, A., CALLEGARI, E., HAMSTEN, A., CATAPANO, A. L. & 
ERIKSSON, P. 2003. Gene expression and intracellular pathways involved 
in endothelial dysfunction induced by VLDL and oxidised VLDL. 
Cardiovascular Research, 59, 169-180. 
O'SULLIVAN, A. J. 2009. Does oestrogen allow women to store fat more 
efficiently? A biological advantage for fertility and gestation. Obesity 
Reviews, 10, 168-177. 
OHANIAN, J., FORMAN, S. P., KATZENBERG, G. & OHANIAN, V. 2012. Endothelin-
1 Stimulates Small Artery VCAM-1 Expression through p38MAPK-Dependent 
Neutral Sphingomyelinase. Journal of Vascular Research, 49, 353-362. 
OKEREKE, N. C., HUSTON-PRESLEY, L., AMINI, S. B., KALHAN, S. & CATALANO, P. 
M. 2004. Longitudinal changes in energy expenditure and body 
composition in obese women with normal and impaired glucose tolerance. 
Am J Physiol Endocrinol Metab, 287, E472-479. 
ONKELINX, S., CORNELISSEN, V., GOETSCHALCKX, K., THOMAES, T., VERHAMME, 
P. & VANHEES, L. 2012. Reproducibility of different methods to measure 
the endothelial function. Vascular Medicine, 17, 79-84. 
PACKARD, C., BEZLYAK, V., MCLEAN, J., BATTY, G. D., FORD, I., BURNS, H., 
CAVANAGH, J., DEANS, K., HENDERSON, M., MCGINTY, A., MILLAR, K., 
SATTAR, N., SHIELS, P., VELUPILLAI, Y. & TANNAHILL, C. 2011. Early life 
socioeconomic adversity is associated in adult life with chronic 
inflammation, carotid atherosclerosis, poorer lung function and decreased 
cognitive performance: a cross-sectional, population-based study. BMC 
Public Health, 11, 42. 
PARADISI, G., BIAGGI, A., FERRAZZANI, S., DE CAROLIS, S. & CARUSO, A. 2002. 
Abnormal Carbohydrate Metabolism During Pregnancy: Association with 
endothelial dysfunction. Diabetes Care, 25, 560-564. 
PAVAN, L., HERMOUET, A., TSATSARIS, V., THEROND, P., SAWAMURA, T., EVAIN-
BRION, D. & FOURNIER, T. 2004. Lipids from Oxidized Low-Density 
Lipoprotein Modulate Human Trophoblast Invasion: Involvement of 
Nuclear Liver X Receptors. Endocrinology, 145, 4583-4591. 
PEET, D. J., JANOWSKI, B. A. & MANGELSDORF, D. J. 1998. The LXRs: a new class 
of oxysterol receptors. Current Opinion in Genetics & Development, 8, 
571-575. 
PIPE, N. G., SMITH, T., HALLIDAY, D., EDMONDS, C. J., WILLIAMS, C. & COLTART, 
T. M. 1979. Changes in fat, fat-free mass and body water in human normal 
pregnancy. Br J Obstet Gynaecol. , 86, 929-40. 
PLOSCH, T., VAN STRATEN, E. M. & KUIPERS, F. 2007. Cholesterol transport by 
the placenta: placental liver X receptor activity as a modulator of fetal 
cholesterol metabolism? Placenta, 28, 604-10. 
  260 
POSTON, L., BRILEY, A., BARR, S., BELL, R., CROKER, H., COXON, K., ESSEX, H., 
HUNT, C., HAYES, L., HOWARD, L., KHAZAEZADEH, N., KINNUNEN, T., 
NELSON, S., OTENG-NTIM, E., ROBSON, S., SATTAR, N., SEED, P., WARDLE, 
J., SANDERS, T. & SANDALL, J. 2013. Developing a complex intervention 
for diet and activity behaviour change in obese pregnant women (the 
UPBEAT trial); assessment of behavioural change and process evaluation 
in a pilot randomised controlled trial. BMC Pregnancy and Childbirth, 13, 
148. 
POU, K. M., MASSARO, J. M., HOFFMANN, U., VASAN, R. S., MAUROVICH-HORVAT, 
P., LARSON, M. G., KEANEY, J. F., JR., MEIGS, J. B., LIPINSKA, I., 
KATHIRESAN, S., MURABITO, J. M., O'DONNELL, C. J., BENJAMIN, E. J. & 
FOX, C. S. 2007. Visceral and Subcutaneous Adipose Tissue Volumes Are 
Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: 
The Framingham Heart Study. Circulation, 116, 1234-1241. 
PRENTICE, A. & GOLDBERG, G. 2000. Energy adaptations in human pregnancy: 
limits and long-term consequences. Am J Clin Nutr., 71(5 Suppl), 1226S-
32S. 
PRESLEY, L. H., WONG, W. W., ROMAN, N. M., AMINI, S. B. & CATALANO, P. M. 
2000. Anthropometric estimation of maternal body composition in late 
gestation. Obstetrics and Gynaecology, 96, 33-37. 
PRIMEAU, V., CODERRE, L., KARELIS, A. D., BROCHU, M., LAVOIE, M. E., MESSIER, 
V., SLADEK, R. & RABASA-LHORET, R. 2011. Characterizing the profile of 
obese patients who are metabolically healthy. Int J Obes, 35, 971-981. 
RADAELLI, T., LEPERCQ, J., VARASTEHPOUR, A., BASU, S., CATALANO, P. M. & 
HAUGUEL-DE MOUZON, S. 2009. Differential regulation of genes for 
fetoplacental lipid pathways in pregnancy with gestational and type 1 
diabetes mellitus. Am J Obstet Gynecol, 201, 209e1-e10. 
RAMSAY, J. E., FERRELL, W. R., CRAWFORD, L., WALLACE, A. M., GREER, I. A. & 
SATTAR, N. 2002a. Maternal Obesity Is Associated with Dysregulation of 
Metabolic, Vascular, and Inflammatory Pathways. J Clin Endocrinol 
Metab, 87, 4231-4237. 
RAMSAY, J. E., FERRELL, W. R., GREER, I. A. & SATTAR, N. 2002b. Factors 
Critical to Iontophoretic Assessment of Vascular Reactivity: Implications 
for Clinical Studies of Endothelial Dysfunction. Journal of Cardiovascular 
Pharmacology, 39, 9-17. 
RANDLE, P. J., GARLAND, P. B., HALES, C. N. & NEWSHOLME, E. A. 1963. THE 
GLUCOSE FATTY-ACID CYCLE ITS ROLE IN INSULIN SENSITIVITY AND THE 
METABOLIC DISTURBANCES OF DIABETES MELLITUS. The Lancet, 281, 785-
789. 
RASMUSSEN, J., ESCHEN, R., AARDESTRUP, I., DETHEFSEN, C., GRIFFIN, B. & 
SCHMIDT, E. 2009a. Flow-mediated vasodilatation: variation and 
interrelationships with plasma lipids and lipoproteins. Scandinavian 
Journal of Clinical & Laboratory Investigation, 69, 156-160. 
RASMUSSEN, K. M., CATALANO, P. M. & YAKTINE, A. L. 2009b. New guidelines for 
weight gain during pregnancy: what obstetrician/gynecologists should 
know. Current Opinion in Obstetrics and Gynecology, 21, 521-526 
10.1097/GCO.0b013e328332d24e. 
RAVIKUMAR, B., GERRARD, J., DALLA MAN, C., FIRBANK, M. J., LANE, A., 
ENGLISH, P. T., COBELLI, C. & TAYLOR, R. 2008. Pioglitazone Decreases 
Fasting and Postprandial Endogenous Glucose Production in Proportion to 
Decrease in Hepatic Triglyceride Content. Diabetes, 57, 2288-2295. 
RCOG 2006. Exercise in Pregnancy. Statement number 4. 
  261 
RCOG 2010. Management of the women with obesity in pregnancy Centre for 
Maternal and Child Enquires and Royal College of Obstetricians and 
Gynaecologists Joint Guideline. 
RETNAKARAN, R., HANLEY, A. J. G., RAIF, N., CONNELLY, P. W., SERMER, M. & 
ZINMAN, B. 2003. C-Reactive Protein and Gestational Diabetes: The 
Central Role of Maternal Obesity. Journal of Clinical Endocrinology & 
Metabolism, 88, 3507-3512. 
RISÉ, P., CAMERA, M., CARUSO, D., GHEZZI, S., VISIOLI, F. & GALLI, C. 2004. 
Synthesis of long-chain polyunsaturated fatty acids is inhibited in vivo in 
hypercholesterolemic rabbits and in vitro by oxysterols. Prostaglandins, 
Leukotrienes and Essential Fatty Acids, 71, 79-86. 
ROBINSON, N. M., LJ. MYERS, JE, HUBEL, CA. CROCKER, IP. 2009. A potential 
role for free fatty acids in the pathogenesis of preeclampsia. Journal of 
Hypertension, 27, 1293-302. 
RODRIGUEZ, A., GARCÍA-ESTEBAN, R., BASTERRETXEA, M., LERTXUNDI, A., 
RODRÍGUEZ-BERNAL, C., IÑIGUEZ, C., RODRIGUEZ-DEHLI, C., TARDÓN, A., 
ESPADA, M., SUNYER, J. & MORALES, E. 2014. Associations of maternal 
circulating 25-hydroxyvitamin D3 concentration with pregnancy and birth 
outcomes. BJOG: An International Journal of Obstetrics & Gynaecology, 
n/a-n/a. 
RODRÍGUEZ, I. & GONZÁLEZ, M. 2014. Physiological mechanisms of vascular 
response induced by shear stress and effect of exercise in systemic and 
placental circulation. Frontiers in Pharmacology, 5. 
ROGERS, I. & EMMETT, P. 1998. Diet during pregnancy in a population of 
pregnant women in South West England. ALSPAC Study Team. Avon 
Longitudinal Study of Pregnancy and Childhood. Eur J Clin Nutr., 52, 246-
50. 
ROSDAHL, H., GULLSTRAND, L., SALIER-ERIKSSON, J., JOHANSSON, P. & 
SCHANTZ, P. 2010. Evaluation of the Oxycon Mobile metabolic system 
against the Douglas bag method. European Journal of Applied Physiology, 
109, 159-171. 
ROSS, R., ARU, J., FREEMAN, J., HUDSON, R. & JANSSEN, I. 2002a. Abdominal 
adiposity and insulin resistance in obese men. Am J Physiol Endocrinol 
Metab, 282, E657-663. 
ROSS, R., FREEMAN, J., HUDSON, R. & JANSSEN, I. 2002b. Abdominal Obesity, 
Muscle Composition, and Insulin Resistance in Premenopausal Women. J 
Clin Endocrinol Metab, 87, 5044-5051. 
RYYSY, L., HÄKKINEN, A. M., GOTO, T., VEHKAVAARA, S., WESTERBACKA, J., 
HALAVAARA, J. & YKI-JÄRVINEN, H. 2000. Hepatic fat content and insulin 
action on free fatty acids and glucose metabolism rather than insulin 
absorption are associated with insulin requirements during insulin therapy 
in type 2 diabetic patients. Diabetes, 49, 749-758. 
SABEN, J., LINDSEY, F., ZHONG, Y., THAKALI, K., BADGER, T. M., ANDRES, A., 
GOMEZ-ACEVEDO, H. & SHANKAR, K. 2014. Maternal obesity is associated 
with a lipotoxic placental environment. Placenta, 35, 171-177. 
SALAMEH, W. & MASTROGIANNIS, D. 1994. Maternal hyperlipidemia in pregnancy. 
Clin Obstet Gynaecol, 37, 66-77. 
SÁNCHEZ-VERA, I., BONETA, B., VIANAB, M., QUINTANARC, A., MARTÍNC, M., 
BLANCOC, P., DONNAYC, S. & ALBIC, M. 2007. Changes in plasma lipids 
and increased low-density lipoprotein susceptibility to oxidation in 
pregnancies complicated by gestational diabetes: consequences of 
obesity. Metabolism, 56, 1527-33. 
  262 
SANTOLAYA, J. & FARO, R. 2012. Twins--twice more trouble? Clin Obstet 
Gynecol., 55, 296-306. 
SANTOSA, S., HENSRUD, D. D., VOTRUBA, S. B. & JENSEN, M. D. 2008. The 
influence of sex and obesity phenotype on meal fatty acid metabolism 
before and after weight loss. The American Journal of Clinical Nutrition, 
88, 1134-1141. 
SATTAR, N., CLARK, P., HOLMES, A., LEAN, M., WALKER, I. & GREER, I. 2001. 
Antenatal waist circumference and hypertension risk. Obstet Gynecol. , 
97, 268-71. 
SATTAR, N., GREER, I. A., LOUDEN, J., LINDSAY, G., MCCONNELL, M., SHEPHERD, 
J. & PACKARD, C. J. 1997. Lipoprotein Subfraction Changes in Normal 
Pregnancy: Threshold Effect of Plasma Triglyceride on Appearance of 
Small, Dense Low Density Lipoprotein. Journal of Clinical Endocrinology & 
Metabolism, 82, 2483-2491. 
SATTAR, N., MCCONNACHIE, A., SHAPER, A., BLAUW, G., BUCKLEY, B., DE 
CRAEN, A., FORD, I., FOROUHI, N., FREEMAN, D., JUKEMA, J., LENNON, 
L., MACFARLANE, P., MURPHY, M., PACKARD, C., STOTT, D., 
WESTENDORP, R., WHINCUP, P., SHEPERD, J. & WANNAMETHEE, S. 2008. 
Can metabolic syndrome usefully predict cardiovascular disease and 
diabetes? Outcome from two prospective studies. Lancet, 371, 1927-1935. 
SAVALE, L., TU, L., RIDEAU, D., IZZIKI, M., MAITRE, B., ADNOT, S. & EDDAHIBI, S. 
2009. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension 
and lung inflammation in mice. Respiratory Research, 10, 6. 
SCIFRES, C. M., CATOV, J. M. & SIMHAN, H. N. 2014. The impact of maternal 
obesity and gestational weight gain on early and mid-pregnancy lipid 
profiles. Obesity, 22, 932-938. 
SIDEBOTTOM, A. C., BROWN, J. E. & JACOBS, D. R. 2001. Pregnancy-related 
changes in body fat. European Journal of Obstetrics & Gynecology and 
Reproductive Biology, 94, 216-223. 
SILVER, A. E., BESKE, S. D., CHRISTOU, D. D., DONATO, A. J., MOREAU, K. L., 
ESKURZA, I., GATES, P. E. & SEALS, D. R. 2007. Overweight and Obese 
Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-
p47phox Expression and Evidence of Endothelial Oxidative Stress. 
Circulation, 115, 627-637. 
SNIJDER, M. B., DEKKER, J. M., VISSER, M., BOUTER, L. M., STEHOUWER, C. D., 
YUDKIN, J. S., HEINE, R. J., NIJPELS, G. & SEIDELL, J. C. 2004a. Trunk fat 
and leg fat have independent and opposite associations with fasting and 
postload glucose levels: the Hoorn study. Diabetes Care, 27, 372-7. 
SNIJDER, M. B., VISSER, M., DEKKER, J. M., GOODPASTER, B. H., HARRIS, T. B., 
KRITCHEVSKY, S. B., DE REKENEIRE, N., KANAYA, A. M., NEWMAN, A. B., 
TYLAVSKY, F. A. & SEIDELL, J. C. 2005. Low subcutaneous thigh fat is a 
risk factor for unfavourable glucose and lipid levels, independently of high 
abdominal fat. The Health ABC Study. Diabetologia, 48, 301-308. 
SNIJDER, M. B., ZIMMET, P. Z., VISSER, M., DEKKER, J. M., SEIDELL, J. C. & 
SHAW, J. E. 2004b. Independent and opposite associations of waist and 
hip circumferences with diabetes, hypertension and dyslipidemia: the 
AusDiab Study. Int J Obes Relat Metab Disord, 28, 402-409. 
SOHLSTROM, A. & FORSUM, E. 1995. Changes in adipose tissue volume and 
distribution during reproduction in Swedish women as assessed by 
magnetic resonance imaging. The American Journal of Clinical Nutrition, 
61, 287-95. 
SOLTANI, H. & FRASER, R. B. 2000. A longitudinal study of maternal 
anthropometric changes in normal weight, overweight and obese women 
  263 
during pregnancy and postpartum. British Journal of Nutrition, 84, 95-
101. 
STEFAN, N., KANTARTZIS, K., MACHANN, J. & ET AL. 2008. IDentification and 
characterization of metabolically benign obesity in humans. Archives of 
Internal Medicine, 168, 1609-1616. 
STEWART, F., FREEMAN, D. J., RAMSAY, J. E., GREER, I. A., CASLAKE, M. & 
FERRELL, W. R. 2007a. Longitudinal assessment of maternal endothelial 
function and markers of inflammation and placental function throughout 
pregnancy in lean and obese mothers. The Journal of Clinical 
Endocrinology & Metabolism, 92, 969-975. 
STEWART, F., RODIE, V. A., RAMSAY, J. E., GREER, I. A., FREEMAN, D. J. & 
MEYER, B. J. 2007b. Longitudinal assessment of erythrocyte fatty acid 
composition throughout pregnancy and post partum. Lipids, 42, 335-44. 
STEWART, F. M. 2007. The impact of maternal obesity on vascular and 
metabolic function throughout pregnancy. MD, University of Glasgow. 
SUI, Z. & DODD, J. 2013. Exercise in obese pregnant women: positive impacts 
and current perceptions. Int J Womens Health. , 3, 389-98. 
SUKALICH, S., MINGIONE, M. J. & GLANTZ, J. C. 2006. Obstetric outcomes in 
overweight and obese adolescents. American Journal of Obstetrics and 
Gynecology, 195, 851-855. 
SUN, M., YANG, Z. & MA, R. 2012. Effect of high-fat diet on liver and placenta 
fatty infiltration in early onset preeclampsia-like mouse model. Chin Med 
J (Engl), 125, 3532-8. 
SUPER, M., SUMMERS, E. & MEYLAN, B. 1991. Preventing neural tube defects. 
Lancet, 338, 755-6. 
TAGGART, N. R., HOLLIDAY, R. M., BILLEWICZ, W. Z., HYTTEN, F. E. & 
THOMSON, A. M. 1967. Changes in skinfolds during pregnancy. British 
Journal of Nutrition, 21, 439-51. 
TAYLOR, R. 2008. Pathogenesis of type 2 diabetes: tracing the reverse route 
from cure to cause. Diabetologia, 51, 1781-1789. 
TAYLOR, R. 2013. Banting Memorial Lecture 2012 Reversing the twin cycles of 
Type 2 diabetes. Diabetic Medicine, 30, 267-275. 
THANGARATINAM, S., ROGOZIŃSKA, E., JOLLY, K., GLINKOWSKI, S., ROSEBOOM, 
T., TOMLINSON, J. W., KUNZ, R., MOL, B. W., COOMARASAMY, A. & KHAN, 
K. S. 2012. Effects of interventions in pregnancy on maternal weight and 
obstetric outcomes: meta-analysis of randomised evidence. BMJ, 344. 
TOESCU, V., NUTTALL, S., MARTIN, U., NIGHTINGALE, P., KENDALL, M., BRYDON, 
P. & DUNNE, F. 2004. Changes in plasma lipids and markers of oxidative 
stress in normal pregnancy and pregnancies complicated by diabetes. Clin 
Sci (Lond), 106, 93-8. 
TRAUNER, M., ARRESE, M. & WAGNER, M. 2010. Fatty liver and lipotoxicity. 
Biochim Biophys Acta. , 1801, 299-310. 
TROST, S. G., MCIVER, K. L. & PATE, R. R. 2005. Conducting Accelerometer-
Based Activity Assessments in Field-Based Research. Medicine & Science in 
Sports & Exercise, 37, S531-S543. 
UAUY, R., MENA, P. & ROJAS, C. 2000. Essential fatty acids in early life: 
structural and functional role. Proceedings of the Nutrition Society, 59, 3-
15. 
VALDES, G., KAUFMANN, P., CORTHORN, J., ERICES, R., BROSNIHAN, K. B. & 
JOYNER-GRANTHAM, J. 2009. Vasodilator factors in the systemic and local 
adaptations to pregnancy. Reproductive Biology and Endocrinology, 7, 79. 
VAN POPPEL, M. N. M., OOSTDAM, N., EEKHOFF, M. E. W., WOUTERS, M. G. A. 
J., VAN MECHELEN, W. & CATALANO, P. M. 2013. Longitudinal 
  264 
Relationship of Physical Activity With Insulin Sensitivity in Overweight and 
Obese Pregnant Women. The Journal of Clinical Endocrinology & 
Metabolism, 98, 2929-2935. 
VAN RAAIJ, J. M., PEEK, M. E., VERMAAT-MIEDEMA, S. H., SCHONK, C. M. & 
HAUTVAST, J. G. 1988. New equations for estimating body fat mass in 
pregnancy from body density or total body water. The American Journal 
of Clinical Nutrition, 48, 24-9. 
VAN REYK, D. M., BROWN, A. J., HULT'EN, L. M., DEAN, R. T. & JESSUP, W. 2006. 
Oxysterols in biological systems: sources, metabolism and 
pathophysiological relevance. Redox Report, 11, 255-262. 
VEJUX, A. & LIZARD, G. 2009. Cytotoxic effects of oxysterols associated with 
human diseases: Induction of cell death (apoptosis and/or oncosis), 
oxidative and inflammatory activities, and phospholipidosis. Molecular 
Aspects of Medicine, 30, 153-170. 
VILLAMOR, E. & CNATTINGIUS, S. 2006. Interpregnancy weight change and risk of 
adverse pregnancy outcomes: a population-based study. The Lancet, 368, 
1164-1170. 
VINCENT, H. K., INNES, K. E. & VINCENT, K. R. 2007. Oxidative stress and 
potential interventions to reduce oxidative stress in overweight and 
obesity. Diabetes, Obesity and Metabolism, 9, 813-839. 
VINCENT, H. K. & TAYLOR, A. G. 2005. Biomarkers and potential mechanisms of 
obesity-induced oxidant stress in humans. Int J Obes, 30, 400-418. 
VISSERS, D., HENS, W., TAEYMANS, J., BAEYENS, J., POORTMANS, J. & VAN 
GAAL, L. L. 2013. The effect of exercise on visceral adipose tissue in 
overweight adults: a systematic review and meta-analysis. 
. PLoS One, 8, e56415. doi: 10.1371/journal.pone.0056415. Epub 2013 Feb 8. 
VOTRUBA, S. B., MATTISON, R. S., DUMESIC, D. A., KOUTSARI, C. & JENSEN, M. 
D. 2007. Meal fatty acid uptake in visceral fat in women. Diabetes, 56, 
2589-2597. 
VULLIEMOZ, N., MCVEIGH, E. & KURINCZEK, J. 2010. RCOG Scientific Advisory 
Committee: Nutrition in Pregnancy: Scientific Impact Paper No 18. 
WANG, Y. C., MCPHERSON, K., MARSH, T., GORTMAKER, S. L. & BROWN, M. 
2011. Health and economic burden of the projected obesity trends in the 
USA and the UK. The Lancet, 378, 815-825. 
WESTERTERP, K. R. 2008. Physical activity as determinant of daily energy 
expenditure. Physiology & Behavior, 93, 1039-1043. 
WESTGARTH, C., LIU, J., HERON, J., NESS, A., BUNDRED, P., GASKELL, R., 
GERMAN, A., MCCUNE, S. & DAWSON, S. 2012. Dog ownership during 
pregnancy, maternal activity, and obesity: a cross-sectional study. PLoS 
One., 7, e31315. 
WHITE, E., PIVARNIK, J. & PFEIFFER, K. 2013. Resistance Training During 
Pregnancy and Pregnancy and Birth Outcomes. J Phys Act Health., [Epub 
ahead of print]. 
WHO 2004. BMI classifications. 
WHO 2013. Obesity and overweight. 
WILLIAMS, I., WHEATCROFT, S., SHAH, A. & KEARNEY, M. 2002. Obesity, 
atherosclerosis and the vascular endothelium: mechanisms of reduced 
nitric oxide bioavailability in obese humans. Int J Obes Relat Metab 
Disord. , 26, 754-64. 
WILLIAMS, I. L., CHOWIENCZYK, P. J., WHEATCROFT, S. B., PATEL, A., 
SHERWOOD, R., MOMIN, A., SHAH, A. M. & KEARNEY, M. T. 2006. Effect of 
fat distribution on endothelial-dependent and endothelial-independent 
  265 
vasodilatation in healthy humans. Diabetes, Obesity and Metabolism, 8, 
296-301. 
XING, D., NOZELL, S., CHEN, Y.-F., HAGE, F. & OPARIL, S. 2009. Estrogen and 
Mechanisms of Vascular Protection. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 29, 289-295. 
YAMAKAGE, H., ITO, R., TOCHIYA, M., MURANAKA, K., TANAKA, M., MATSUO, Y., 
ODORI, S., KONO, S., SHIMATSU, A. & SATOH-ASAHARA, N. 2014. The 
utility of dual bioelectrical impedance analysis in detecting intra-
abdominal fat area in obese patients during weight reduction therapy in 
comparison with waist circumference and abdominal CT. Endocrine 
Journal, 61, 807-819. 
YOSHIDA, Y. & NIKI, E. 2006. Bio-markers of lipid peroxidation in vivo: 
hydroxyoctadecadienoic acid and hydroxycholesterol. Biofactors, 27, 195-
202. 
ZANINOTTO, P., WARDLE, H., STAMATAKIS, E., MINDELL, J. & HEAD, J. 2006. 
Forecasting Obesity to 2010 Department of Health. 
ZHAO, R., MA, X., XIE, X. & SHEN, G. X. 2009. Involvement of NADPH oxidase in 
oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen 
activator inhibitor-1 in vascular endothelial cells. American Journal of 
Physiology - Endocrinology and Metabolism, 297, E104-E111. 
ZHOU, Q., WASOWICZ, E., HANDLER, B., FLEISCHER, L. & KUMMEROW, F. A. 
2000. An excess concentration of oxysterols in the plasma is cytotoxic to 
cultured endothelial cells. Atherosclerosis, 149, 191-197. 
 
 
  266 
Accompanying Material 
 
 
 
 
  267 
 
 
 
 
 
 
 
 
  268 
 
 
 
 
 
 
 
 
  269 
Anatomical Adiposity & Metabolic Response in Lean and Non-Lean 
Pregnancies 
Maternal obesity is a risk factor for GDM. Adipocyte dysregulation is thought to 
be a possible pathway for this pregnancy complication. This longitudinal study 
assessed distribution of subcutaneous fat accumulation in lean pregnancies (LP) 
and non-lean pregnancies (NLP) and whether different anatomical sites had 
impact on metabolic markers (glucose, insulin, TG, NEFA). Adipose tissue 
accumulation was measured by skinfold thickness by the same trained operator. 
Plasma markers were measured by routine methodology. Statistical analysis was 
performed using paired t-test, and Pearson’s correlations. 
 
There was no significant difference in gestational weight gained by LP (n=27) 
compared to the NLP (n=8). In healthy LP there was a significant increase in 
abdominal skinfolds (costal, suprailiac) (28.9mm v 34.4mm p=<0.0001) and lower 
body peripheral (midthigh, suprapatellar) (35.0mm v 43.5mm p=<0.0001) across 
gestation. In NLP, upper body peripheral (biceps, triceps, subscapular) (73.2mm 
v 86.7mm p=0.012) and lower body peripheral skinfolds (61.4mm v 75.1mm 
p=0.002) were significantly increased over gestation. 
 
In LP there was significant gestational increases in insulin (3.0mU/L v 6.7 
p=<0.0001) and TG (1.2mmol/l v 2.5 p=<0.0001) but not Glucose or NEFA.  In LP 
gestational changes in insulin were inversely correlated with deposition in upper 
body peripheral during pregnancy (r=-0.55, p=0.009). 
 
In NLP there was significant gestational increases in TG (1.8mmol/l v 3.0 
p=0.003) but not insulin, glucose or NEFA. In NLP upper body skinfolds were 
correlated with gestational change (GC) in fasting glucose (r=0.91, p=0.002) and 
GC in TG (r=0.97, p=0.002).  
 
We found that LP has significant increase in central adiposity, but this does not 
drive metabolic response. Although NLP gain fat preferentially in lower body 
depots, this does not have an effect on the changes seen in TG and glucose. We 
continue to collect data on the NLP (n=16 in total) for validation of findings and 
investigate the effect of fat accumulation on endothelial function, oxidised LDL 
and superoxide formation in LP and NLP. 
 
